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1. Introduction 
 
In 2008 approximately 12.7 million cases of cancer were diagnosed and 7.6 million 
patients died because of this disease worldwide (http: //globocan.iarc.fr. 2010). This 
makes malignant neoplasm the leading cause of death in economically developed 
countries and the second leading in developing countries. Global cancer rates have 
been increasing due to the aging of the population and lifestyle change, for example 
fatty diets, smoking or physical inactivity (Jemal et al. 2011). Depending on the grade 
of the cancer, tumor location and general patient condition therapy options include 
surgery, chemotherapy, radiation therapy (RT) and palliative care. 
The development of radiation therapy has been driven by constant technological and 
medical advances since the discovery of X-rays by Wilhelm Conrad Röntgen in 1895. 
Ionizing radiation (IR) is currently utilized in ~50% of patients with solid tumors at 
some stage of their treatment (Bernier et al. 2004). The objective of such therapy is 
to deliver the optimal radiation dose to kill the tumor cells while sparing the non-
tumorigenic tissue. Benefits of radiotherapy are patient cure, organ preservation and 
cost efficiency. Recent improvements, including intensity-modulated and image-
guided RT, have increased the precision of irradiation, but there are still some 
limitations and side effects that can lead to treatment failure (Bischoff et al. 2009). 
Therefore, radiation therapy is usually combined with surgery and chemotherapeutics 
in a personalized strategy against cancer. 
 
1.1 Cellular response to radiation-induced damage 
 
Radiation leads to the disruption of chemical bonds in all basic components of the 
cell such as membranes, lipids, proteins and, most importantly, DNA (Ward et al. 
1981). DNA lesions arise as a consequence of direct and indirect effects of IR. 
Radiation-induced, charged particles cause direct breaks in the phosphodiester 
backbone of nucleic acid (van der Schans et al. 1973). Indirect damage is caused by 
the ionization of water molecules, which leads to the building of hydrated electrons, 
hydrogen atoms and hydroxyl radicals that interact with DNA (von Sonntag et al. 
1987). These direct and indirect interactions result in base and sugar-derived 
products, single and double strand breaks (SSBs and DSBs) as well as 
Introduction 
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DNA-protein crosslinks. Moreover, the radiation-induced DNA damage is not 
uniformly distributed throughout the genome, but the lesions cluster on the DNA 
within 0-20 bp (Burdak-Rothkamm et al. 2009).  
It is commonly known that DNA lesions, and particularly double strand breaks, have 
the greatest potential for cell killing (Ward et al. 1975). Therefore, counteracting 
mechanisms evolved to repair these DNA DSBs and to protect the cells from 
genomic instability. Generally, DNA damage response (DDR) involves DNA repair 
and cell cycle checkpoint pathways. Failure to repair the damage, or its misrepair, 
may result in chromosomal rearrangements, including deletions and translocations, 
and/or lead to cell death (Fig. 1).  
 
 
 
 
Figure 1. Cellular response to irradiation-induced DNA damage. When DNA lesion 
occurs, the cell activates DNA damage response (DDR) pathways. Cells can stop the 
cell cycle progression to enable initiation of DNA repair pathways, leading to the cell 
survival. For restoration of DNA DSBs there are two possible repair pathways: non-
homologous end joining (NHEJ) and homologous recombination (HR). If the damage 
is too big or cannot be restored, the accumulation of genetic aberrations follows and 
the cells dies (see details in text). 
 
The appearance of DNA DSB activates a signal transduction process that can 
initiate, depending on the scale of damage, the repair of the lesion, cell cycle arrest 
or programmed cell death (Fig. 1). One of the earliest events after DNA double 
strand break is the phosphorylation of serine 139 of the C-terminal tail of histone 
H2AX (phosphorylated form known as γH2AX, Rogakou et al. 1998). Next, multiple 
Activation of DDR 
Cell cycle arrest DNA repair 
NHEJ HR 
 
CELL SURVIVAL 
Damage is too extensive 
or misrepaired 
Mitotic 
catastrophe 
Apoptosis 
CELL DEATH 
Irradiation-induced DNA damage 
Damage is repairable 
failed 
Necrosis 
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proteins of DDR, such as transcription factors, cell-cycle regulation proteins and DSB 
repair proteins, are recruited to the site of the damage. Among them, the mammalian 
transducer kinases ATM (ataxia telangiectasia-mutated) and ATR (ataxia 
telangiectasia and Rad-3 related), together with DNA-PKcs (DNA-dependent protein 
kinase catalytic subunit), play a central role in damage repair initiation (Van Attikum 
et al. 2005). ATM and ATR phosphorylate proteins that activate cell cycle 
checkpoints and DNA repair pathways. Another important factor is the MRN complex, 
composed of Mre11, Rad50 and Nbs1, that is rapidly localized to nuclear foci at sites 
of DNA damage in response to radiation (Maser et al. 1997). Further H2AX become 
phosphorylated and the signal spreads to larger chromatin domains on either side of 
DSB (Rogakou et al. 1998). Then, depending on the amount of damage and cell 
cycle phase the lesion can be repaired. Two DNA double strand break repair 
pathways exist in human cells: non-homologous end joining and homologous 
recombination (Fig. 2). Non-homologous end joining (NHEJ) is considered to be the 
major pathway for the restoration of IR-induced DSBs, although it is error prone due 
to the lack of template strand (Burdak-Rothkamm et al. 2009). The first stage of 
NHEJ involves binding of the Ku70/Ku80 heterodimer to DSB ends and recruitment 
of DNA-PKcs. When the DNA-PK complex is assembled, it is responsible for DNA 
end processing and rejoining. If no further processing of the ends is necessary, DNA 
ligase IV completes the rejoining reaction. Alternatively, end processing may require 
the activities of other proteins, for instance the nuclease Artemis (Wyman et al. 
2006). NHEJ is predominant in the G0/G1 phase, but it can also occur throughout 
other phases of the cell cycle. 
 
Introduction 
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Figure 2. Homologous recombination and non-homologous end joining pathways. 
HR takes place in the S and G2 phases of the cell cycle and requires a template 
strand. The resection of the DNA strands is performed by the protein complex 
containing RAD51 recombinase. Then, the DNA synthesis of the lacking fragment 
and the rejoining of DNA ends follows. NHEJ can be initiated throughout every cell 
cycle phase and restores DNA DSBs without the template strand. DNA processing is 
controlled by Ku70/Ku80, together with DNA-PK. Ligase IV (Lig4) joins the DNA ends 
(adapted from Van Attikum et al. 2005). 
 
Alternatively, DNA DSBs can be restored by homologous recombination (HR) 
pathway (Fig. 2). It is active mainly in the S and G2 phases of the cell cycle and 
allows error-free repair using the information from the undamaged sister chromatid or 
homologous chromosome. Recent evidence showed that HR can only repair a 
fraction of DSBs, which localize to heterochromatic DNA regions (Jeggo et al. 2011). 
After a DSB occurs, sections of DNA around the 5’ ends are resected and one of the 
3’ single-stranded ends can invade an intact template strand. It results in the 
formation of a hybrid DNA molecule called displacement-loop (D-loop). This reaction
DNA-PK 
Homologous 
recombination 
Non-homologous 
end joining 
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is performed by a nucleoprotein filament composed of the 3’ single-stranded
DSB-end coated with RAD51 recombinase. Then, DNA polymerase can extend the 
end of 3’ invading strand by synthesizing new DNA and the lesion is restored (Li et 
al. 2008).  
The irradiation-induced DNA damage can activate checkpoint pathways that inhibit 
the cell cycle progression at G1/S or G2/M checkpoint and induce a transient delay of 
the S phase. The phase of the cell cycle where the cycle arrests after IR depends on 
the p53 status; cells with wild type p53 arrest predominantly in the G1 phase, while 
cells with mutant p53 fail to arrest in G1, but rather accumulate in the S and G2 
phases (Eastman et al. 2004). p53 is a tumor suppressor protein that induces the 
expression of multiple genes including cell cycle inhibitors (i.e. p21Waf1, GADD45a, 
14-3-3σ) and apoptosis promoting genes (i.e. PUMA, Bax, Bak). In tumors, the 
activity of p53 is frequently abrogated or altered by mutations enabling them to 
proliferate uncontrolled and evade cell death (Reinhardt et al. 2012). The activity of 
p53 is regulated by interactions with MDM2 protein (Haupt et al. 1997). MDM2 binds 
to p53 and thereby blocks its ability to regulate target genes and keeps it in unstable 
form. On the other hand, p53 activates the expression of the mdm2 gene in an 
autoregulatory feedback loop (Haupt et al. 1997). In addition, MDM2 acts as ubiquitin 
ligase, thus targeting p53 for proteasome-mediated degradation.  
Checkpoint pathways are coordinated with DNA damage repair and apoptosis, 
together determining the final cell response to DNA lesion. When DNA damage 
occurs in the G1 phase, ATM and ATR kinases phosphorylate and activate 
checkpoint kinases Chk2 and Chk1 respectively (Fig. 3). Chk2 and Chk1 
phosphorylate and in this way inhibit the functioning of phosphatase CDC25, 
preventing the activation of Cdk4-cyclin D and arresting the cell cycle at the G1/S 
checkpoint (Iliakis et al. 2003). This response is initiated rapidly after DNA damage 
and is independent from p53 status. Additionally, the activated cell cycle inhibitor p16 
can suppress Cdk4- and Cdk6-mediated phosphorylation of Rb, contributing to the 
G1/S arrest.  
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Figure 3. Induction of the cell cycle checkpoint pathway after DNA damage in the G1 
phase. DNA DSB activates ATR and ATM kinases, which phosphorylate checkpoint 
kinases Chk1 and Chk2 to initiate p53-dependent and independent pathways that 
lead to the cell cycle arrest at G1/S transition point (adapted from Iliakis et al. 2003). 
 
The G1/S arrest can also be induced by a p53-dependent mechanism. ATM and ATR 
kinases phosphorylate the p53 protein and disrupt its interaction with MDM2, which in 
turn leads to the increase of p53 transcriptional activity. Among the transcribed genes 
is p21Waf1, which binds to and inactivates Cdk-cyclin complex, which results in pRb 
hypophosphorylation and sustained cell cycle arrest at the G1/S transition (Stewart et 
al. 2001, Kastan et al. 2004). MDM2 itself is also a target of ATM and ATR kinases 
after DNA damage resulting in the disruption of the complex with p53 (Fig. 3). 
The G2/M arrest prevents the cells from initiating mitosis when they experience DNA 
damage during the G2 phase (Fig. 4). The general mechanism of the G2/M 
checkpoint involves activation of Chk1 and Chk2, which phosphorylate CDC25 to 
block its functions, which in turns inhibits the Cdk1-cyclin B activity and arrests the 
cell cycle (Iliakis et al. 2003). CDC25 can be also deactivated by members of Polo-
like kinases (PLK) family (Kastan et al. 2004). Apart from down-regulating CDC25, 
Chk1 
DNA  DSB 
ATR ATM 
Chk2 
CDC25 
p53 MDM2 
p21Waf1 Cdk4-cyclin D 
Cdk2-cyclin E 
 
Progression to S 
phase 
Introduction 
- 7 - 
 
Chk1 and Chk2 phosphorylate and activate Wee1 kinase that inhibits Cdk1-cyclin B 
activity. DNA damage can influence the subcellular localization of cyclin B, disabling 
its translocation from cytoplasm to the nucleus, which is the other possibility of 
stopping the cell cycle before entering mitosis (Pines et al. 1991, Jin et al. 1998). The 
maintenance of G2/M checkpoint relies on the activity of proteins transcriptionally 
regulated by p53 and BRCA1. Their activation leads to the up-regulation of p21Waf1, 
GADD45a and 14-3-3σ proteins that can inhibit the progression into mitosis (Taylor 
et al. 2001). 
 
Figure 4. Induction of the cell cycle checkpoint pathway after DNA damage in the G2 
phase. DNA DSB activates ATR and ATM kinases that phosphorylate checkpoint 
kinases Chk1 and Chk2. This initiates p53-dependent and independent pathways 
that lead to the cell cycle arrest at the G2/M transition point (adapted from Iliakis et 
al. 2003). 
 
Depending on the extent of DNA damage, the cell can activate pro-survival pathways 
(DNA repair and cell cycle arrest) or can eliminate damaged cells by cell death 
programs (Fig. 1). There are several mechanisms leading to cell killing following 
exposure to irradiation, but it is mainly a result of a mitotic catastrophe or an 
apoptosis (Eriksson et al. 2010). Mitotic catastrophe occurs when cells proceed 
through mitosis with unrepaired or misrepaired DNA damage that prevents error-free
DNA  DSB 
ATR ATM 
Chk2 Chk1 
CDC25 
p53 
PLK 
p21Waf1 
Cdk1-cyclin B 
 
Progression to M 
phase 
Wee1 
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replication and separation of the genetic material (Portugal et al. 2010). This is 
associated with the accumulation of multinucleated, giant cells containing 
uncondensed chromosomes, chromosome aberrations and micronuclei. It is 
suggested that mitotic catastrophe is a pre-stage for other cell death pathways like 
apoptosis and necrosis (Vakifahmetoglu et al. 2008). 
 
 
Figure 5. p53-dependent apoptotic pathway. Extrinsic and intrinsic stress factors can 
lead to the activation of apoptosis. p53 induces the expression of pro-apoptotic 
proteins (e.g. Apaf1, Bax, PUMA), which promote the release of cytochrome c and 
AIF from mitochondria. After formation of apoptosome, the caspase cleavage 
cascade is activated, which leads to the proteolytical degradation of the cellular 
components and following cell death (adapted from Riedl et al. 2004). 
 
Apoptotic pathway (Fig. 5) can be activated when the cell encounters external (i.e. 
ligand binding to the cell membrane) or internal (i.e. disruption of mitochondrial 
functions) stimuli (Helton et al. 2007). Under situation of extreme DNA damage, the 
cell can initiate p53-dependent apoptosis, which occurs within a few hours after 
irradiation, without the requirement of cell division. p53 promotes the extrinsic cell 
death pathway through up-regulation of death receptors (i.e. DR4, DR5). It can also 
 
Mitochondrion 
Extrinsic stimuli 
p53 
PUMA Bax 
Bcl-2 
AIF cytochrome c 
Apaf1 
caspase 9 
caspase 3 
CELL DEATH 
 
Apoptosome p53 
survivin 
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activate the intrinsic pathway by induction of pro-apoptotic proteins, including Apaf1 
(apoptotic protease activating factor 1) or members of the Bcl-2 family (i.e. Bax, 
PUMA). Through translocation to the mitochondria, p53 initiates apoptosis by 
provoking the release of several proteins into cytoplasm, for instance cytochrome c 
or the apoptosis-inducing factor (Mihara et al. 2003, Riedl et al. 2004). When in 
cytoplasm, cytochrome c binds with Apaf1, ATP and pro-caspase 9 to create a 
protein complex known as apoptosome (Riedl et al. 2007). Formation of the 
apoptosome activates the caspase cleavage cascade. Caspase 3 plays a central role 
in the execution of the apoptotic program through proteolytical degradation of further 
intracellular proteins (Porter et al. 1999). It is primarily responsible for the cleavage of 
poly (ADP-ribose) polymerase (PARP), considered as an indicator of late apoptosis 
(D’Amours et al. 2001). It is possible that large amounts of DNA double strand breaks 
can also lead to caspase-independent cell death, like necrosis or autophagy 
(Kroemer et al. 2005). 
 
1.2 Molecularly targeted chemoradiotherapy 
 
A key objective of the radiation therapy is to maximize the radiation dose aiming at 
tumor cells while minimizing the damage to surrounding organs. Effects of the 
radiotherapy are limited by the radiosensitivity of targeted tissue that differs from 
individual to individual. Cellular radiosensitivity is influenced by multiple intrinsic 
factors, such as the accumulation of genetic mutations in oncogenes and tumor 
suppressor genes, DNA damage repair proficiency, cell cycle phase and activation of 
apoptotic programs (Bernier et al. 2004). For example, specific mutations in DNA 
repair pathways lead to enhanced radiosensitivity as shown for ataxia telangiectasia 
syndrome, where gene encoding ATM is mutated (Taylor et al. 1975). Additionally, 
the environmental factors, including oxygen and nutrient supply or elimination of 
metabolic waste, may influence the response to irradiation (Bernier et al. 2004). 
Different cancer types respond differently to radiotherapy and are able to acquire 
mechanisms of resistance during the treatment. 
Chemotherapeutics can be used as a supporting treatment together with radiation 
(so called adjuvant therapy) to improve the overall survival rate and reduce disease-
specific symptoms (Seiwert et al. 2007, Bischoff et al. 2009). Multiple proteins 
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involved in the signal transduction pathways, cell cycle checkpoints or the initiation of 
cell death have been identified as potential targets for chemoradiotherapy (Ma et al. 
2003). Many of these molecules are mutated, abnormally expressed, or have 
alternative functions in tumor cells, which distinguishes them from non-malignant 
cells and confirms them as available drug targets. A group of proteins have been 
identified that regulate the radiation response and are involved in acquiring 
radioresistance (i.e. ATM, PARP, EGFR, Akt). Targeting radioresistance-associated 
proteins can lead to the sensitization of tumor cells to IR. For instance, it has been 
shown that the radiation response of cancer cells might be modulated by targeting of 
growth factor receptors (i.e. EGFR, VEGFR) due to the improvement of the 
oxygenation level of tumors and the reduction of their proliferation rate (Bussink et al. 
2007). Furthermore, the activation of pro-survival PI3K-Akt pathway has been 
associated with radioresistance in many cancers including those of the colon, brain, 
prostate and cervix (Li et al. 2009b). Inhibition of Akt impairs DNA repair after IR and 
results in the enhancement of the radiation response of several cancer cell lines 
(Toulany et al. 2008). Mutant activation of the ras oncogene and following 
downstream Raf-MEK-ERK pathway is also involved in acquiring radioresistance by 
tumor cells (Gupta et al. 2001). Inhibition of individual members of this pathway (i.e. 
Raf-1 or MEK) leads to radiosensitization of human cancer cell lines (Gupta et al. 
2000, Kasid et al. 2003). 
These, and many other potential therapeutic single targets, have been discovered in 
the recent years, but when applied to a clinical setting the effects have been 
generally weaker than expected and cell type-dependent (Camphausen et al. 2007). 
Cancer cells are often capable of activating parallel signaling cascades or negative 
feedback loops to evade the inhibitory effects of the drugs. Therefore, it is of special 
interest to search for targets that would influence more than one radioresistance-
associated protein and to use a so called multi-target approach to radiosensitization 
(Camphausen et al. 2007). A promising protein that could fulfill this criterion is the 
heat shock protein 90 (Hsp90). 
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1.3 Heat shock protein 90 (Hsp90) 
 
Hsp90 belongs to a group of proteins highly conserved in the evolution and whose 
expression is induced in response to extrinsic or intrinsic stress factors. These 
proteins function as molecular chaperones, assisting by folding and unfolding of other 
proteins. Mammalian heat shock proteins (Hsps) are classified in five families 
according to their molecular weight: Hsp110, Hsp90, Hsp70, Hsp40 and small Hsps 
with molecular weight 15–30 kDa (Kampinga et al. 2009). Among Hsps are 
constitutively expressed and stress-induced proteins, which are present in different 
subcellular compartments. Tumor cells are often characterized by the up-regulation 
of heat shock proteins. Clinical studies correlate the expression of Hsps with poor 
prognosis and resistance to therapies (Calderwood et al. 2006). 
The rapid induction of Hsps expression in response to stress stimuli is regulated by a 
series of events known as heat shock response (HSR). HSR is mediated by three 
heat shock factors, of which Hsf1 is a central player (Powers et al. 2007b). Under 
normal conditions, Hsf1 is kept in inactive monomeric form through the transient 
interaction with Hsp90 (Guo et al. 2001). In response to stress, it is activated and 
dissociates from its complex with Hsp90. Then, Hsf1 undergoes homotrimerization 
and phosphorylation, and translocates to the nucleus. There, Hsf1 binds to the heat-
shock elements that drive the expression of responsive genes, among others of 
various heat shock proteins (Mahalingam et al. 2009).  
The Hsp90 family comprises five members including Hsp90α – major, stress-
inducible and Hsp90β – minor, constitutive isoform, which are encoded by two 
different genes. Additionally, Grp94, which is found in endoplasmic reticulum, and 
TRAP1 in the mitochondria belong to the Hsp90 family (Csermely et al.1998).
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Table 1. Heat shock proteins mentioned in this thesis (adapted from Kampinga et al. 
2009). 
 
Hsp90 is mainly a constitutive homodimer (αα or ββ); however, monomers (α or β), 
heterodimers (αβ) and oligomers of both isoforms can also exist. There is evidence 
that Hsp90 isoforms fulfill different functions in cell differentiation and embryonic 
development in various organisms (Sreedhar et al. 2004). 
Hsp90 monomer consists of three functional domains (Fig. 6): i) the N-terminal 
domain with adenine binding pocket, which is responsible for ATPase activity of 
Hsp90; ii) the middle domain where co-chaperones (i.e. Hsp70, p23, Aha1) can bind; 
and iii) the C-terminal domain responsible for the dimerization of the chaperone 
(Pearl et al. 2006). Further co-chaperones can bind to the C-terminal domain due to 
the presence of the tetratricopeptide repeat-binding (TRP) motif (Jego et al. 2010).
Family No. of family members Protein Gene name Human gene ID 
Hsp90 (HSPC) 5 
Hsp90α 
Hsp90β 
Grp94 
TRAP1 
HSPC1 
HSPC3 
HSPC4 
HSPC5 
3320 
3326 
7184 
10131 
Hsp70 (HSPA) 13 Hsp70 
Hsc70 
HSPA1A 
HSPA8 
3303 
3312 
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Figure 6. Functional domains of Hsp90 and Hsp70. The Hsp90 monomer consists of 
the N-terminal domain with ATP binding pocket, the middle domain necessary for 
client binding and the C-terminal domain responsible for dimerization and co-
chaperone binding (adapted from Pearl et al. 2006).  
Hsp70 is made up of 4 domains, at the N-terminus the ATPase domain is present, 
followed by the peptide binding domain and the region with protease sensitive site. 
The C-terminal domain is the binding site for other Hsps and co-chaperones 
(adapted from Daugaard et al. 2007). 
 
Heat shock protein 90 is a highly abundant chaperone protein expressed by all 
eukaryotic cells and often up-regulated in cancer cells (Neckers et al. 2007). Hsp90, 
together with various co-chaperones, (i.e. Hsp70, Hop, p23) builds a multi-chaperone 
complex essential for the folding, stabilization and activation of more than 200 
proteins, so called Hsp90 clients (Picard et al. 2002, Zhang et al. 2004; for complete 
list of Hsp90 clients see http://www.picard.ch/Hsp90Int). Different post-translational 
modifications of Hsp90 (i.e. phosphorylation, acetylation, nitrosylation) regulate the 
functions of the chaperone complex by modulating the Hsp90 cycle rate and 
delivering specific substrates (Taipale et al. 2010). 
The Hsp90 multi-chaperone complex cycles between two major conformations: the 
open and the closed state (Fig. 7). The open state allows for the loading of a client 
protein onto Hsp90, and then the energy from ATP is needed to switch to the closed 
state conformation, in which N-terminal domains are dimerized and associated with 
middle domains. When the complex is closed, the conformational maturation and 
activation of client protein follows. Next, the N-terminal domains dissociate, ADP and 
client protein are released, whereas Hsp90 returns to the open conformation. If the 
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client protein cannot be folded, Hsp90 directs them to the ubiquitin-proteasome 
system for degradation (Li et al. 2011d, Taipale et al. 2010). 
 
 
Figure 7. The Hsp90 chaperone cycle. 1) The C-terminal domains (dark blue) are 
responsible for Hsp90 dimerization. Chaperone is in the open state. 2) Co-
chaperones (e.g. Hop, Hsp70 and Hsp40) deliver Hsp90 client, which binds to the 
middle domain (green) of Hsp90. 3) The energy from ATP is needed for switching to 
the closed state conformation. ATP binding site is present on the N terminus (orange) 
of Hsp90 monomer. 4) Further co-chaperones can bind to the chaperone complex 
(i.e. p23, CYP40). The maturation of the client takes place. 5) Mature client and ADP 
are released, and Hsp90 returns to the open state (adapted from Taipale et al. 2010). 
 
Apart chaperoning functions, heat shock protein 90 is also involved in the regulation 
of apoptosis, through the stabilization of several client proteins such as Akt, survivin 
or death associated protein kinase 1 (Piper et al. 2011). Furthermore, Hsp90 can 
inhibit the formation of the apoptosome by binding to Apaf1 (Pandey et al. 2000). 
Hsp90 clients include members of the steroid receptor family, transcription factors, 
receptor tyrosine kinases and cell cycle regulators (Zhang et al. 2004). Many of the 
clients are involved in signal transduction pathways, contributing to the initiation and 
development of malignancies. Thus, it is suggested that heat shock protein 90 
facilitates the so called oncogene addiction of tumor cells and promotes their survival 
(Luo et al. 2009, Trepel et al. 2010). 
It has been reported that, in cancer cells of different origin (i.e. lung carcinoma, 
melanoma or lymphoma), part of Hsp90 is specifically expressed on the cell surface, 
where it is responsible for cell motility and invasiveness (Tsutsumi et al. 2007).  
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1.4 Hsp90 inhibition as a method for sensitizing tumor cells to 
irradiation 
 
Given the importance of multiple Hsp90 clients in the development and maintaining 
of carcinogenesis (Fig. 8), this chaperone became an interesting target for cancer 
treatment.  
 
 
 
Figure 8. Hsp90 clients (example proteins below every characteristic) contribute to 
six hallmarks of tumor cells: the uncontrolled growth and cell division; the 
independence from growth factors, the evasion of apoptosis; the ability to migrate, 
invade and promote blood vessel growth. Additionally, Hsp90 clients involved in 
resistance to chemo- and radiotherapy have been identified (adapted from Hanahan 
et al. 2000, Zhang et al. 2004). 
 
It has been suggested that Hsp90 inhibition would result in the simultaneous 
disruption or blockade of many oncogenic signal transduction pathways leading to 
enhanced tumor cell killing. This idea has been intensively investigated since the 
discovery of the earliest Hsp90 inhibitors geldanamycin and radicicol. Geldanamycin 
was shown to deplete Hsp90 clients and exhibit anti-tumor effects in vitro, but it failed 
the in vivo tests because of the poor solubility and significant hepatotoxicity (Supko et 
al. 1995). Nevertheless, the studies on geldanamycin and resolving the crystal 
structure of Hsp90 protein (Stebbins et al. 1997) enabled the development of more 
efficient and clinically applicable small Hsp90 inhibitors. Drugs targeting Hsp90 can 
be classified into several groups: i) molecules that inhibit the binding of ATP in the 
adenine-binding pocket (so called N-terminal inhibitors), ii) C-terminal Hsp90 
inhibitors, iii) substances that disrupt the binding of co-chaperones and
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iv) modulators of Hsp90 post-translational modifications (Patel et al. 2012). Most 
research has been concentrated on N-terminal Hsp90 inhibitors (starting from 
geldanamycin and radicicol), which lock the Hsp90 chaperone complex in the open 
state, disabling its functions and leading to the degradation of client protein via a 
ubiquitin-proteasome pathway (Zhang et al. 2004). Among the N-terminal 
compounds targeting Hsp90 several classes can be distinguished based on their 
structure, including pyrazole/isoxazole inhibitors (Eccles et al. 2008), benzoquinone 
ansamycins (Smith et al. 2005) and drugs with purine scaffold (Lundgren et al. 2009; 
Table 2). 
Different Hsp90 clients show different sensitivity to Hsp90 inhibitors. For instance, 
ErbB2 (also known as Her-2) is one of the most sensitive clients, being degraded 
within 2 hours after Hsp90 suppression, whereas the down-regulation of Akt only 
starts 24 hours later (Zhang et al. 2004). It is likely that malignancies dependent on 
more sensitive Hsp90 clients will better respond to Hsp90 inhibition (Patel et al. 
2012). Indeed, to date the best clinical results, as shown by tumor regression, were 
obtained with 17-DMAG when given in combination with trastuzumab (EGFR 
inhibitor) to patients with metastatic breast cancer expressing ErbB2 (ErbB2+ breast 
cancer, Miller et al. 2007). Further potential malignancies that could benefit most 
from Hsp90 inhibition are small cell lung cancer (SCLC) with activated Akt, 
melanoma with B-Raf mutations, chronic myelogeonous leukemia (CML) with Bcr-Abl 
gene fusions or non-small cell lung cancer (NSCLC) with ALK (anaplastic lymphoma 
kinase) rearrangements (Patel et al. 2012). 
Because Hsp90 protects cells from stress factors, it was hypothesized that Hsp90 
inhibitors will sensitize tumor cells to the toxic effects of chemotherapeutics and 
radiotherapy. Many studies in vitro and in animal models have confirmed synergistic 
or additive effects of Hsp90 inhibition in combination with drugs used in 
chemotherapy, including taxanes, histone deacetylase or proteasome inhibitors 
(Jhaveri et al. 2012b). At the moment there are 34 open clinical studies testing the 
clinical activity of the most promising Hsp90 inhibitors alone or in combination with 
other chemotherapeutics (according to www.clinicaltrials.gov). 
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Table 2. Chemical structure of chosen Hsp90 inhibitors. 
N-terminal Hsp90 inhibitors 
Benzoquinone ansamycins 
 
Geldanamycin 
 
17-AAG (tanespimycin)  17-DMAG (alvespimycin) 
Pyrazole/isoxazole derivatives 
 
NVP-AUY922 
 
 
 
Radicicol 
Purine scaffold 
 
BIIB021 
 
Debio-0932 
Other 
 
NVP-BEP800 
 
SNX-5422 
C-terminal Hsp90 inhibitors 
 
Novobiocin 
 
Epigallocatechin-3-gallate 
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Furthermore, many studies have corroborated that drugs targeting Hsp90 are able to 
increase the radiation response of cancer cells (Enmon et al. 2003, Machida et al. 
2003, Russell et al. 2003, Bull et al. 2004, Dote et al. 2005, Noguchi et al. 2006, 
Shintani et al. 2006, Koll et al. 2008, Schilling et al. 2011). For instance, 17-AAG 
potentiated both the in vitro and in vivo radiation response of cervical carcinoma cells 
(Bisht et al. 2003). The radiosensitization was observed when cells were exposed to 
IR within 6 to 48 hours after drug treatment. Machida et al. 2003 reported similar 
findings for combined geldanamycin-IR treatment in lung carcinoma and colon 
adenocarcinoma cell lines in vitro. Most studies with Hsp90 inhibitors have used a 
schedule whereby drug exposure was followed by irradiation (Bisht et al. 2003, 
Machida et al. 2003, Bull et al. 2004, Dote et al. 2006, Noguchi et al. 2006, Shintani 
et al. 2006). Koll et al. 2008 tested several schedules for the combination of 17-
DMAG and IR treatment in NSCLC cell lines. Cells were irradiated before, after or 
simultaneously with 17-DMAG treatment and the sequence of administration was 
critical for gaining synergistic effects (Koll et al. 2008). In the report from Enmon et al. 
2003, human prostate tumor cells in the form of spheroids were incubated for 96 
hours with increasing doses of 17-AAG before and after irradiation. The radiation-first 
schedule was the most effective in delaying spheroid growth (Enmon et al. 2003). It 
is apparent that the schedule of treatment is crucial in combination studies with 
Hsp90 inhibitors and IR to obtain the best therapeutic outcome. 
The major concern relating to Hsp90 inhibition was the fact that this chaperone is 
abundantly expressed not only in cancer cells, but also in non-malignant tissues, and 
therefore Hsp90 targeting could impair their proper functioning. Fortunately, it was 
shown that Hsp90 inhibitors concentrate in tumor tissue, while being rapidly removed 
from healthy tissues and blood (Banerji et al. 2005). Other group observed that 
vascular smooth muscle cells (pericytes) in vitro had to be treated with 10-fold higher 
doses of 17-AAG to achieve similar inhibition of cell proliferation as gastric cancer 
cells (Lang et al. 2007). 
The exact mechanism of Hsp90 inhibitors’ selectivity towards malignant cells has not 
yet been elucidated. It is suggested that cancer cells are more dependent or addicted 
to Hsp90 chaperoning functions because of stressful environmental conditions and 
the accumulation of oncoproteins. A report from Kamal et al. 2003 showed that 
Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than 
Hsp90 does from normal cells. 
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Nevertheless, there are some limitations associated with Hsp90 inhibitors that have 
to be taken into consideration when planning studies with these substances. It has 
been shown that, in some cases, 17-AAG apart from depleting many Hsp90 clients 
was able to transiently activate Src kinase in prostate and breast cancer, which led to 
development of bone metastases (Price et al. 2005).  
It is apparent that tumors can exhibit resistance to some Hsp90 inhibitors, both 
intrinsic and acquired. Geldanamycin derivatives are substrates of the P-glycoprotein 
(P-gp) efflux pump that contributes to multi-drug resistance and its over-expression is 
related with resistance to Hsp90 inhibitors (Zhang et al. 2010, Piper et al. 2011). Low 
activity of NQO1/DT-diaphorase has been linked in vitro and in vivo to intrinsic 
resistance to these Hsp90 inhibitors (Kelland et al. 1999). NQO1/DT-diaphorase is an 
obligate, two-electron reducing, flavin-containing enzyme catalyzing the direct 
reduction of quinones to hydroquinones. 17-AAG and 17-DMAG are metabolized by 
this enzyme to their more active hydroquinone forms. A study from Gaspar et al. 
2009 described the mechanism of acquired resistance to 17-AAG in four 
glioblastoma cell lines, which exhibited lower NQO1/DT expression. Apart from being 
catalyzed by NQO1/DT-diaphorase, the benzoquinone ansamycins can also undergo 
reduction by other enzymes such as cytochrome P450 reductase (Piper et al. 2011). 
Resistance to 17-AAG or 17-DMAG of cancer cells can be avoided by using other 
Hsp90 inhibitors that do not possess quinone moiety, such as NVP-AUY922 or 
BIIB021.  
The activation of the heat shock response is now recognized as one of the most 
important causes of acquired resistance to all N-terminal Hsp90 inhibitors. The anti-
apoptotic properties of Hsp90 itself and of other heat shock proteins (especially heat 
shock protein 70) counteract the activity of the Hsp90 targeting drugs. One solution is 
switching to the C-terminal Hsp90 inhibitors that do not induce such strong HSR 
(Piper et al. 2011). Alternatively it should be possible to overcome the induction of 
HSR by combining the N-terminal Hsp90 inhibitors with other drugs, i.e. Hsf1 or 
Hsp70 inhibitors. 
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1.5 Heat shock protein 70 (Hsp70) 
 
It has been demonstrated that heat shock protein 70 (Hsp70) is a key co-chaperone 
in the Hsp90 chaperone complex (Hutchison et al. 1994, Taipale et al. 2010). Hsp70 
(encoded by the HSPA1A gene) belongs to a family of thirteen homologous 
chaperone proteins (Kampinga et al. 2009; Table 1). Proteins from the Hsp70 family 
have a similar structure, consisting of i) the conserved ATPase domain, ii) the 
peptide-binding domain, iii) the middle region with protease sensitive site and iv) the 
C-terminal region containing the binding site for co-chaperones and other Hsps (Fig. 
6). The regulation of Hsp70 activity involves cooperation with co-chaperones such as 
Hsp40, Bag-1, Hip and Hop (Daugaard et al. 2007). 
In response to stress, Hsp70 expression massively increases and the chaperone 
protects its protein substrates from denaturation or aggregation until the conditions 
improve. Hsp70 also assists in the folding of newly synthesized proteins, the 
transport of the proteins and the formation of protein complexes (Evans et al. 2010). 
Hsp70 is a protein with strong anti-apoptotic properties; it interferes directly with 
apoptotic pathway at all major levels and protects cells from cell death (Lanneau et 
al. 2007, Fig. 9). At the pre-mitochondrial level, Hsp70 binds to c-Jun N-terminal 
kinase 1 and blocks its functions, disabling the signal initiating apoptosis (Park et al. 
2001). At the level of mitochondria, Hsp70 inhibits the translocation of Bax protein, 
thereby preventing the release of cytochrome c and AIF (Stankiewicz et al. 2005). It 
has been shown that Hsp70 can bind directly to Apaf1, disabling the building of 
apoptosome (Beere et al. 2000). Heat shock protein 70 is also able to rescue the 
cells from later phases of apoptosis, downstream of caspase 3 activation, as well as 
prevent caspase-independent pathways (Jaattela et al. 1998). 
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Figure 9. Anti-apoptotic properties of heat shock protein 70. Hsp70 can block the 
signal initiating apoptosis (i.e. by binding to c-Jun N-terminal kinase 1) at the pre-
mitochondrial level. Later, it prevents the release of cytochrome c and AIF from 
mitochondria. Hsp70 can bind to Apaf1 to inhibit the formation of apoptosome. At 
later phases, Hsp70 interacts with the caspase cascade, protecting the cell from the 
proteolytical degradation (adapted from Riedl et al. 2004, Lanneau et al. 2007). 
 
Another important Hsp70 family member is Hsc70 or heat shock cognate 70 protein, 
which is constitutively expressed (Kampinga et al. 2009). Hsc70 is considered an 
essential house-keeping protein, indispensable for the cell survival of non-malignant 
cells. Hsc70 knock-out in mice is lethal (Florin et al. 2004) and RNA interference-
based knock-down of the protein results in cell death in various cell types (Rohde et 
al. 2005). Hsc70 has been reported to be involved in the folding of nascent proteins, 
protein translocation and chaperone-mediated autophagy (Daugaard et al. 2007). 
It was reported that cancer cells from different origin exhibit up-regulated expression 
of Hsp70 and Hsc70. The expression of heat shock protein 70 in malignant tumors 
correlates with increased cell proliferation, poor differentiation, lymph node 
metastases and poor therapeutic outcome (Daugaard et al. 2007). Hsp70 seems to 
be an essential regulator of tumor cell survival by maintaining the protein 
homeostasis. Additionally, it was shown that the induction of Hsp70 reduces the 
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effects of Hsp90 inhibition in the human prostate (Gabai et al. 2005) and leukaemia 
cell lines (Guo et al. 2005). 
 
1.6 Inhibition of Hsp70 in cancer therapy 
 
The inhibition of Hsp70 proved to be more challenging than Hsp90 targeting, 
because of the structure of the ATP binding pocket (Massey et al. 2010) and high 
similarities between members of the Hsp70 family. At the moment there are several 
small molecule inhibitors that bind to both Hsp70 and Hsc70, including 15-
deoxyspergualin, dihydropirymidines (Evans et al. 2010) or VER-155008 (Massey et 
al. 2010; Table 3). VER-155008 is an adenosine derived compound that binds to 
ATPase domain of Hsp70 family members and it was shown to induce apoptosis in 
breast cancer cells and colon cancer cells in vitro, but has not been yet tested in vivo 
(Massey et al. 2010). 
A recent report from Leu et al. 2009 presented a potentially new drug, a small 
molecule 2-phenylethynesulfonamide (PES) that specifically interacts with Hsp70, 
which lead to the aggregation of misfolded proteins and to the destabilization of 
lysosome membranes. PES selectively killed cells from several types of cancer 
through caspase-dependent apoptosis (Leu et al. 2009).  
Specific targeting of Hsp70 or Hsc70 can be achieved by RNA interference or 
antisense oligonucleotides. Peptide aptamers and siRNAs are isoform specific and 
were shown to induce apoptosis and to increase sensitivity to other 
chemotherapeutics such as cisplatin (Rerole et al. 2011). Interestingly, it has been 
demonstrated that simultaneous Hsc70/Hsp70 silencing induced effects mimicking 
Hsp90 inhibition in cancer cell lines, whereas the same combination of siRNA did not 
influence the response of non-tumorigenic cells (Powers et al. 2007a).  
A different approach for Hsp70 inhibition is targeting its interaction with co-
chaperones. For example, MAL3-101 inhibits the ability of Hsp40 co-chaperone to 
stimulate Hsp70 ATPase activity (Braunstein et al. 2011). Exposure to MAL3-101 
inhibited the cell proliferation of multiple myeloma cells in vitro and in vivo. The cell 
growth inhibition was associated with cell cycle arrest and initiation of apoptosis 
(Braunstein et al. 2011). 
Another method of indirect Hsp70 inhibition is the use of Hsf1 inhibitors, for instance 
quercetin or KNK437, which hinder the synthesis of stress-inducible heat shock 
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proteins including Hsp70, Hsp110, Hsp40 (Yokota et al. 2000). In our group, the 
inhibitory effects of KNK437 increased the radiation response of lung carcinoma cells 
(Stingl et al. 2011). 
 
Table 3. Chemical structure of chosen Hsp70 inhibitors. 
Hsp70 inhibitors 
binding to Hsp70 only 
 
 
PES 
binding to Hsc70 and Hsp70 
 
 
 
 
15-deoxyspergualin  VER-155008 
indirect Hsp70 inhibitors 
 
MAL3-101 
(inhibits interaction between Hsp40 and 
Hsp70) 
 
 
 
 
 
 
KNK437 
(inhibits synthesis of stress-inducible 
Hsps) 
 
 
 
 
quercetin 
(HSR inhibitor) 
 
Cancer cells can be distinguished from non-malignant cells because they express 
Hsp70 on the plasma membrane. This fact was utilized to generate specific 
monoclonal antibody cmHsp70.1mAb (Stangl et al. 2011). It has been demonstrated 
that this antibody can induce cytotoxicity in mouse tumor cells in vitro. When injected 
into tumor-bearing mice, cmHsp70.1mAb inhibited tumor growth and enhanced the 
overall survival rate (Stangl et al. 2011). 
The role of Hsp70 inhibition in the radiosensitization of malignant cells has to be 
elucidated. To our knowledge, there is only one study showing that Hsp70 silencing 
by siRNA sensitized the endometrial cancer cell line to irradiation (Du et al. 2009). 
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In the previous chapter, the combination of Hsp90 and Hsp70 inhibitors was 
mentioned as a possible solution to overcome the induction of heat shock response. 
Powers et al. 2007a tested the effect of 17-AAG on the proliferation of HCT116 colon 
and A2780 ovarian carcinoma cell lines transfected with Hsp70 siRNA. In this study 
Hsp70 knock-down resulted in increased 17-AAG-induced apoptosis (Powers et al. 
2007a). Similar results were obtained in myeloma cells which were transfected with 
specific shRNA targeting Hsp70 and treated with 17-AAG (Davenport et al. 2010), as 
well as in breast cancer cell lines silenced for Hsp70 and treated with geldanamycin 
(Havik et al. 2007). 
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2. Objectives 
 
Heat shock protein 90 is in the focus of research and development efforts due to its 
interactions with multiple oncogenic pathways (Zhang et al. 2004, Whitesell et al. 
2005). It has been demonstrated that Hsp90 inhibitors have anti-tumor activities and 
proved to be beneficial in cancer treatment (Supko et al. 1995, Smith et al. 2005, 
Trepel et al. 2010). However, the most commonly used Hsp90 inhibitors, including 
17-AAG and 17-DMAG, exhibit some limitations, for instance toxicity, poor solubility 
or drug-resistance (Solit et al. 2007, Porter et al. 2010). These problems led to 
synthesis of further Hsp90 inhibitors with improved pharmacokinetic properties. One 
of them is NVP-AUY922, which was able to reduce tumor growth in a variety of 
cancer cell lines and human xenograft models (Brough et al. 2008). Exposure to 
NVP-AUY922 induced the same effects on the protein level, such as Hsp70 over-
expression and depletion of Hsp90 clients, as treatment with geldanamycin or its 
derivatives (Brough et al. 2008, Eccles et al. 2008, Stühmer et al. 2008). Cell fate 
following NVP-AUY922-treatment differed between cell lines and involved cytostasis 
or caspase-dependent and –independent cell death (Eccles et al. 2008).  
Another promising novel inhibitor is NVP-BEP800, a fully synthetic, orally 
bioavailable drug that binds to the N-terminal domain of Hsp90 and has exhibited 
inhibitory effects in a panel of tumor cell lines and xenografts (Brough et al. 2009). 
NVP-BEP800 showed the greatest selectivity towards Hsp90 versus Grp94 and 
TRAP1 in comparison with other Hsp90 targeting drugs (Massey et al. 2010). NVP-
AUY922 and NVP-BEP800 are the most potent N-terminal Hsp90 inhibitors 
described thus far (Brough et al. 2008, 2009).  
Taking into account the strong anti-tumor activities and optimal pharmacokinetic 
profile of these two Hsp90 inhibitors, the radiosensitizing potential of NVP-AUY922 
and NVP-BEP800 in several cancer cell lines was tested by our group. Tumor cells of 
different origin pre-treated with either Hsp90 inhibitor for 24 hours were sensitized to 
the following irradiation (Stingl et al. 2010). In the literature on combination studies 
with geldanamycin derivatives and irradiation there were some discrepancies 
regarding the sequence of the treatment (Enmon et al. 2003, Russell et al. 2003, Bull 
et al. 2004, Dote et al. 2005, Koll et al. 2008). Most studies reported that drug-first 
treatment increases the radiosensitivity of cancer cell lines (i.e. Bisht et al. 2003,
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 Machida et al. 2003, Bull et al. 2004). In contrast, others showed that irradiation 
before Hsp90 inhibition is superior in tumor cell killing (Enmon et al. 2003, Koll et al. 
2008). In this work we tested whether a schedule other than drug-first treatment 
could sensitize cancer cells to irradiation. Lung carcinoma (A549) and glioblastoma 
(SNB19) cells were treated with NVP-AUY922 or NVP-BEP800 shortly before 
irradiation and incubated in a drug-containing medium for up to 48 hours post IR (this 
will be referred as simultaneous drug-IR treatment). We have analyzed the colony-
forming ability, radiation-induced DNA damage and repair, cell cycle distribution and 
expression of Hsp90 and its clients at different time points after drug-IR treatment. 
 
The introduction of novel drugs into clinical studies depends not only on their anti-
tumor potential, but also on their impact on non-malignant tissue. It has been 
demonstrated that NVP-AUY922 and NVP-BEP800 are potent agents for cancer 
treatment (Brough et al. 2008, 2009), but their effects on non-malignant cells were 
not evaluated. Therefore, we have investigated the cellular response of two human 
normal skin fibroblast strains (HFib1 and HFib2) to treatment with NVP-AUY922 or 
NVP-BEP800 in combination with radiation. As with tumor cell lines (A549 and 
SNB19) the Hsp90 inhibitor was applied on fibroblasts one hour before IR, and then 
left in the medium for up to 48 hours post-radiation. Then, at various time points, the 
colony-forming ability, radiation-induced DNA damage and repair, cell cycle 
distribution and expression of several marker proteins were examined. 
 
As expected from previous studies with NVP-AUY922 and NVP-BEP800 (Eccles et 
al. 2008, Stühmer et al. 2009, Stingl et al. 2010), the treatment resulted in the 
induction of the heat shock response and the up-regulation of heat shock proteins, 
including Hsp90 and Hsp70. It has been suggested that anti-apoptotic activities of 
Hsp70 could reduce the therapeutic potential of Hsp90 inhibitors (Gabai et al. 2005, 
Guo et al. 2005). Therefore, the objective of the third part of this thesis was to 
prevent the induction of Hsp70 with the help of specific siRNA-mediated knock-down. 
We have applied siRNAs targeting Hsp70 and its closest relative Hsc70 separately or 
simultaneously in two cancer cell lines: A549 and SNB19. Pre-silencing was used to 
reduce the NVP-AUY922-mediated Hsp70 over-expression and to increase the 
radiosensitizing effect of the drug. The cellular response of transfected, drug-treated 
and irradiated cells was analyzed by proliferation and colony forming assays. We 
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examined the expression of heat shock proteins and several marker proteins (Akt, 
Raf-1, Cdk1, Cdk4, caspase 3). To assess the level of DNA damage and repair 
kinetics, as well as cell cycle distribution flow cytometrical measurements were 
performed. 
The questions of this thesis can be summarized as follows: 
1. How important is drug and irradiation schedule? 
• Can the Hsp90 inhibitors added simultaneously with IR and kept thereafter 
better radiosensitize tumor cells?  
• Which pathways are involved in the cellular response to the simultaneous 
drug-IR treatment? 
• If there are any differences between tested cell lines, what are the underlying 
causes? 
2. What are the effects of Hsp90 inhibition in combination with irradiation on non-
malignant cells? 
• How do normal human skin fibroblasts respond to NVP-AUY922-IR or NVP-
BEP800-IR treatment? 
• What is the response of non-malignant cells to the simultaneous drug-IR 
treatment in comparison to tumor cells? 
3. Is it possible to increase the radiosensitizing potential of NVP-AUY922? 
• Does the knock-down of proteins from Hsp70 family affect the radiation 
response of tumor cells? 
• Can Hsp70 pre-silencing influence the activity of Hsp90 inhibitor? 
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3. Materials and methods 
 
3.1 Materials 
 
3.1.1 Antibodies 
In Tables 4, 5 and 6 antibodies used in this thesis are listed. 
 
Table 4. Primary antibodies. 
Name Origin Molecular weight Supplier 
Akt rabbit polyclonal 60 kDa 
pAkt (Ser473) mouse monoclonal 60 kDa 
Bcl-xL rabbit polyclonal 30 kDa 
caspase 3 mouse polyclonal 17, 19, 35 kDa 
cleaved caspase 3 rabbit monoclonal 17, 19 kDa 
Cdk1 (=Cdc2) mouse monoclonal 34 kDa 
Ku80 rabbit polyclonal 86 kDa 
Ku70 rabbit polyclonal 70 kDa 
p24 MAP Kinase rabbit polyclonal 42 kDa 
PARP rabbit polyclonal 116, 89 kDa 
cleaved PARP rabbit monoclonal 89 kDa 
PI3K p110 rabbit polyclonal 110 kDa 
PI3K p85 rabbit polyclonal 85 kDa 
PTEN rabbit polyclonal 54 kDa 
pRb rabbit polyclonal 110 kDa 
Cell Signalling 
Technology Inc. 
(Danvers, MA, USA) 
Cdk4 rabbit polyclonal 33 kDa 
Hsc70 rabbit polyclonal 70 kDa 
k-RAS mouse monoclonal 21 kDa 
MDM2 mouse monoclonal 90 kDa 
p16 mouse polyclonal 16 kDa 
p19ARF rabbit polyclonal 19 kDa 
Raf-1 rabbit polyclonal 72 kDa 
Santa Cruz 
Biotechnology Inc. 
(Santa Cruz, CA, 
USA) 
Hsp90 mouse polyclonal 90 kDa 
Hsp70 mouse polyclonal 70 kDa 
BD Pharmigen 
(Heidelberg, 
Germany) 
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Continuation of Table 4 from previous page. 
 
Name Origin Molecular weight Supplier 
ß-actin mouse monoclonal 42 kDa Sigma-Aldrich 
(Deisenhofen, 
Germany) 
p21Waf1 mouse monoclonal 21 kDa Fischer Scientific 
GmbH (Schwerte, 
Germany) 
p53 mouse polyclonal 53 kDa Calbiochem (Merck 
KGA, Darmstadt, 
Germany) 
survivin rabbit polyclonal 19 kDa R&D Systems 
(Minneapolis, USA) 
 
Table 5. Secondary antibodies 
Name Origin Supplier 
anti-mouse goat polyclonal, HRP-
conjugated 
anti-rabbit goat polyclonal, HRP-
conjugated 
DAKO (Hamburg, 
Germany) 
 
Table 6. Antibodies conjugated with fluorescent dye 
Name Origin Supplier 
phospho-H2AX (Ser139), 
FITC conjugate mouse Milipore (Temecula, USA) 
phospho-H2AX (Ser139), 
Alexa Fluor®647 
conjugate 
mouse 
BD Pharmigen 
(Heidelberg, Germany) 
 
3.1.2 Buffers and reagents 
10x PBS 80 g NaCl 
2 g KCl 
14.4 g Na2HPO4 
2.4 g KH2PO4 
set pH at 7.4, fill with H2O to final volume 1000 ml 
 
Colony survival assay 
Fixing solution methanol : acetic acid (3:1), ice-cold 
Crystal violet 0.6% in H2O 
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Cell lysates 
RIPA buffer 790 mg Tris-base 
900 mg NaCl, set pH at 7.4 
10 ml of 10% NP-40 
2.5 ml of 10% sodium deoxycholate 
1 ml of 100 mM EDTA 
fill with H2O to final volume of 100 ml 
Protease inhibitors 
(for 1 ml RIPA buffer) 
10 µl of 1 mM DTT 
0.5 µl of 1 µg/ml aprotitin 
2 µl of 1 µg/ml leupeptin 
2 µl of 1 µg/ml pepstatin A 
Phosphatase 
inhibitors 
(for 1 ml RIPA buffer) 
 
2 µl of 500 nM NaVO3 
1 µl of 1 M NaF 
Western blot 
pre-cast gels NuPAGE® 4-12% Bis-Tris Gel, 
NuPAGE® 3-8% Tris acetate Gel 
sample reagents NuPAGE® 4x LDS Sample buffer, 
NuPAGE® 10x Sample Reducing 
Agent, NuPAGE® Antioxidant 
running buffer NuPAGE® 20x MOPS SDS Running 
buffer, NuPAGE® 20x Tris-Acetate 
SDS Running buffer  
transfer buffer NuPAGE® Transfer buffer 
Life Technologies 
GmbH (Darmstadt, 
Germany) 
protein molecular 
weight marker 
Precision Plus All Blue Protein 
Ladder 
BioRAD (Munich, 
Germany) 
 
Protein expression analysis 
blocking buffer 4% milk powder/BSA, 0.1% Tween in PBS 
washing buffer 0.1% Tween in PBS 
home made ECL 0.25 g/l luminol sodium salt in 0.1 M Tris-HCl, pH 8.6 
(solution A) 
1.1 mg/ml p-coumaric acid in DMSO (solution B) 
Shortly before use mix: 5 ml solution A with 0.5 ml solution 
B and 5 µl 30% H2O2  
 
Flow cytometry 
Block 9 0.1 g BSA 
8 ml mouse serum 
1 ml of 10 mg/ml RNase 
1 ml of 1M NaF 
200 µl of 500 nM NaVO3 
0.025 g herring sperm DNA 
100 µl Triton X-100 
2.5 ml of 200 mM EDTA 
2.5 ml of 2% NaN3 
10 ml 10x PBS 
fill with H2O to final volume of 100 ml 
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DNA staining solution 1% saponin in PBS 
20 µg/ml PI 
50 µg/ml RNase 
 
RT-PCR 
agarose 
ethidium bromide Roth (Karlsruhe, Germany) 
6x DNA Loading Dye  
50x TAE 
electrophoresis buffer  
Fischer Scientific GmbH (Schwerte, Germany) 
Quick load 100 bp 
DNA Ladder New England Biolabs (Frankfurt, Germany) 
 
3.1.3 siRNA sequences 
Name Target Sequence (5’→3’) Source 
1 Hsc70 CCG AAC CAC UCC AAG CUA U 
2 Hsc70 CUG UCC UCA UCA AGC GUA A 
Powers et al. 
2007a 
3 Hsp70 GGA CAU CAG CCA GAA CAA G 
4 Hsp70 GCG AGA GGG UGU CAG CCA A Wu et al. 2009 
AllStars Neg. 
Control 
non-
silencing 
unknown 
Mm/Hs_MAPK1 
control siRNA 
MAPK1 UGC UGA CUC CAA AGC UCU 
GTT 
Qiagen (Hilden, 
Germany) 
siRNAs 1-4 were purchased by Eurofins MWG Operon (Ebersberg, Germany) 
 
3.1.4 Primers 
Target Forward/reverse Sequence (5’→3’) 
Hsc70 forward GGA GCC AGG CCT ACA CCC CA 
Hsc70 reverse GAC CTT GGG CCT GCC AGC AT 
Hsp70 forward TCA CCA ACG ACA AGG GCC GC 
Hsp70 reverse ACA GCA ATC TTG GAA AGG CCC C 
Hsp90α forward CAA GAC CAA CCG ATG GAG G 
Hsp90α reverse ACC AGC CTG CAA AGC TTC C 
GAPDH forward CAA GGT CAT CCA TGA CAA CTT TG 
GAPDH reverse GTC CAC CAC CCT GTT GCT GTA G 
All oligonucleotides were purchased by Eurofins MWG Operon (Ebersberg, 
Germany). 
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3.1.5 Equipment 
Name Supplier 
Spectrophotometer SmartSpecTM Plus 
trUViewTM Cuvette 
High Current Supplier PowerPacTM HC 
C100 Thermocycler 
BioRAD (Munich, Germany) 
XCell SureLock™ blot module Life Technologies GmbH (Darmstadt, 
Germany) 
X-Ray film processor ECOMAX™ Protec Medical Systems (Oberstenfeld, 
Germany) 
Gel documentation system Gel iX Imager Intas (Göttingen, Germany) 
FACSCaliburTM 
FACSCantoIITM BD Biosciences (Heidelberg, Germany) 
 
3.1.6. Others 
The chemicals were obtained from Roth (Karlsruhe, Germany), Serva (Heidelberg, 
Germany), BD Pharmigen (Heidelberg, Germany) or Sigma (Deisenhofen, Germany).  
Plastic and glass materials were purchased from Greiner (Frickenhausen, Germany), 
Eppendorf (Hamburg, Germany) and Merck (Darmstadt, Germany). 
 
3.2 Methods 
 
3.2.1 Cell lines and cell culture 
Tumor cell lines A549 and SNB19 were obtained from the American Type Culture 
Collection (Manassas, USA). Human skin fibroblast cell lines HFib1 and HFib2 were 
purchased from Cell Lining GmbH (Berlin, Germany). A summary of characteristics of 
tumor and normal cell lines is presented in Table 7. Cell culture media and reagents 
were obtained from PAA Laboratorie GmbH (Pasching, Austria).  
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Table 7. Short characteristics of used cell lines 
Cell line Cell type Origin Characteristics 
A549 human lung 
carcinoma 
established from 
explanted lung tumor 
from a 58-year-old man 
hypotriploid; mutations reported 
in genes: CDKN2A, KRAS, 
SMARCA4, STK11 
SNB19 human 
astrocytoma 
established from the 
resection of glioblastoma 
from a 47-year-old man 
hypotriploid; mutations reported 
in genes: CDKN2A, PTEN, 
TP53 
HFib1 human skin 
fibroblast 
established from healthy 
41-year-old woman 
diploid 
HFib2 human skin 
fibroblast 
established from healthy 
32-year-old woman 
diploid 
Mutation status according to Catalogue of Somatic Mutations in Cancer (COSMIC). 
 
Cells were grown at 37oC in a humidified atmosphere of 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM low glucose) supplemented with 10% FCS, 1 mM 
L-glutamine and antibiotics (100 Units/ml penicillin and 100 µg/ml streptomycin). 
Cells were routinely split three times a week to keep the cultures in exponential 
phase. 
 
3.2.2 Drug treatment 
Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 were kindly provided by Novartis 
Institute for Biomedical Research (Basel, Switzerland). Drugs were diluted in DMSO 
and stored at -20oC. Either Hsp90 inhibitor (200 nM) was added to the complete 
growth medium one hour before irradiation and left in CGM for up to 48 hours. 
Control cells were treated in parallel with respective amounts of DMSO as a vehicle 
control. In the experiment with Hsp70 knock-down, the concentration of Hsp90 
inhibitor was reduced to 50 nM. 
 
3.2.3 X-ray irradiation 
Irradiation was performed at room temperature using a 6 MV Siemens linear 
accelerator (Siemens, Concord, USA) at a dose rate of 2 Gy/min. After irradiation, 
cells were kept in a drug-containing CGM for the indicated time until harvest. 
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3.2.4 Cell viability assay 
Cell viability was determined based on the intracellular ATP level with CellTiter-Glo 
Luminescent Cell Viability Assay from Promega (Madison, USA) according to the 
manufacturer’s instructions. Cells were treated for 24 and 48 hours with serial 
dilutions of Hsp90 inhibitors (5 nM - 5 µM) in CGM. The cytotoxicity of each drug was 
determined in at least three quadruplicate experiments. Control samples contained 
the respective amount of DMSO. Mean ATP content data (±SE) were normalized 
against DMSO-treated controls to generate dose response curves and then analyzed 
with the standard four-parameter logistic model (4PLM): 
 
(Eq. 1), 
 
where Y is the cell viability; the abscissa c is drug concentration given in nM; A1 and 
A2 are the upper and lower asymptotes, respectively; IC50 is the 50% inhibitory 
concentration (nM); and p is the Hill slope. 
 
3.2.5 Colony survival assay 
Cell survival curves were generated by a standard colony survival assay (Djuzenova 
et al. 2004). Subconfluent monolayers of control and drug-treated cells were 
irradiated at room temperature with a single radiation dose within range of 0-10 Gy. 
Then, the cells were seeded in Petri dishes according to schema (Table 8) and 
incubated for 10-14 days in normal growth conditions (37oC, 5% CO2). Four 
replicates were carried out for each exposure point. After incubation, the cells were 
fixed and stained with crystal violet. Colonies of at least 50 cells were scored as 
survivors. Mean survival data (±SE) for each individual cell line were fitted to the 
linear quadratic (LQ) model: 
   
( )2exp XXSF β−α−=     (Eq. 2), 
where SF is the survival fraction, X is the radiation dose and α and β are the fitted 
parameters. Calculations and fitting of the curves were done with Origin 8.5 
(Micrococal Software Inc, Northampton, USA). For better comparison, the values of 
plating efficiency (PE), survival fraction at 2 Gy (SF2), radiation dose yielding 10% 
survival (D10) and growth inhibition factor (IF10) were calculated. 
A1-A2 
1 + (c/IC50)p 
+ A2 Y = 
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Table 8. Seeding schema for colony survival assay 
 Amount of seeded cells (pro Petri dish) 
Dose (Gy) A549 SNB19 HFib1 HFib2 
0 500 1000 500 1000 
2 1000 1000 1000 2000 
3 1000 2000 1000 2000 
5 2000 2000 10000 10000 
7 2000 5000 15000 20000 
8 5000 5000 20000 20000 
 
3.2.6 Cell lysates 
Subconfluent monolayers of non-treated and drug-treated cells were irradiated at 
room temperature with a single dose (2 or 8 Gy). After that, the samples, together 
with non-irradiated controls, were cultivated in the drug-containing medium. Thirty 
minutes, 24 hours and 48 hours post IR, floating cells were collected and the 
adherent cells were trypsinized according to standard procedures. After washing it 
with PBS, the pellet was lysed in the RIPA buffer supplemented with protease and 
phosphatase inhibitors for 30 minutes on ice. After this time the probes were 
centrifuged (12 min, 12000 rpm, 4°C) and supernatants were collected for storage at 
-20oC until analysis. 
 
3.2.7 Western blot 
Protein concentration in cell lysates was determined by DC Protein Assay Kit from 
BioRAD (Munich, Germany). Samples equivalent to 5-40 µg of protein were 
separated using SDS-PAGE and transferred to nitrocellulose membranes according 
to manufacturer’s prescriptions (Life Technologies GmbH, Darmstadt, Germany). For 
protein detection, the membrane was incubated with the respective primary antibody 
(Table 4) in the blocking buffer overnight at +4oC. After washing steps, the incubation 
with the species-specific peroxidase-labeled secondary antibody (Table 5) followed. 
Home made ECL reaction enabled detection of selected proteins (3.1.2). Levels of 
protein expression were quantified using the ImageJ (Wane Rasband, NIH, USA) 
and normalized to the β-actin levels.  
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3.2.8 Detection of histone γH2AX expression and cell cycle phase distribution 
by flow cytometry  
Non-treated and drug-treated cell cultures were irradiated with a single dose (2 or 8 
Gy) at room temperature. Afterwards, cells were incubated in the drug-containing 
medium under standard conditions and analyzed by flow cytometry 30 minutes, 1 day 
and 2 days after IR. For analysis, floating cells were collected and the adherent cells 
were trypsinized. After washing them twice with PBS, the samples were fixed 30 
minutes, 24 and 48 hours post IR and stained with anti-γH2AX antibody (Table 6) for 
DNA double strand breaks (Muslimovic et al. 2008). For the cell cycle analysis the 
samples were counterstained with propidium iodide (Djuzenova et al. 1994). At least 
20,000 cells were assayed for histone γH2AX expression and cell cycle distribution 
using a flow cytometer FACSCalibur or FACSCantoII (BD Biosciences, Heidelberg). 
In fibroblast samples, we additionally analyzed the extent of hypodiploid cells and 
cellular debris (PI in logarithmic scale). HIstograms were analyzed using WinMDI 
obtained from J. Trotter (Scripps Research Institute, La Jolla, USA) and ModFit LT 
(Verity Software House, Topsham, USA). 
 
3.2.9 siRNA transfection  
Prior to transfection, cells were seeded in 6-well plates (2x105 cells/well) or petri 
dishes (1x106 cells/dish) and were incubated overnight under normal growth 
conditions. HiPerfect Transfection Reagent (Qiagen, Hilden, Germany) was used, as 
recommended by the manufacturer. Cells were transfected with 100 nM siRNA for 
transfection with Hsp70 siRNA or Hsc70 siRNA (sequences in 3.1.3). 
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 A549 
 Light microscopy Fluorescent microscopy 
24 h 
  
48 h 
  
 SNB19 
 Light microscopy Fluorescent microscopy 
24 h 
  
48 h 
  
Figure 10 Representative photographs from light (on the left) and fluorescent (on the 
right) microscopy of tumor cell lines A549 and SNB19 transfected with non-silencing 
control siRNA coupled with Alexa488. Twenty four and forty eight hours after 
transfection, cells were trypsinized and analyzed under epifluorescence microscope. 
 
For simultaneous Hsc70/Hsp70 the cells were transfected with 50 nM of each target 
specific siRNA. 25 nM non-silencing siRNA (Qiagen, Hilden, Germany) served as 
negative control (referred to henceforth as control siRNA). As a positive control we 
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used siRNA targeting MAP kinase (Qiagen, Hilden, Germany). To control the 
transfection efficiency we used negative control siRNA coupled with Alexa488 
(Qiagen, Hilden, Germany) and examined the cells (Fig. 10) under Leica DMLB 
epifluorescence microscope coupled with CCD camera (Olympus Europa GmbH, 
Hamburg, Germany). As seen in Figure 10, nearly 100% of A549 and SNB19 cells 
were successful transfected with non-silencing siRNA. 
 
3.2.10 RT-PCR 
Cells pre-silenced with specific siRNA and non-transfected controls were trypsinized 
24 or 48 hours after transfection. Cell pellets were used for total RNA isolation by SV 
Total RNA Isolation Kit (Promega, Madison, USA) according to the manufacturer’s 
protocol. This system incorporates the DNase digestion step and yields up to 50 µg 
RNA that was stored at -70oC. Isolated RNA was used to generate cDNA with First 
Strand cDNA Synthesis Kit (Fischer Scientific GmbH, Schwerte, Germany) using 
random hexamer primers and M-MuLV Reverse Transcriptase (see Table 9). cDNA 
coding the housekeeping gene GAPDH was amplified as control. Using specific 
primers and GoTaq® PCR Core System (Promega, Madison, USA) Hsp70, Hsc70 
and Hsp90α genes were amplified (Table 9). The amount of MgCl2 and the number 
of reaction cycles was optimized for each PCR product. PCR products were analyzed 
by agarose gel electrophoresis. Levels of mRNA were quantified using ImageJ 
(Wane Rasband, NIH, USA) and normalized to GAPDH le
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Table 9. PCR reaction conditions 
cDNA synthesis - mastermix PCR conditions 
5x reaction buffer 
RiboLockTM RNase inhibitor 
10 mM dNTP mix 
M-MuLV Reverse transcriptase 
total RNA 
random hexamer primer 
H2O 
4 µl 
1 µl 
2 µl 
2 µl 
0.1-5 µg 
1 µl 
to 20 µl 
5 min, 25oC 
60 min, 37oC 
5 min, 70oC 
GoTaq® PCR - mastermix PCR conditions 
25 mM MgCl2 
5x Green GoTaq® Flexi Buffer 
10 mM PCR Nucleotide Mix 
forward primer 
reverse primer 
5 U/µl GoTaq® DNA polymerase 
cDNA 
H2O 
2-8 µl 
10 µl 
1 µl 
5-50 pmol 
5-50 pmol 
0.25 µl 
0.5-1 µg 
to 50 µl 
2 min, 95oC (1 cycle) 
30 s, 95oC  
15 s, 58oC       (25-35 cycles) 
30 s, 72oC 
5 min, 72oC (1 cycle) 
 
3.2.11 Cell growth after transfection  
Cells were seeded in 12-well plates (1x105 cells/well) and transfected with non-
silencing siRNA, Hsp70 siRNA, Hsc70 siRNA, or both siRNAs simultaneously. 
Samples that were non-transfected or incubated with only HiPerfect Transfection 
Reagent (Qiagen, Hilden, Germany) served as controls. Control and transfected cells 
were trypsinized 24, 48, 72 and 96 hours after transfection. Cell numbers were 
determined by counting in haemocytometer every day up to 96 hours after 
transfection. 
 
3.2.12 BrdU incorporation assay 
Twenty four hours after irradiation control, transfected and drug-treated cell samples 
were incubated with 5-bromo-2'-deoxyuridine (BrdU) for one hour and stored at -80oC 
until staining. Thawed cells were stained according to BrdU Flow Kit Staining 
Protocol (BD Pharmigen, Heidelberg, Germany) with FITC-conjugated anti-BrdU 
antibody and analyzed for the DNA synthesis frequency using FACSCalibur flow 
cytometer (BD Biosciences, Heidelberg, Germany). Together with BrdU-FITC 
staining, we stained the DNA with 7-AAD dye to enable the analysis of cell cycle 
progression. Output data presented as dot blots were analyzed using WinMDI 
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obtained from J. Trotter (Scripps Research Institute, La Jolla, USA) and ModFit LT 
(Verity Software House, Topsham, USA).  
 
3.2.13 Statistics 
Data are presented as means (±SD or ±SE). Mean values were compared by the 
Student’s t-test. The threshold of statistical significance was set at p < 0.05.
Statistics and fitting of experimental curves were performed with Origin 8.5 
(Micrococal Software Inc., Northampton, USA). 
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4. Results 
 
4.1 Effects of NVP-AUY922 and NVP-BEP800 on radiation response 
of lung carcinoma A549 and glioblastoma SNB19 cell lines 
 
Previous studies with various Hsp90 inhibitors (e.g. geldanamycin, 17-DMAG) 
showed that Hsp90 inhibition can sensitize cancer cells to irradiation (Russell et al. 
2003, Koll et al. 2004, Bull et al. 2008). Recent findings in our group demonstrated 
that the Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 added 24 hours before 
irradiation can radiosensitize tumor cell lines under normoxic (Stingl et al. 2010) as 
well as under hypoxic conditions (Djuzenova et al. 2012).  
 
A) drug-first treatment (Stingl et al. 2010) 
 
 
 
B) simultaneous drug-IR treatment (Niewidok et al. 2012) 
 
 
 
Figure 11. Comparison of treatment schedules used in the combination studies with 
Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 and irradiation, (A) drug-first 
treatment and (B) simultaneous drug-IR treatment. 
 
In the first experimental part of the thesis we investigated the importance of the 
sequence of Hsp90 inhibition and irradiation on the radiosensitivity of A549 and 
SNB19 tumor cell lines. In contrast to the drug-first treatment used in report from 
Sting et al. 2010 (Fig. 11A), here we added the Hsp90 inhibitors shortly before IR and 
kept up to 48 hours thereafter (Fig. 11B).  
Cell seeding Treatment with Hsp90 inhibitor 
Removal of 
the drug & 
irradiation 
24 h 
Analysis 
Cell seeding Treatment with 
Hsp90 inhibitor 
1 h 
Irradiation 
Incubation in drug-
containing medium 
 & analysis 
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4.1.1 Cytotoxicity of Hsp90 inhibitors to tumor cells 
 
First, we determined the cytotoxic potential of NVP-AUY922 and NVP-BEP800. To 
this end, cell lines A549 and SNB19 were treated with either Hsp90 inhibitor over a 
concentration range from 10 nM to 5 µM and incubated in the drug-containing 
medium for 24 and 48 hours. Then, the cell viability was assessed with ATP-based 
assay as described in the section 3.2.4. Cellular ATP levels were normalized against 
DMSO-treated controls, plotted versus drug concentration and fitted to the 4PLM 
model (Fig. 12). 
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Figure 12. Changes of intracellular ATP levels in A549 (A) and SNB19 (B) cell lines. 
Samples were treated with serial dilutions of NVP-AUY922 (red triangles) and NVP-
BEP800 (blue circles) for 24 or 48 hours (open and filled symbols respectively). Data 
from at least three experiments were averaged and normalized against DMSO-
treated controls. ATP levels (±SE) are given as a percentage to the corresponding 
controls. The vertical, dashed line indicates the concentration of 200 nM, which was 
used for further experiments (modified from Niewidok et al. 2012 with kind permission 
from Neoplasia Press).  
 
As evident from Figure 12, ATP content depends on the drug concentration and on 
the duration of the drug treatment. The cell viability decreased with increasing 
concentration of each Hsp90 inhibitor 24 hours post treatment. Forty-eight hour 
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incubation shifted the dose-response curve of A549 and SNB19 cell lines toward 
lower drug concentrations (Fig. 12). Intermediate concentrations of NVP-AUY922 
were more toxic to A549 (the ATP level ≈ 0.2 a.u.) than to SNB19 cells (ATP ≈ 0.45 
a.u.). For further experiments, the working concentration of 200 nM of NVP-AUY922 
or NVP-BEP800 was chosen. In both tested cell lines, 24-hour long incubation with 
such concentration of either Hsp90 inhibitor reduced the cell ATP content to ~0.8 a.u. 
The exposure for 48 hours to 200 nM NVP-AUY922 further decreased the ATP 
content in A549 to ~0.3 a.u. and on SNB19 to ~0.4 a.u. The cell viability after 48-hour 
incubation with 200 nM NVP-BEP800 dropped to ~0.5 a.u. in lung carcinoma and to 
~0.6 a.u. in glioblastoma samples (Fig. 12). 
 
4.1.2 Colony survival of irradiated A549 and SNB19 cells after treatment with 
NVP-AUY922 and NVP-BEP800 
 
Control and drug-treated lung carcinoma A549 and glioblastoma SNB19 cell lines 
were irradiated with a single dose up to 10 Gy and kept in culture for 30 minutes, 24 
hours or 48 hours until plated for colony-forming assay (3.2.5). Normalized cell 
survival responses were plotted versus the radiation dose as shown in Figure 13. 
Experiments were repeated at least three times and the following parameters were 
calculated: plating efficiency of non-irradiated samples, surviving fraction at 2 Gy 
(SF2), radiation dose resulting in 10% survival (D10) and growth inhibition factor IF10 
(Table 10). 
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Figure 13. Representative clonogenic survival curves of A549 (A) and SNB19 (B) cell 
lines. Cells were treated with DMSO (black squares), NVP-AUY922 (red circles) or 
NVP-BEP800 (blue triangles), irradiated one hour later with single dose and plated 
for colony-forming assay at indicated time point. After staining and scoring the 
colonies, the cell survival curves were generated. The experiment was repeated at 
least three times. Significant differences between controls and cells treated with 
Hsp90 inhibitor are indicated *p < 0.05, **p < 0.01 (reproduced from Niewidok et al. 
2012 with kind permission from Neoplasia Press). 
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Table 10. Plating efficiencies and radiosensitivity parametersa of drug-treated and 
irradiated cancer cell lines A549 and SNB19 (reproduced from Niewidok et al. 2012 
with kind permission from Neoplasia Press). 
 
 PE SF2 b D10 c (Gy) IF10 d 
A549 
30 minutes post radiation 
DMSO 0.4±0.1 0.59±0.1 6.1 1.0 
NVP-AUY922 0.4±0.1 0.55±0.1 5.6 1.1 
NVP-BEP800 0.4±0.1 0.60±0.1 5.9 1.1 
24 hours post radiation 
DMSO 0.5±0.2 0.61±0.1 6.2 1.0 
NVP-AUY922 0.2±0.1 0.65±0.2 6.4 1.0 
NVP-BEP800 0.3±0.2 0.54±0.2 5.6 1.1 
48 hours post radiation 
DMSO 0.4±0.07 0.60±0.2 6.9 1.0 
NVP-AUY922 0.06±0.02 0.73±0.2 7.6 0.9 
NVP-BEP800 0.1±0.06 0.72±0.2 7.1 1.1 
SNB19 
30 minutes post radiation 
DMSO 0.1±0.03 0.56±0.2 5.7 1.0 
NVP-AUY922 0.1±0.03 0.50±0.2 5.0 1.1 
NVP-BEP800 0.08±0.0 0.71±0.2 6.7 0.9 
24 hours post radiation 
DMSO 0.09±0.01 0.76±0.2 7.6 1.0 
NVP-AUY922 0.03±0.01 0.45±0.3 4.5 1.9 
NVP-BEP800 0.06±0.01 0.58±0.2 4.9 1.5 
48 hours post radiation 
DMSO 0.1±0.09 0.72±0.2 8.0 1.0 
NVP-AUY922 0.03±0.02 0.30±0.1 3.9 2.0 
NVP-BEP800 0.06±0.05 0.23±0.2 3.0 3.2 
    a
 Mean (±SD) from at least three independent experiments 
    b
 SF2 is the surviving fraction at 2 Gy 
    c
 D10 is the radiation dose resulting in 10% cell survival 
    d
 IF10 was calculated as (D10 control)/(D10 inhibitor) 
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The changes of plating efficiency of non-irradiated cells indicate the possible 
cytotoxic and/or anti-proliferative effects of Hsp90 inhibitors. Table 10 shows that the 
PE values of both cell lines decreased with increasing incubation time in the drug-
containing medium. Forty-eight-hour treatment with NVP-AUY922 reduced the PE of 
A549 cells from 0.4 to 0.06, whereas incubation with NVP-BEP800 changed it from 
0.4 to 0.1. In the case of SNB19, the plating efficiency diminished from 0.1 to 0.03 for 
NVP-AUY922 and to 0.06 for NVP-BEP800 (48 hours after drug treatment). 
Treatment with NVP-AUY922 or NVP-BEP800 did not influence the radiation 
response of A549 cells throughout the whole range of incubation times (0.5-48 
hours). The dose-response curves of treated cells overlap with the control curves; 
accordingly, there were no changes in the SF2 and D10 values (compare Table 10; 
SF2≈ 0.65±0.2 and D10≈ 6.6±1.0). In contrast, Hsp90 inhibition in SNB19 cells 
sensitized them significantly to ionizing radiation (Fig. 13B). The longer the 
incubation with either NVP-AUY922 or NVP-BEP800, the more sensitive 
glioblastoma cells were to IR. In concordance, the SF2 values decreased from 0.7 in 
the DMSO control to 0.3 for NVP-AUY922 and to 0.23 for NVP-BEP800 48 hours 
post drug-IR treatment (Table 10).  
 
4.1.3 Influence of Hsp90 inhibition and IR on the expression of Hsp90 clients 
and apoptotic marker proteins in tumor cells 
 
Sub-confluent A549 and SNB19 cell cultures were treated with 200 nM NVP-AUY922 
or NVP-BEP800 one hour before irradiation. Cell lysates were prepared according to 
protocol (3.2.6) and the samples were probed for the expression of various proteins. 
Firstly, we tested examined the expression of Hsp90, Hsp70, Akt, Raf-1 and survivin 
at different time points after drug-only, IR-only or combined drug-IR treatment. 
Representative results are shown in Figures 14 and 15; protein expression was 
quantified by the protein/actin ratios given in arbitrary units.  
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Figure 14. Expression of Hsp90, Hsp70, Akt, Raf-1 and survivin in A549 cells. 
Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated 
(with 2 or 8 Gy). Each protein band was normalized to β-actin and the ratios are 
given in numbers (reproduced from Niewidok et al. 2012 with kind permission from 
Neoplasia Press). 
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Figure 15. Expression of Hsp90, Hsp70, Akt, Raf-1 and survivin in SNB19 cells. 
Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated 
(with 2 or 8 Gy). Each protein band was normalized to β-actin and the ratios are 
given in numbers (reproduced from Niewidok et al. 2012 with kind permission from 
Neoplasia Press). 
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NVP-AUY922 or NVP-BEP800 alone did not change the expression of analyzed 
proteins 30 minutes after treatment compared with DMSO-treated control cells (Figs. 
14, 15). Twenty four and forty eight hours after drug-only treatment we observed an 
increase in the expression of heat shock proteins Hsp90 and Hsp70 in lung 
carcinoma cells (Fig. 14, Hsp90: 0.5 -> 0.7 a.u., Hsp70: 0.6 -> 1.0 a.u., 48 hours post 
NVP-AUY922 treatment). Exposure for 48 hours to either Hsp90 inhibitor induced the 
down-regulation of Akt (from 0.8 to 0.4 a.u.) and the depletion of Raf-1 (from 0.8 to 
~0 a.u.) in A549 samples. Moreover, the treatment with NVP-AUY922 reduced the 
expression of survivin (from 1.6 to 1.2 a.u.). 
Irradiation with 2 Gy of DMSO-treated cells resulted in no changes in the expression 
of Hsp90, Hsp70, Akt and Raf-1. At the same time we observed a decrease in the 
amount of survivin (from 1.0 to 0.7 a.u.). When the radiation dose increased to 8 Gy, 
there were no changes in the levels of Hsp90, Hsp70, Akt and survivin, whereas Raf-
1 was down-regulated by ~50% (from 0.8 to 0.4 a.u.). The combination of irradiation 
with Hsp90 inhibition in A549 cells triggered no additional changes in the expression 
of studied marker proteins (Hsp90, Hsp70, Akt, and Raf-1), with the exception of 
survivin, whose expression decreased 48 hours after NVP-AUY922-IR treatment 
(Fig. 14).  
Alterations in the expression of chosen proteins in SNB19 (Fig. 15) resembled the 
changes observed in lung carcinoma cells. The induction of heat shock proteins was 
greater than in A549 (48 hours post NVP-AUY922-IR treatment), for Hsp90 from 0.7 
to 1.2 a.u., and Hsp70 from 0.7 to 1.3 a.u. In contrast, we observed weaker reduction 
of Akt in SNB19 (1.4 to 1.0 a.u.) than in A549 cells. Another difference between the 
cell lines was the expression of survivin, whose expression remained constant in 
glioblastoma samples independent from the applied treatment. Furthermore, the 
administration of NVP-AUY922 for 48 hours caused Raf-1 to vanish, whereas NVP-
BEP800 only partially depleted this protein (from 0.6 to 0.3 a.u.) in SNB19 cells (Fig. 
15). 
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Figure 16. Expression of k-RAS, PTEN and two subunits of PI3K in A549 cells. 
Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated 
(with 2 or 8 Gy). Each protein band was normalized to β-actin and the ratios are 
given in numbers (modified from Niewidok et al. 2012 with kind permission from 
Neoplasia Press).  
 
Contrasting results from the colony-forming assay prompted us to look closer at the 
differences between A549 and SNB19 cell lines. After database research for 
mutations we identified p53, k-RAS and PTEN (Table 7, chapter 3.2.1) as potential 
key regulators of the cellular response. Therefore, we tested A549 and SNB19 
samples for the expression of these oncoproteins and some of their downstream 
targets after combined drug-IR treatment (Figs. 16-21).  
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Figure 17. Expression of k-RAS, PTEN and two subunits of PI3K in SNB19 cells. 
Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated 
(with 2 or 8 Gy). Each protein band was normalized to β-actin and the ratios are 
given in numbers (modified from Niewidok et al. 2012 with kind permission from 
Neoplasia Press). 
 
Forty-eight-hour exposure of A549 cells to NVP-AUY922 (with or without IR) down-
regulated k-RAS (0.6 -> 0.1 a.u.), whereas NVP-BEP800 had to be combined with IR 
to decrease the level of this protein (Fig. 16). At the same time, the expression level 
of k-RAS in glioblastoma samples remained unchanged, independent from the 
applied drug-IR treatment (Fig. 17). 
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Figure 18. Expression of p53, MDM2, p16, p19ARF and p21Waf1 in A549 cells. 
Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated 
(with 2 or 8 Gy). Each protein band was normalized to β-actin and the ratios are 
given in numbers (modified from Niewidok et al. 2012 with kind permission from 
Neoplasia Press). 
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Figure 19. Expression of p53, MDM2, p16, p19ARF and p21Waf1 in SNB19 cells. 
Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated 
(with 2 or 8 Gy). Each protein band was normalized to β-actin and the ratios are 
given in numbers (modified from Niewidok et al. 2012 with kind permission from 
Neoplasia Press). 
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The incubation of A549 samples with NVP-AUY922 (independent from IR) for 48 
hours induced the down-regulation of cell cycle inhibitors p16 (0.2 -> 0.0 a.u.) and 
p21Waf1 (1.0 -> 0.7 a.u.), but not of p19ARF (Fig. 18). In SNB19 the expression of p16 
was under the detection level. At the same time, NVP-AUY922 slightly up-regulated 
the levels of p19 (0.6 -> 0.8 a.u.), whereas the amount of p21Waf1 decreased (0.9 -> 
0.4 a.u.; Fig. 19). 
 
 
Figure 20. Expression of Bcl-xL, caspase 3 and PARP in A549 cells. Samples were 
treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 Gy). 
Each protein band was normalized to β-actin and the ratios are given in numbers 
(modified from Niewidok et al. 2012 with kind permission from Neoplasia Press). 
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Figure 21. Expression of Bcl-xL, caspase 3 and PARP in SNB19 cells. Samples 
were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 
Gy). Each protein band was normalized to β-actin and the ratios are given in 
numbers (modified from Niewidok et al. 2012 with kind permission from Neoplasia 
Press). 
 
Forty-eight-hour incubation with NVP-AUY922 down-regulated the expression of anti-
apoptotic protein Bcl-xL in A549 cells (0.9 -> 0.4 a.u.; Fig. 20), whereas in SNB19 its 
level did not change (Fig. 21). Furthermore, in lung carcinoma we observed signs of 
apoptosis, in the form of decreased amount of caspase 3 (0.7 -> 0.1 a.u.) and PARP 
cleavage (48 hours post NVP-AUY922-IR, Fig. 20). At the same time, in glioblastoma 
cells caspase 3 and PARP levels remained at the level of control samples (Fig. 21). 
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4.1.4 Effects of Hsp90 inhibition and irradiation on the induction and repair of 
DNA damage in A549 and SNB19 cells 
 
One of the reasons for the radiosensitization could be the higher amount of DNA 
damage or the impairment of DNA damage repair pathways. As a marker for DNA 
damage we measured the expression of phosphorylated H2AX (γH2AX), which is 
one of the earliest events after DNA double strand break. A549 and SNB19 cell 
samples were drug-treated and irradiated (as described in section 3.2.8). Thirty 
minutes, 24 hours and 48 hours after IR the cells were fixed in ice-cold ethanol and 
stained with anti-γH2AX antibody. Representative histograms are shown in Figure 
22.  
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Figure 22. Histograms showing distribution of γH2AX, as a marker of DNA double 
strand breaks, in A549 (A) and SNB19 (B) cells. DMSO-treated controls and samples 
treated with NVP-AUY922 or NVP-BEP800 were irradiated with single dose (8 Gy, 
black histograms) and incubated in the drug-containing medium for indicated time. 
Gray histograms represent corresponding non-irradiated samples. Numbers denote 
the mean γH2AX expression for the respective cell sample. The vertical, dashed line 
marks the γH2AX value of DMSO-treated, non-irradiated control (reproduced from 
Niewidok et al. 2012 with kind permission from Neoplasia Press). 
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As shown in Figure 22, the background expression level of γH2AX was similar in 
control samples of A549 and SNB19 (Fig. 22A, B). Thirty minutes after irradiation 
with 8 Gy, the amount of γH2AX increased from 30 to 73 a.u. in A549 cells (Fig. 22A) 
and in SNB19 from 22 to 113 a.u. (Fig. 22B). After one day, the IR-induced DNA 
damage in lung carcinoma A549 cells was restored to background level (from 73 to 
30 a.u.). In contrast, SNB19 only partially repaired the damage (from 113 to 54 a.u.). 
Prolonging the time of incubation to 48 hours post IR did not further affect the γH2AX 
expression in both cell lines. 
Thirty-minute incubation with either Hsp90 inhibitor alone induced no or few changes 
in the level of DNA damage in both examined cell lines (Fig. 22A, B; first row, gray 
histograms). The extension of incubation time to 24 and 48 hours also did not 
influence the γH2AX expression in A549 cells. As opposed to A549, longer exposure 
of glioblastoma cells to NVP-AUY922 increased the amount of the γH2AX three-fold 
(to 72 a.u.) and to NVP-BEP800 even four-fold (to 103 a.u.) when compared with 
DMSO-treated controls (Fig. 22B).  
The combination of each Hsp90 inhibitor and irradiation induced the accumulation of 
γH2AX from 31-36 a.u. for drug-treated, non-irradiated A549 cells to 93-94 a.u. for 
the combined drug-IR treatment (Fig. 22A, first row, black histograms). One and two 
days later the expression of γH2AX was restored to background level, suggesting 
that DNA damage repair pathways functioned efficiently. In glioblastoma samples, 
the combined drug-IR treatment (Fig. 22B, first row) increased the γH2AX amount 
four to five times (113-127 a.u.) compared with drug-treated cells (24-25 a.u.). 
Interestingly, SNB19 cells seemed to be unable to repair the DNA damage; 24 and 
48 hours after drug-IR treatment the γH2AX levels remained elevated (for NVP-
AUY922) or even further increased with time (for NVP-BEP800). 
In addition to γH2AX measurements, we tested the expression of the proteins playing 
important role in DNA DSB repair (Fig. 23 and 24). 
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Figure 23. Expression of Rad50, Ku70 and Ku80 in A549 cells. Samples were 
treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 Gy). 
Each protein band was normalized to β-actin and the ratios are given in numbers 
(reproduced from Niewidok et al. 2012 with kind permission from Neoplasia Press). 
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Figure 24. Expression of Rad50, Ku70 and Ku80 in SNB19 cells. Samples were 
treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 Gy). 
Each protein band was normalized to β-actin and the ratios are given in numbers 
(reproduced from Niewidok et al. 2012 with kind permission from Neoplasia Press). 
 
The combination of Hsp90 inhibition and irradiation did not influence the expression 
of Rad50 (protein forming MRN complex) in tested cell lines (Fig. 23, 24). Thirty 
minutes after drug-IR treatment in A549 cells we detected an increase of Ku80 (1.1 -
> 2.3 a.u. NVP-BEP800-IR), protein playing an important role in non-homologous end 
joining (Fig. 23). After 2 days the levels of Ku80 dropped to a level below control 
samples. There were no significant changes in the expression of Ku70 and Ku80 in 
glioblastoma cells throughout the time of experiments (Fig. 24). 
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4.1.5 Changes in the cell cycle progression after Hsp90 inhibition and 
irradiation in tumor cell lines A549 and SNB19 
 
Simultaneously, with the measurements of γH2AX expression, we analyzed the cell 
cycle phase distribution in A549 and SNB19 samples (according to protocol in 3.2.8). 
Representative histograms are shown in Figures 25 and 26 and a statistical summary 
can be found in Tables 11 and 12. 
Thirty minutes after irradiation only, we observed no changes in the cell cycle 
distribution in either examined cell line (Fig. 25A, 26A). The radiation-induced 
changes appeared 24 and 48 hours after IR, and in these samples we observed the 
S phase depletion together with an increase in G2/M peak (Figs. 25, 26B, C).  
The administration of each Hsp90 inhibitor alone to A549 and SNB19 samples 
resulted in changes in the cell cycle distribution similar to these seen after irradiation 
alone. Short exposure (30 minutes) to the drug triggered no or little changes (Figs. 
25A, 26A, first row), but 24 and 48 hours incubation shifted the cells from S phase to 
G2/M phase (Figs. 25, 26B, C). 
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Figure 25. Cell cycle distribution of A549 cells treated with DMSO (unfilled 
histograms), NVP-AUY922 (gray histograms) or NVP-BEP800 (black histograms) 
and irradiated (8 Gy). Samples were fixed for staining 30 minutes (A), 24 hours (B) 
and 48 hours (C) post irradiation. The percentage of cells in each phase (G1%-S%-
G2%) and G2/G1 ratio are shown (reproduced from Niewidok et al. 2012 with kind 
permission from Neoplasia Press). 
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Figure 26. Cell cycle distribution of SNB19 cells treated with DMSO (unfilled 
histograms), NVP-AUY922 (gray histograms) or NVP-BEP800 (black histograms) 
and irradiated (8 Gy). Samples were fixed for staining 30 minutes (A), 24 hours (B) 
and 48 hours (C) post irradiation. The percentage of cells in each phase (G1%-S%-
G2%) and G2/G1 ratio are shown. Arrows indicate polyploid cells (reproduced from 
Niewidok et al. 2012 with kind permission from Neoplasia Press). 
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Table 11. Cell cycle distribution in A549 cells detected 30 minutes (A), 24 hours (B) 
and 48 hours (C) after simultaneous drug-IR treatment. Data are presented as 
means (±SD) from at least three independent experiments (reproduced from 
Niewidok et al. 2012 with kind permission from Neoplasia Press). 
 
Dose Treatment G0/G1, % S, % G2/M, % G2/G1 
 
A) 30 minutes post radiation 
0 Gy DMSO 58±6 26±3 16±4 0.3 
 NVP-AUY922 56±5 27±2 18±3 0.3 
 NVP-BEP800 59±5 24±2 18±3 0.3 
8 Gy DMSO 56±6 26±3 18±4 0.3 
 NVP-AUY922 58±6 26±3 16±3 0.3 
 NVP-BEP800 60±5 25±3 16±2 0.3 
 
B) 24 hours post radiation 
0 Gy DMSO 58±1 32±2 10±1 0.2 
 NVP-AUY922 42±8 7±3 52±11 1.2 
 NVP-BEP800 48±7 21±6 31±12 0.6 
8 Gy DMSO 61±5 12±3 27±6 0.4 
 NVP-AUY922 48±2 2±0 50±2 1.0 
 NVP-BEP800 54±7 5±2 41±9 0.8 
 
C) 48 hours post radiation 
0 Gy DMSO 77±4 13±3 10±1 0.1 
 NVP-AUY922 44±7 6±4 51±12 1.1 
 NVP-BEP800 52±14 11±1 38±14 0.7 
8 Gy DMSO 70±5 5±1 25±5 0.4 
 NVP-AUY922 48±2 2±2 50±3 1.0 
 NVP-BEP800 50±9 5±1 44±9 1.1 
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Table 12. Cell cycle distribution in SNB19 cells detected 30 minutes (A), 24 hours (B) 
and 48 hours (C) after simultaneous drug-IR treatment. Data are presented as 
means (±SD) from at least three independent experiments (reproduced from 
Niewidok et al. 2012 with kind permission from Neoplasia Press). 
 
Dose Treatment G0/G1, % S, % G2/M, % G2/G1 
 
A) 30 minutes post radiation 
0 Gy DMSO 41±4 30±4 29±2 0.7 
 NVP-AUY922 42±3 31±2 27±2 0.7 
 NVP-BEP800 42±4 29±3 29±2 0.7 
8 Gy DMSO 39±4 30±3 30±2 0.8 
 NVP-AUY922 40±5 31±4 28±3 0.7 
 NVP-BEP800 43±3 30±4 26±2 0.6 
 
B) 24 hours post radiation 
0 Gy DMSO 55±4 24±2 21±2 0.4 
 NVP-AUY922 34±3 11±1 54±2 1.4 
 NVP-BEP800 48±2 15±1 36±2 0.7 
8 Gy DMSO 47±5 7±1 46±6 0.9 
 NVP-AUY922 19±5 13±2 68±5 3.5 
 NVP-BEP800 15±3 14±3 71±4 4.9 
 
C) 48 hours post radiation 
0 Gy DMSO 72±3 10±1 18±2 0.3 
 NVP-AUY922 44±4 2±2 54±2 1.3 
 NVP-BEP800 20±3 32±3 48±1 2.4 
8 Gy DMSO 38±5 16±0 45±5 1.3 
 NVP-AUY922 20±5 5±1 74±5 4.6 
 NVP-BEP800 5±1 20±1 74±2 14.2 
 
The combination of NVP-AUY922 or NVP-BEP800 with irradiation did not affect the 
cell cycle distribution of A549 samples when compared with drug or IR alone. 
Interestingly, SNB19 responded with a significant increase in G2/M peak and a 
higher amount of cells with hyperdiploid DNA content after combined drug-IR 
treatment (Fig. 26B, C). The very high G2/M-to-G1 ratio (Table 12, G2/G1=14.2) of 
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NVP-BEP800-treated and irradiated SNB19 cells suggested an additive effect of 
combined treatment (Fig. 26B, C). 
 
4.1.6 Influence of Hsp90 inhibition and IR on the expression of cell cycle-
related proteins in tumor cell lines A549 and SNB19 
 
Among Hsp90 clients are proteins regulating the progression of the cell cycle, 
therefore we analyzed the expression of several marker proteins including Cdk1, 
Cdk4 and pRb (Figs. 27, 28). 
 
Figure 27. Expression of Cdk1, Cdk4 and pRb in A549 cells. Samples were treated 
with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 Gy). Each 
protein band was normalized to β-actin and the ratios are given in numbers 
(reproduced from Niewidok et al. 2012 with kind permission from Neoplasia Press).
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Figure 28. Expression of Cdk1, Cdk4 and pRb in SNB19 cells. Samples were treated 
with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 Gy). Each 
protein band was normalized to β-actin and the ratios are given in numbers 
(reproduced from Niewidok et al. 2012 with kind permission from Neoplasia Press). 
 
Irradiation alone triggered a significant decrease in the level of pRb 24 hours after IR 
(0.8 -> 0.1 a.u.), but did not influence the expression of cyclin-dependent kinases in 
lung carcinoma cells (Fig. 27). Twenty-four-hour treatment of A549 with NVP-
AUY922 or NVP-BEP800 alone induced the down-regulation of Cdk4 (0.6 -> 0.3 a.u.) 
and pRb (0.8 -> 0.5 a.u.), but not Cdk1. In SNB19, pRb (0.5 -> 0.2 a.u.) and Cdk4 
(1.0 -> 0.7 a.u.) were also down-regulated (Fig. 28), but to a lesser extent than in 
A549 cells. In contrast, the Hsp90 inhibitors caused the depletion of Cdk1 (0.7 -> 0 
a.u.) in SNB19 cells. The combined drug-IR treatment induced no additional changes 
in the expression of chosen cell cycle-related proteins in comparison to drug 
treatment alone (Figs. 27, 28).  
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To summarize, data presented in chapter 4.1 showed that simultaneous Hsp90 
inhibition and ionizing radiation may induce radiosensitization or cytotoxicity, 
depending on the cell type. These results confirmed the importance of time schedule 
when the Hsp90 inhibition is combined with radiation therapy. A short 30-minute 
exposure to each Hsp90 inhibitor did not affect the radiosensitivity of the examined 
A549 and SNB19 cells. Longer incubation enhanced the radiation response of 
glioblastoma SNB19 cells, which correlated with an increased amount of DNA 
damage, impairment of DNA damage repair and massive cell cycle alterations. For 
lung carcinoma A549 cells the combined drug-IR treatment was highly cytotoxic. 
Furthermore, we observed the depletion of Hsp90 clients Akt and Raf-1 in both cell 
lines examined, and, additionally, survivin in A549. We analyzed the expression of 
potential oncoproteins, including p53, k-RAS and PTEN, regulating the response of 
the two lines tested.  
We have shown that NVP-AUY922 and NVP-BEP800 are potent agents that, in 
combination with radiation, enhanced the killing of cancer cells in vitro (Stingl et al. 
2010, Djuzenova et al. 2012, Niewidok et al. 2012). These results prompted us to 
further investigate the effects of NVP-AUY922 and NVP-BEP800 on non-malignant 
cells, which will be described in chapter 4.2. In the last chapter (4.3) we have 
evaluated whether Hsp70 pre-silencing could increase the radiosensitizing potential 
of Hsp90 inhibitor NVP-AUY922. 
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4.2 Effects of NVP-AUY922 and NVP-BEP800 on the radiation 
response of normal skin fibroblast strains HFib1 and HFib2 
 
In chapter 4.1 we have shown that Hsp90 inhibition in cancer cells leads to the 
impairment of multiple signaling pathways and, in combination with irradiation 
induces tumor cell killing. Success of Hsp90 inhibition as a multi-target therapy 
depends on the selectivity of the drug towards tumor cells over non-malignant cells. 
Until now, the activity of NVP-AUY922 and NVP-BEP800 has not been tested in non-
malignant tissues. In the second experimental chapter we added either NVP-AUY922 
or NVP-BEP800 shortly before irradiation to the normal human skin fibroblast strains 
HFib1 and HFib2. Exposure to the drug lasted up to 48 hours after radiation, and the 
cellular response of HFib1 and HFib2 to drug only, IR only or combined drug-IR 
treatment was analyzed. The schedule of the experiments was identical with that 
previously described for tumor cell lines A549 and SNB19 (Fig. 11B). 
 
4.2.1 Cytotoxicity of Hsp90 inhibitors to fibroblast cell lines 
 
Firstly, we tested the cytotoxic potential of NVP-AUY922 and NVP-BEP800 on non-
irradiated HFib1 and HFib2 fibroblast strains. Cells were treated with either Hsp90 
inhibitor over a concentration range from 5 nM to 1 µM for 24 and 48 hours. The cell 
viability was determined based on cellular ATP levels (as described in section 3.2.4), 
which were normalized against DMSO-treated cells and are shown in Figure 29. 
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Figure 29. Changes of intracellular ATP levels in HFib1 (A) and HFib2 (B) cell lines. 
Samples were treated with serial dilutions of NVP-AUY922 (red triangles) and NVP-
BEP800 (blue circles) for 24 or 48 hours (open and filled symbols respectively). Data 
from at least three experiments were averaged and normalized against DMSO-
treated controls. ATP levels (±SE) are given as a percentage to the corresponding 
controls. The vertical, dashed line indicates the concentration of 200 nM, which was 
used for further experiments. 
 
NVP-AUY922 was more cytotoxic to both examined fibroblast strains than NVP-
BEP800 (Fig. 29). Twenty-four-hour incubation with NVP-AUY922 at small 
concentrations (5-50 nM) decreased the cell viability to ~0.6 a.u. in HFib1 and HFib2 
cells (Fig. 29). Further increase of NVP-AUY922 concentration (100-5000 nM) did not 
affect the ATP content in either strain examined. Twenty-four-hour exposure to NVP-
BEP800 (concentration range 5-200 nM) did not influence the cell viability of HFib1 
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and HFib2 cells. Increasing the concentration to 500 nM NVP-BEP800 resulted in the 
diminishing of ATP levels in HFib1 and HFib2 strains, reaching ~0.6 a.u. for the 
highest used concentration (5000 nM). 
Further incubation (48 hours) with NVP-AUY922 reduced the ATP levels in fibroblast 
strains, reaching ~0.3-0.4 a.u. already at 50 nM concentration and remaining at this 
level with the increasing concentration (Fig. 29). In the case of NVP-BEP800, small 
concentrations (5-100 nM) of Hsp90 inhibitor caused only moderate reduction of ATP 
content, to ~0.9 a.u. The further increase of NVP-BEP800 concentration led to the 
decrease of viability of HFib1 to ~0.4 a.u. and of HFib2 to ~0.3 a.u. (Fig. 29; 48-hour 
incubation, 5000 nM).  
For further experiments, the working concentration of 200 nM of each Hsp90 inhibitor 
was chosen (Fig. 29). Incubation with 200 nM NVP-AUY922 led to the decrease of 
HFib1 and HFib2 cell viability to ~0.6 a.u. (24 hours) and ~0.3-0.4 a.u. (48 hours). 
Twenty-four-hour exposure to 200 nM NVP-BEP did not influence the ATP levels of 
examined fibroblast strains. Longer incubation with 200 nM NVP-BEP800 resulted in 
decrease of HFib1 and HFib2 cell viability to ~0.9 a.u. 
 
4.2.2 Colony survival of irradiated normal human fibroblast strains HFib1 and 
HFib2 after treatment with NVP-AUY922 and NVP-BEP800 
 
To determine the radiation response of HFib1 and HFib2 cell strains, the samples 
were treated with either NVP-AUY922 or NVP-BEP800 (200 nM), irradiated one hour 
later and seeded out for colony-forming assay 30 minutes, 24 and 48 hours post IR. 
Figure 30 shows the representative normalized survival response of HFib1 cells 
compared with glioblastoma cell line SNB19, tested in the chapter 4.1. The colony 
survival assay of HFib1 and HFib2 cell lines was repeated at least three times and 
the following parameters were calculated with the linear quadratic (LQ) model: PE, 
SF2, D10 and IF10 (Table 13).  
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Figure 30. Representative clonogenic survival of HFib1 (A) and SNB19 (B) cell lines. 
Cells were treated with DMSO (squares), NVP-AUY922 (red circles) or NVP-BEP800 
(blue triangles), irradiated one hour later with single dose and plated for colony-
forming assay at indicated time point. After staining and scoring the colonies, cell 
survival curves were generated. Detailed data for SNB19 cells are presented in 
section 4.1.2. The experiment was repeated at least three times. 
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Table 13. Plating efficiencies and radiosensitivity parametersa of drug-treated and 
irradiated fibroblast strains HFib1 and HFib2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Mean (±SD) from at least three independent experiments 
b
 SF2 is the surviving fraction at 2 Gy 
c
 D10 is the radiation dose resulting in 10% cell survival 
d
 IF10 was calculated as (D10 control)/(D10 inhibitor) 
 PE SF2 b D10 c (Gy) IF10 d 
HFib1  
30 minutes post radiation 
DMSO 0.06±0.05 0.29±0.1 3.6 1.0 
NVP-AUY922 0.06±0.04 0.29±0.1 3.6 1.0 
NVP-BEP800 0.04±0.03 0.45±0.02 4.6 0.8 
24 hours post radiation 
DMSO 0.03±0.01 0.68±0.2 7.3 1.0 
NVP-AUY922 0.02±0.01 0.62±0.1 6.4 1.1 
NVP-BEP800 0.03±0.01 0.62±0.2 6.4 1.1 
48 hours post radiation 
DMSO 0.02±0.02 0.61±0.3 6.0 1.0 
NVP-AUY922 0.02±0.01 0.52±0.2 5.1 1.4 
NVP-BEP800 0.02±0.01 0.51±0.1 6.6 0.8 
HFib2  
30 minutes post radiation 
DMSO 0.05±0.01 0.43±0.3 4.2 1.0 
NVP-AUY922 0.04±0.01 0.37±0.3 3.7 1.1 
NVP-BEP800 0.06±0.02 0.60±0.2 4.9 0.9 
24 hours post radiation 
DMSO 0.02±0.01 0.76±0.1 7.1 1.0 
NVP-AUY922 0.03±0.02 0.42±0.1 5.1 1.3 
NVP-BEP800 0.02±0.01 0.65±0.2 6.8 1.0 
48 hours post radiation 
DMSO 0.04±0.02 0.58±0.1 6.5 1.0 
NVP-AUY922 0.03±0.02 0.69±0.1 5.5 1.3 
NVP-BEP800 0.03±0.01 0.61±0.2 7.4 1.0 
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As seen in Figure 30, the radiation response of drug-treated fibroblasts differed 
strongly from the response of malignant SNB19 cells. Glioblastoma cells were 
sensitized to irradiation 24 and 48 hours after NVP-AUY922 as well as after NVP-
BEP800 treatment (Fig. 30B). Forty-eight-hour exposure to NVP-BEP800 induced 
stronger radiosensitization in SNB19 cells than exposure to NVP-AUY922 (for details 
see section 4.1.2).  
In contrast to previously described tumor cell lines (4.1.2, Table 10), the plating 
efficiency of non-irradiated and drug-treated fibroblast strains did not change (Table 
13). After 48-hour incubation, the PE of HFib1 cells sustained at ~0.02, 
independently from the applied Hsp90 inhibitor. In the case of HFib2 cell line, 48 
hours treatment with NVP-AUY922 and NVP-BEP800 resulted in the decrease of PE 
from ~0.04 to ~0.03 (Table 13). Plating efficiency of glioblastoma cells diminished 2- 
to 3-fold 48 hours after treatment with either Hsp90 inhibitor (Table 10). 
Thirty-minute and twenty-four-hour exposure to either Hsp90 inhibitor did not affect 
the dose-response curves of the examined fibroblast strains (Fig. 30A). Accordingly, 
the calculated values of SF2 or D10 were similar to the corresponding DMSO-treated 
controls. Forty eight hours after NVP-AUY922-IR treatment, HFib1 (Fig. 30A) and 
HFib2 cells were moderately sensitized to irradiation. The D10 value decreased from 
~6.0 to ~5.1 for HFib1 cells and from ~6.5 to ~5.5 for HFib2 respectively (Table 13). 
On the contrary, 48 hours incubation of fibroblasts after NVP-BEP800-IR treatment 
induced some resistance to IR as indicated by the increased D10 values from ~6.0 to 
~6.6 and from ~6.5 to ~7.4 in HFib1 and HFib2 respectively (Table 13). 
The findings presented in Figure 30 and Table 13 showed that the novel Hsp90 
inhibitors NVP-AUY922 and NVP-BEP800 more strongly radiosensitized malignant 
cells compared with normal tissue. Next, we explored the possible mechanism(s) for 
this drug selectivity.  
 
4.2.3 Influence of Hsp90 inhibition and IR on the expression of Hsp90 clients 
and apoptotic marker proteins in fibroblasts 
 
The expression of Hsp90, Hsp70, and several marker proteins involved in the 
regulation of proliferative and apoptotic pathways (Akt, pAkt, Raf-1, survivin, PARP, 
caspase 3 and Bcl-xL) in drug-treated and irradiated HFib1 and HFib2 cells was 
Results 
- 76 - 
 
analyzed. Protein expression was quantified by the protein/actin ratios given in 
arbitrary units and the representative results are shown in Figures 31-34.  
 
 
Figure 31. Expression of Hsp90, Hsp70, Akt, pAkt and Raf-1 in HFib1 cells. Samples 
were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 
Gy). Each protein band was normalized to β-actin and the ratios are given in 
numbers. 
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Figure 32. Expression of Hsp90, Hsp70, Akt, pAkt and Raf-1 in HFib2 cells. Samples 
were treated with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 
Gy). Each protein band was normalized to β-actin and the ratios are given in 
numbers. 
 
A thirty-minute exposure to either NVP-AUY922 or NVP-BEP800 alone did not affect 
the expression of chosen proteins in examined fibroblast strains (Figs. 31-34).
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Further incubation (24 and 48 hours) up-regulated the expression of heat shock 
proteins in HFib1 cells, i.e. 24 hours after NVP-AUY922 treatment from 0.7 to 0.9 a.u. 
for Hsp90 and from 0.2 to 0.5 a.u. for Hsp70 respectively (Fig. 31). 
 
 
Figure 33. Expression of PARP, cleaved PARP, survivin, caspase 3 and Bcl-xL in 
HFib1 cells. Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and 
irradiated (with 2 or 8 Gy). Each protein band was normalized to β-actin and the 
ratios are given in numbers. 
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Figure 34. Expression of PARP, cleaved PARP, survivin, caspase 3 and Bcl-xL in 
HFib2 cells. Samples were treated with DMSO, NVP-AUY922 or NVP-BEP800 and 
irradiated (with 2 or 8 Gy). Each protein band was normalized to β-actin and the 
ratios are given in numbers. 
 
The over-expression of heat shock proteins was also observed in HFib2 cells (i.e. 
Fig. 32, 24 hours post NVP-AUY922 treatment, Hsp90: from 0.8 to 0.9 a.u., Hsp70: 
from 0.4 to 0.7 a.u.). After twenty-four-hour incubation with NVP-AUY922 we 
detected the down-regulation of Akt (HFib1: 1.1 -> 0.1 a.u., HFib2: 2.1 -> 1.8 a.u.), 
pAkt (HFib1: 0.2 -> 0.0 a.u., HFib2: 0.5 -> 0.2 a.u.) and Raf-1 (HFib1: 0.6 -> 0.0 a.u., 
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HFib2: 0.9 -> 0.1 a.u.) in both fibroblast strains (Figs. 31, 32). Depletion of these 
Hsp90 clients (Akt, pAkt and Raf-1) was sustained 48 hours post NVP-AUY922 
treatment. Another Hsp90 client, survivin, was down-regulated 48 hours after NVP-
AUY922 treatment in both examined fibroblast strains (Figs. 31, 32; HFib1: 1.5 -> 1.1 
a.u., HFib2: 0.2 -> 0.1 a.u.). In addition, 48-hour incubation with NVP-AUY922 
induced the cleavage of PARP in HFib1 and HFib2 cells (Figs. 33, 34) which may be 
a sign of ongoing apoptosis. 
The exposure of HFib1 and HFib2 to NVP-BEP800 for 24 and 48 hours led to the 
down-regulation of several marker proteins (Figs. 31, 32). For example, after 24 
hours incubation, the Akt level decreased from 1.1 to 0.3 a.u. in HFib1 and from 2.1 
to 1.9 a.u. in HFib2 samples. Twenty-four-hour treatment with NVP-BEP800 resulted 
in complete depletion of pAkt in HFib1 cells (Fig. 31), whereas it had no impact on 
this protein in HFib2 samples (Fig. 32). At the same time point, Raf-1 was down-
regulated in both fibroblast strains (HFib1: 0.6 -> 0.1 a.u., HFib2: 0.9 -> 0.7 a.u.). The 
expression of survivin remained unchanged independently from the duration of NVP-
BEP800 treatment (Figs. 33, 34). 
As evident from Figures 31-34, thirty-minute incubation after irradiation alone (2 or 8 
Gy) did not induce alterations in the expression of examined marker proteins in 
HFib1 cells. In contrast, in HFib2 samples the expression of PARP (0.9 -> 0.5 a.u.) 
and Bcl-xL (0.2 -> 0.1 a.u.) decreased (Fig. 34, 30 minutes post IR). Prolonging the 
incubation to 24 hours after irradiation in both fibroblast strains decreased the 
expression of survivin (Figs. 33, 34; 24 hours post IR). Additionally, in irradiated 
HFib1 cells we detected increase in the expression of Bcl-xL (Fig. 33, 24 hours post 
IR, 0.2 -> 0.4 a.u.).  
The combination of Hsp90 inhibition with ionizing radiation (2 or 8 Gy) induced no 
additional changes in the protein expression in comparison to these observed after 
Hsp90 inhibition alone (Figs. 31-34). The only exception was the down-regulation of 
the pro-survival protein Bcl-xL 24 and 48 hours post NVP-AUY922-IR treatment in 
both examined fibroblast strains (Figs. 32, 33), indicating the activation of pathway 
leading to cell death. However, the expression of caspase 3 remained unchanged, 
independent from applied drug and IR treatment (Figs. 32, 33). 
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4.2.4. Effects of Hsp90 inhibitors and irradiation on the induction and repair of 
DNA damage in HFib1 and HFib2 cells 
 
As the next step, we evaluated the induction and repair kinetics of DNA double 
strand breaks measured by the expression of histone γH2AX in human skin 
fibroblasts HFib1 and HFib2 after a combination of Hsp90 inhibition and IR. Cell 
samples were fixed at different time points (0.5, 24, 48 hours after IR) and stained 
with anti-γH2AX antibody as described in section 3.2.9. Representative histograms 
are shown in Figure 35.  
The background γH2AX expression was at a similar level in examined fibroblast 
strains, 60 a.u. and 64 a.u. in HFib1 and HFib2 respectively (Fig. 35). Application of 
NVP-AUY922 or NVP-BEP800 alone on HFib1 and HFib2 cells for 30 minutes 
induced no changes in γH2AX expression (Fig. 35, gray histograms). In HFib2 
samples incubated with NVP-AUY922 for 24 hours we observed an increase of 
γH2AX expression from 49 to 68 a.u. Forty eight hours exposure of fibroblasts to 
NVP-AUY922 led to the accumulation of DNA DSBs (HFib1 from 50 to 75 a.u., HFib2 
from 66 to 163 a.u.). In addition, we observed an increase of events with low γH2AX 
expression (~5-6 a.u.) in both fibroblasts strains examined (Fig. 35, 48 hours after 
NVP-AUY922 treatment). Presumably this was cell debris with defragmented DNA, 
coming from cells going through apoptosis. 
Irradiation alone (8 Gy) resulted in an increase of γH2AX expression in HFib1 from 
60 to 105 a.u., in HFib2 from 64 to 126 a.u. compared to non-irradiated controls (Fig. 
35, 30 minutes, black histograms). Measurements at 24 and 48 hours after IR alone 
showed that the amount of irradiation-induced DNA DSBs returned to background 
level, indicating that the DNA damage repair took place. 
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Figure 35. Histograms showing distribution of γH2AX, as a marker of DNA double 
strand breaks, in HFib1 (A) and HFib2 (B) cells. DMSO-treated controls and samples 
treated with NVP-AUY922 or NVP-BEP800 were irradiated with single dose (8 Gy, 
black histograms) and incubated in drug-containing medium for indicated time. Gray 
histograms represent corresponding non-irradiated samples. Numbers denote the 
mean γH2AX expression for the respective cell sample. The vertical, dashed line 
marks the γH2AX value of DMSO-treated, non-irradiated control. 
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Thirty minutes after combined drug-IR treatment (either with NVP-AUY922 or NVP-
BEP800) we observed no additional DNA damage when compared with irradiated 
controls (Fig. 35). Twenty four hours later in both HFib1 and HFib2 cell lines the 
amount of DNA DSBs induced by drug-IR treatment decreased (HFib1: 106 -> 59 
a.u., HFib2: 127 -> 75 a.u. for NVP-AUY922-IR; HFib1: 107 -> 50 a.u., HFib2: 130 -> 
74 a.u. for NVP-BEP800-IR). Prolonging the incubation after NVP-BEP800-IR 
treatment to 48 hours did not further affect the amount of DNA damage in either 
examined fibroblast strain (Fig. 35). In contrast, 48-hour incubation of NVP-AUY922-
treated and irradiated HFib1 cells led to an increase of γH2AX expression, in the 
same way as after drug treatment alone (to 79 a.u.). In HFib2 samples the 
combination of NVP-AUY922 and IR resulted in the accumulation of DNA DSBs to 
~203 a.u. as compared with ~163 a.u. for non-irradiated controls (Fig. 35B, 48 hours 
after NVP-AUY922-IR). 
 
4.2.5 Changes in the cell cycle progression of fibroblast strains HFib1 and 
HFib2 after Hsp90 inhibition and irradiation 
 
Cell probes analyzed for γH2AX expression were counterstained with propidium 
iodide to examine the cell cycle progression (according to protocol in section 3.2.9). 
The representative cell cycle distributions of drug-treated and irradiated HFib1 and 
HFib2 cells 30 minutes, 24 and 48 hours after treatment are shown in Figures 36 and 
37. The statistical summary is presented in Tables 14 and 15.  
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Figure 36. Cell cycle distribution of HFib1 cells treated with DMSO (unfilled 
histograms), NVP-AUY922 (gray histograms) or NVP-BEP800 (black histograms) 
and irradiated (8 Gy). Samples were fixed for staining 30 minutes (A), 24 hours (B) 
and 48 hours (C) post irradiation. The percentage of cells in each phase (G1%-S%-
G2%) and G2/G1 ratio are shown.  
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Figure 37. Cell cycle distribution of HFib2 cells treated with DMSO (unfilled 
histograms), NVP-AUY922 (gray histograms) or NVP-BEP800 (black histograms) 
and irradiated (8 Gy). Samples were fixed for staining 30 minutes (A), 24 hours (B) 
and 48 hours (C) post irradiation. The percentage of cells in each phase (G1%-S%-
G2%) and G2/G1 ratio are shown. 
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Table 14. Cell cycle distribution in HFib1 cells detected 30 minutes (A), 24 hours (B) 
and 48 hours (C) after simultaneous drug-IR treatment. Data are presented as 
means (±SE) from at least three independent experiments. 
 
Dose Treatment G0/G1, % S, % G2/M, % G2/G1 
 
A) 30 minutes post radiation 
0 Gy DMSO 60±6 21±5 17±1 0.3 
 NVP-AUY922 59±5 24±4 18±1 0.3 
 NVP-BEP800 59±5 21±4 18±1 0.3 
8 Gy DMSO 60±5 22±4 16±2 0.3 
 NVP-AUY922 61±7 21±5 17±1 0.3 
 NVP-BEP800 61±8 22±7 16±1 0.3 
 
B) 24 hours post radiation 
0 Gy DMSO 76±2 13±2 10±2 0.1 
 NVP-AUY922 61±5 4±1 34±4 0.6 
 NVP-BEP800 80±1 7±3 11±2 0.1 
8 Gy DMSO 67±6 2±1 30±4 0.5 
 NVP-AUY922 58±5 6±2 36±3 0.6 
 NVP-BEP800 69±4 1±1 29±5 0.4 
 
C) 48 hours post radiation 
0 Gy DMSO 87±2 4±1 8±2 0.1 
 NVP-AUY922 62±6 6±1 31±7 0.5 
 NVP-BEP800 86±2 4±1 8±2 0.1 
8 Gy DMSO 71±2 1±1 28±1 0.4 
 NVP-AUY922 57±5 5±1 37±5 0.7 
 NVP-BEP800 67±2 3±2 28±3 0.4 
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Table 15. Cell cycle distribution in HFib2 cells detected 30 minutes (A), 24 hours (B) 
and 48 hours (C) after simultaneous drug-IR treatment. Data are presented as 
means (±SE) from at least three independent experiments. 
 
Dose Treatment G0/G1, % S, % G2/M, % G2/G1 
 
A) 30 minutes post radiation 
0 Gy DMSO 66±3 19±3 14±2 0.2 
 NVP-AUY922 65±4 21±4 12±2 0.2 
 NVP-BEP800 66±4 21±4 13±3 0.2 
8 Gy DMSO 66±3 21±3 12±2 0.2 
 NVP-AUY922 65±3 22±4 11±1 0.2 
 NVP-BEP800 64±3 21±3 13±3 0.2 
 
B) 24 hours post radiation 
0 Gy DMSO 73±2 12±2 14±1 0.2 
 NVP-AUY922 65±4 4±2 29±2 0.5 
 NVP-BEP800 72±2 10±1 16±1 0.2 
8 Gy DMSO 65±2 1±1 33±2 0.5 
 NVP-AUY922 61±3 5±3 32±1 0.5 
 NVP-BEP800 62±3 2±1 34±2 0.5 
 
C) 48 hours post radiation 
0 Gy DMSO 85±2 7±1 7±1 0.1 
 NVP-AUY922 61±2 2±2 36±1 0.6 
 NVP-BEP800 86±1 4±1 8±1 0.1 
8 Gy DMSO 69±1 0±1 30±1 0.4 
 NVP-AUY922 60±3 0±1 38±3 0.7 
 NVP-BEP800 67±1 1±0 31±1 0.5 
 
Thirty minutes after irradiation alone or drug treatment alone we did not observe any 
changes in the cell cycle distribution in HFib1 (Fig. 36A) or in HFib2 cells (Fig. 37A). 
Longer incubation (24 and 48 hours) of not-irradiated, DMSO-treated fibroblasts led 
to cell cycle arrest at the G1/S checkpoint (Figs. 36, 37B, C). Incubation of HFib1 and 
HFib2 after irradiation alone for 24 and 48 hours resulted in the depletion of cells in 
the S phase and an increased G2/M peak (Figs. 36, 37B, C). Similarly, twenty-four-
hour exposure to NVP-AUY922 shifted more HFib1 and HFib2 cells into the G2/M
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phase and reduced the amount of cells in the S phase (Figs. 36B, 37B). In addition, 
further incubation with NVP-AUY922 (48 hours) resulted in an increase of the sub-G1 
phase in both tested fibroblast strains (Figs. 36, 37). The treatment of fibroblast 
strains with NVP-BEP800 for 24 or 48 hours did not affect the cell cycle distribution 
when compared with control samples (Figs. 36, 37). 
Simultaneous NVP-BEP800-IR treatment led to the depletion of the S phase and to 
the increase of G2/M peak in fibroblasts (24 and 48 hours post drug-IR) as was the 
case with DMSO-treated, irradiated samples (Figs. 36, 37B, C). Combined NVP-
AUY922-IR treatment in HFib1 and HFib2 cells induced stronger G2/M arrest than in 
samples treated with NVP-AUY922 alone (Figs. 36, 37; 24 and 48 hours). 
 
We further analyzed the sub-G1 phase and cellular debris as an indicator of late-
stage apoptosis measured 48 hours post drug-IR treatment. Representative 
histograms are depicted in Figure 38. 
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Figure 38. Percentage of cells with hypodiploid DNA content and cellular debris in 
drug-treated and irradiated HFib1 (A) and HFib2 (B) cells. Samples were incubated 
for 48 hours after DMSO (unfilled histograms), NVP-AUY922 (gray histograms) or 
NVP-BEP800 (black histograms) treatment and IR. Both floating and adherent cells 
were collected, fixed and stained with PI. Depicted are the percentages of events for 
hypodiploid nuclei and debris, computed by WinMDI (Scripps Research Institute, La 
Jolla, USA). The experiment was repeated three times for each cell line.  
 
The combination of NVP-AUY922 and irradiation increased the amount of 
hypodiploid cells in HFib1 to 54%, compared to 24% detected in irradiated controls 
(Fig. 38A). In NVP-AUY922-treated, irradiated HFib2 cells the extent of the sub-G1 
phase (24%) was similar to that observed after NVP-AUY922 treatment only (30%, 
Fig. 38B). In contrast to NVP-AUY922, incubation with NVP-BEP800 did not increase 
the sub-G1 phase of HFib1 or HFib2 cells as was the case with DMSO-treated 
controls (Fig. 38). 
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4.2.6. Influence of Hsp90 inhibition and IR on the expression of cell cycle-
related proteins in fibroblast strains HFib1 and HFib2 
 
Next, we performed an analysis of expression of cell cycle-related proteins, including 
cyclin-dependent kinases Cdk1, Cdk4 and pRb protein (Figs. 38, 39). 
 
 
Figure 39. Expression of Cdk1, Cdk4 and pRb in HFib1 cells. Samples were treated 
with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 Gy). Each 
protein band was normalized to β-actin and the ratios are given in numbers.  
 
Thirty-minute incubation after irradiation alone (2 or 8 Gy) or treatment with either 
Hsp90 inhibitor did not influence the expression of the chosen cell cycle-related 
proteins (Figs. 39, 40). However, the expression of pRb in HFib1 (1.0 -> 0.2 -> 0.2 
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a.u.) and HFib2 (0.7 -> 0.2 -> 0.2 a.u.) control samples decreased with increased 
incubation time. 
 
 
Figure 40. Expression of Cdk1, Cdk4 and pRb in HFib2 cells. Samples were treated 
with DMSO, NVP-AUY922 or NVP-BEP800 and irradiated (with 2 or 8 Gy). Each 
protein band was normalized to β-actin and the ratios are given in numbers.  
 
Twenty four and forty eight hours after treatment with NVP-AUY922, the up-
regulation of Cdk1 was observed in both fibroblast strains examined (i.e. Figs. 39, 40; 
48 hours post drug treatment, HFib1: 0.2 -> 1.1 a.u., HFib2: 0.2 -> 0.9 a.u.). In 
fibroblasts treated with NVP-BEP800, the expression of Cdk1 was similar to that in 
DMSO-treated samples. Incubation with NVP-AUY922 for 24 and 48 hours led to the 
depletion of pRb in HFib1 and HFib2 cells. Treatment with NVP-BEP800 resulted in 
the decrease in the level of pRb in both strains to ~50% (Figs. 39, 40). In NVP-
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AUY922-treated HFib1 cells Cdk4 was down-regulated from 1.1 to 0.8 a.u. In HFib2 
cells, the expression of this cyclin-dependent kinase remained unchanged 24 hours 
after NVP-AUY922 treatment. In contrast to NVP-AUY922, the incubation with NVP-
BEP800 for 24 and 48 hours did not affect the expression of Cdk4 (Figs. 39, 40).  
The combination of NVP-AUY922 and irradiation did not induce any additional 
changes in the expression of examined proteins controlling cell cycle progression. In 
irradiated, NVP-BEP800-treated fibroblasts, Cdk1 was depleted 24 hours after 
treatment (Figs. 39, 40). Additionally, simultaneous NVP-BEP800-IR treatment led to 
the depletion of pRb in HFib1 cells (Fig. 39, 24 and 48 hours post treatment, 0.1 -> 
0.0 a.u.).  
 
To summarize, we analyzed the influence of NVP-AUY922 and NVP-BEP800 in 
combination with irradiation on normal human skin fibroblasts. The response of 
HFib1 and HFib2 fibroblasts to Hsp90 inhibition and irradiation was different from that 
previously described for tumor cell lines A549 and SNB19. The plating efficiency of 
HFib1 and HFib2 strains was not affected by the treatment with either Hsp90 
inhibitor. We have shown that only 48 hours after NVP-AUY922-treatment, HFib1 
and HFib2 cells were moderately sensitized to irradiation. Forty-eight-hour incubation 
of HFib1 and HFib2 strains with NVP-AUY922 led to the accumulation of DNA 
damage and an increased sub-G1 phase, suggesting that this Hsp90 inhibitor can 
induce apoptosis in fibroblasts. At the same time, the treatment with NVP-BEP800 
did not increase the radiosensitivity of the examined fibroblast strains. In 
concordance, we observed no additional DNA damage in NVP-BEP800-treated 
fibroblasts in comparison to control samples. Incubation of HFib1 and HFib2 cells 
with either NVP-AUY922 or NVP-BEP800 (with/without IR) caused the up-regulation 
of Hsp90 and Hsp70, but to a lesser extent than in tumor cell lines. However, the 
depletion of several Hsp90 clients (including Raf-1, Akt and pAkt) after Hsp90 
inhibition alone or in combination with irradiation was similar to that observed in 
tumor cells. 
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4.3 Influence of Hsp70 silencing combined with NVP-AUY922 on the 
radiation response of cancer cell lines A549 and SNB19 
 
As shown previously treatment with Hsp90 inhibitors, including NVP-AUY922 and 
NVP-BEP800, induces the up-regulation of heat shock proteins 90 and 70 through 
heat shock response (Stingl et al. 2010, Niewidok et al. 2012, Patel et al. 2012). The 
drug-induced over-expression of Hsp70 is considered as a major drawback of Hsp90 
inhibition. Therefore, the objective of this part of the thesis was to inhibit Hsp70 up-
regulation induced by NVP-AUY922 in cancer cell lines. Taking into account the lack 
of potent, pharmacological Hsp70 inhibitors (Goloudina et al. 2012), we decided to 
use siRNA technique as the most specific way to inhibit the chaperone. Two proteins 
from the Hsp70 family, constitutively expressed Hsc70 and stress-inducible Hsp70, 
were chosen as targets. Firstly, we tested the effects of siRNA-mediated inhibition on 
the proliferation of tumor cell lines A549 and SNB19.  
 
 
Figure 41. The sequence of experiments. Before analysis tumor cell lines A549 and 
SNB19 were transfected with Hsp70 siRNA, then treated with 50 nM NVP-AUY922 
and irradiated. 
 
Then, Hsp70 pre-silencing was combined with NVP-AUY922 treatment and 
irradiation (Fig. 41) and the cellular response to the applied treatment was analyzed. 
 
4.3.1 Analysis of heat shock proteins’ expression at mRNA and protein level in 
A549 and SNB19 tumor cell lines after Hsc70 and Hsp70 knock-down 
 
In order to optimize the conditions of transfection, two different siRNA sequences for 
Hsp70 and Hsc70 have been tested (siRNA sequences in section 3.1.3). To control 
the efficiency of transfection, A549 and SNB19 cells were transfected with non-
silencing siRNA coupled with the fluorescence molecule Alexa488 (Section 3.2.10, 
Fig. 10). siRNA targeting MAP kinase was used as the positive control. Then, the 
concentration of Hsp70- and Hsc70-siRNAs needed for effective transfection was 
determined (Fig. 42). 
Cell seeding 
    
Analysis Irradiation Treatment with NVP-AUY922 Transfection 
24 h 24 h 
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As seen in Figure 42, Hsp70- and Hsc70-specific siRNAs caused the suppression of 
target proteins up to 72 hours after transfection, independently from used siRNA 
concentration (100 nM and 200 nM). In lung carcinoma A549 cells, transfection with 
Hsp70 siRNA reduced the level of target protein from 1.1 to ~0.6 a.u. (Fig. 42A). 
Hsc70 siRNA caused the decrease from 1.2 to ~0.5-0.7 a.u. of the target (Fig. 42A). 
In SNB19 cell samples, transfection with Hsp70 siRNA and Hsc70 siRNA suppressed 
the expression of the target proteins from 0.6 to 0.3 a.u. and from 0.2 to 0.1 a.u. 
respectively (Fig. 42B). In both cell lines, silencing of Hsc70 resulted in the up-
regulation of Hsp70 (A549: 1.1 -> 1.3 a.u., SNB19: 0.6 -> 1.0 a.u.). 
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Figure 42. Expression of Hsp90, Hsp70, Hsc70 and MAPK in A549 (A) and SNB19 
(B) cell lines. Samples were transfected with negative control siRNA, MAPK siRNA or 
siRNAs targeting Hsc70 and Hsp70. Seventy two hours after transfection the cell 
lysates were prepared and analyzed. Each protein band was normalized to β-actin 
and the ratios are given in numbers. 
 
Both siRNA sequences caused similar silencing of the target proteins, so we chose 
one siRNA pro target for further experiments (section 3.1.3, siRNAs 2 and 3). In the 
following experiments we used siRNAs at 100 nM for single transfection and 50 nM 
for combined Hsc70/Hsp70 knock-down.  
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Then, we examined the changes in mRNA expression by reverse transcriptase-PCR 
after siRNA-mediated Hsp70 and Hsc70 inhibition in tumor cell lines A549 and 
SNB19, as shown in Figure 43. 
 
 
 
Figure 43. mRNA levels of Hsp70, Hsc70 and Hsp90α in A549 (on the left) and 
SNB19 (on the right) tumor cell lines. Cells were treated with control, non-silencing 
siRNA or siRNA targeting Hsp70 and/or Hsc70 and analyzed by RT-PCR 24 hours 
after transfection. Each band was normalized to GAPDH expression and the ratios 
are given in numbers. 
 
Hsp70-siRNA reduced the mRNA level 3-fold in lung carcinoma cells (Fig. 43, on the 
left, 0.6 -> 0.2 a.u.) and completely depleted the transcript in glioblastoma cells (Fig. 
43, on the right, 0.6 -> 0.0 a.u.). The reduction of Hsc70 was stronger in SNB19 (0.9 -
> 0.1 a.u.) than in A549 samples (0.5 -> 0.2 a.u.). Simultaneous knock-down of both 
proteins decreased the mRNA levels to a lesser extent than single siRNAs did (Fig. 
43, A549: Hsp70 0.6 -> 0.4 a.u., Hsc70 0.5 -> 0.4 a.u.; SNB19: Hsp70 0.6 -> 0.1 a.u., 
Hsc70 0.9 -> 0.8 a.u.). In addition, in SNB19 samples transfected with Hsp70 siRNA, 
Hsc70 siRNA or combined siRNAs, Hsp90α mRNA levels increased (0.5 -> ~0.9 
a.u.). Hsp90α is a stress-inducible isoform of Hsp90 (Sreedhar et al. 2004) and its 
increase suggests that transfection could induce stress response in SNB19 cells. In 
contrast, we observed no changes in the Hsp90α mRNA level in A549 cells (Fig. 43, 
on the left). 
 
4.3.2 Influence of Hsc70/Hsp70 silencing on the proliferation of A549 and 
SNB19 cells 
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The effects of single and combined Hsc70/Hsp70 silencing on the growth of lung 
carcinoma and glioblastoma cells were determined as described in section 3.2.12. 
Cell numbers of transfected and non-transfected cells counted up to 4 days post 
transfection were averaged through 4 independent experiments and are shown in 
Figure 44. 
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Figure 44. Proliferation of A549 (on the left) and SNB19 (on the right) cells after 
transfection with negative control siRNA or siRNA targeting Hsc70/Hsp70. Cells were 
seeded (day 0), 24 hours later transfected and during the following 4 days the cell 
numbers were scored. Data are shown as means ± SD from 4 independent 
experiments. According to Student’s t-test there were no significant differences 
between untreated and transfected cells. 
 
As seen in Figure 44, control A549 cells proliferated faster than SNB19 cells (white 
columns). Transfection reagent alone (dotted columns) or non-silencing negative 
control (dashed columns) did not affect the proliferation of both examined cell lines 
(Fig. 44). A549 cells treated with Hsp70 siRNA divided slower than control samples 
at day 4 after transfection (Fig. 44, light gray columns). Double Hsc70/Hsp70 knock-
down resulted in reduced proliferation of A549 cells 72 hours post transfection (Fig. 
44, black columns). In the case of SNB19 cells, Hsp70 siRNA reduced their ability to 
proliferate 72 and 96 hours post transfection (Fig. 44, light gray columns). 
Simultaneous Hsc70/Hsp70 silencing decreased the proliferation rate of SNB19 dells 
to the greatest extent at days 3 and 4 after transfection (Fig. 44, on the right, black 
columns). However, according to Student’s t-test the differences between non-
transfected and transfected cell samples were not significant. 
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Taking into account the anti-apoptotic activities of stress-inducible Hsp70 (see details 
in chapter 1.5) during following experiments we combined Hsp70 pre-silencing with 
Hsp90 inhibition and irradiation. 
 
4.3.3 Analysis of heat shock proteins’ expression at mRNA and protein level in 
A549 and SNB19 cells after combination of Hsp70 knock-down, NVP-AUY922 
addition and IR 
 
The changes at mRNA level after Hsp70 silencing in combination with NVP-AUY922 
treatment were examined by reverse transcriptase PCR, as shown in Figure 45.  
 
 
Figure 45. mRNA levels of Hsp70, Hsc70 and Hsp90α in A549 (on the left) and 
SNB19 (on the right) tumor cell lines. Cells were transfected with either control or 
Hsp70 siRNA and 24 hours after silencing treated with NVP-AUY922. Forty eight 
hours after transfection the samples were analyzed by RT-PCR. Each band was 
normalized to GAPDH expression and the ratios are given in numbers. 
 
A549 and SNB19 cell samples were probed for Hsp70, Hsc70, Hsp90α and GAPDH 
expression. The treatment with NVP-AUY922 alone increased the level of Hsp70 
mRNA in A549 from 0.6 to 0.9 a.u. (Fig. 45, on the left). Twenty four hours after 
Hsp70 siRNA transfection, the mRNA level of the target protein was reduced from 0.6 
to 0.2 a.u. When pre-silenced A549 cells were treated with Hsp90 inhibitor, the 
amount of Hsp70 mRNA decreased from 0.6 to 0.4 a.u. At the same time the levels 
of Hsc70 and Hsp90α (stress-inducible Hsp90 isoform) remained unaffected by the 
applied treatments (Fig. 45, on the left).  
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Exposure of SNB19 cells to NVP-AUY922 led to the up-regulation of Hsp90α at 
mRNA level (0.2 -> 0.4 a.u.), whereas it did not influence the expression of Hsp70 
(~0.4 - 0.3 a.u., Fig. 45, on the right). Transfection with Hsp70 siRNA induced the 
suppression of target mRNA (0.4 -> 0.2 a.u.). The combination of Hsp70 pre-
silencing and NVP-AUY922 in SNB19 cells decreased Hsp70 mRNA level from 0.4 to 
0.1 a.u. At the same time the level of Hsp90α mRNA increased (0.2 -> 0.4 a.u.). 
Hsc70 mRNA levels stayed constant independent from the applied treatment (Fig. 
45, on the right).  
 
Next, the effects of combined Hsp70-siRNA-NVP-AUY922 treatment and IR on the 
protein expression of Hsp90, Hsp70 and Hsc70 in A549 and SNB19 cells were 
investigated (Figs. 46 and 47). 
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Figure 46. Expression of Hsp90, Hsp70 and Hsc70 in A549 cells. Samples were 
transfected, on the next day treated with NVP-AUY922 and irradiated 24 hours later 
(8 Gy). The analysis was performed 30 minutes and 24 hours after IR. Each protein 
band was normalized to β-actin and the ratios are given in numbers. 
 
Treatment with Hsp70 siRNA alone reduced the target protein level from 0.6 for 
controls to 0.4 a.u. in A549 (Fig. 46), and from 0.9 to 0.7 a.u. in SNB19 (Fig. 47) cells 
(48 hours post transfection). At the same time no changes were observed in the 
expression levels of Hsp90 and Hsc70 in both cancer cell lines. NVP-AUY922 alone 
caused strong up-regulation of analyzed heat shock proteins in A549 and SNB19 
cells (Figs. 46, 47, i.e. SNB19: Hsp90 0.7 -> 1.3 a.u., Hsp70 0.9 -> 2.0 a.u., Hsc70 
1.0 -> 2.0 a.u.). In A549 cells pre-silenced for Hsp70 and treated with NVP-AUY922 
we observed the up-regulation of Hsp70 from 0.6 to 1.0 a.u. (Fig. 46, 48 hours post 
transfection).  
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Figure 47. Expression of Hsp90, Hsp70 and Hsc70 in SNB19 cells. Samples were 
transfected, on the next day treated with NVP-AUY922 and irradiated 24 hours later 
(with 8 Gy). The analysis was performed 30 minutes and 24 hours after IR. Each 
protein band was normalized to β-actin and the ratios are given in numbers. 
 
When the Hsp90 inhibitor NVP-AUY922 was added to SNB19 cells transfected with 
Hsp70 siRNA (Fig. 47), the expression of Hsp70 increased (0.9 -> 1.5 a.u.), but the 
induction was weaker than after NVP-AUY922 treatment alone (0.9 -> 2.0 a.u.). 
However, it did not influence the up-regulation of other chaperones i.e. Hsp90 and 
Hsc70 in either examined tumor cell line (Figs. 46, 47). Irradiation (8 Gy) of Hsp70-
presilenced, NVP-AUY922-treated tumor cells did not further affect the expression of 
tested heat shock proteins (Figs. 46, 47). 
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Thus, we have shown that Hsp70 knock-down successfully suppressed the NVP-
AUY922-induced over-expression of heat shock protein 70 at the mRNA and protein 
level. 
 
4.3.4 Colony survival of irradiated A549 and SNB19 cells after Hsp70 pre-
silencing and treatment with NVP-AUY922 
 
Next, colony-forming assay was performed to analyze whether Hsp70 pre-silencing 
could increase the radiosensitizing effect of NVP-AUY922 in A549 and SNB19 cells. 
Representative cell survival curves of transfected, NVP-AUY922-treated samples 
plotted against the radiation dose are shown in Figure 48. The statistical analysis 
was performed from at least 3 independent experiments and summarized in Table 
16. 
0 2 4 6 8
1E-4
1E-3
0.01
0.1
1
1- - NVP-AUY922
2- - control siRNA
3- - control siRNA + AUY
4- - Hsp70 siRNA
5- - Hsp70 siRNA + AUY
A) A549
Su
rv
ivi
n
g 
fra
ct
io
n
Radiation dose (Gy)
1
2
3
4
5
B) SNB19
0 2 4 6 8
1E-4
1E-3
0.01
0.1
1
1- - NVP-AUY922
2- - control siRNA
3- - control siRNA + AUY
4- - Hsp70 siRNA
5- - Hsp70 siRNA + AUY 1
2
3
4
5
Figure 48. Representative clonogenic survival curves of A549 (A) and SNB19 (B) cell 
lines. Cells transfected with control siRNA (unfilled squares) or with Hsp70 siRNA 
(unfilled triangles), treated with NVP-AUY922 (colored symbols) were irradiated and 
seeded for colony-forming assay. After staining and scoring the colonies, cell survival 
curves were generated. 
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Table 16. Plating efficiencies and radiosensitivity parametersa of transfected, NVP-
AUY922-treated and irradiated A549 and SNB19 tumor cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Mean (±SD) from at least three independent experiments 
b
 SF2 is the surviving fraction at 2 Gy 
c
 D10 is the radiation dose resulting in 10% cell survival 
d
 IF10 was calculated as (D10 control)/(D10 inhibitor) 
 
Transfection with Hsp70 siRNA alone did not affect the plating efficiency of either 
examined cancer cell line (Table 16). Treatment with NVP-AUY922 (alone or in 
combination with siRNA) reduced PE from ~0.12 to ~0.07 in glioblastoma cells. In 
lung carcinoma samples, NVP-AUY922 alone decreased PE from ~0.35 to ~0.26, but 
when it was combined with Hsp70 siRNA the decrease was minimal (Table 16, PE≈ 
0.32). 
As evident from Figure 48, treatment with 50 nM NVP-AUY922 alone sensitized both 
examined tumor cell lines to radiation. In SNB19 samples, SF2 was reduced from 
~0.65 to ~0.51 and D10 from 5.7 to 4.2, whereas in A549, D10 decreased from 5.9 to 
4.9, but SF2 did not change markedly (from ~0.59 to ~0.54, Table 16). Hsp70 
silencing alone did not affect the radiosensitivity of SNB19 or A549 cells, as 
 PE SF2 b D10 c (Gy) IF10 d 
A549 
DMSO 0.35±0.1 0.59±0.1 5.9 1.0 
NVP-AUY922 0.26±0.1 0.54±0.2 4.9 1.2 
control siRNA 0.38±0.1 0.57±0.1 5.8 1.0 
control siRNA +AUY 0.23±0.1 0.33±0.1 3.6 1.6 
Hsp70 siRNA 0.38±0.2 0.54±0.1 5.4 1.1 
Hsp70 siRNA +AUY 0.32±0.1 0.43±0.1 4.4 1.3 
SNB19 
DMSO 0.12±0.1 0.65±0.2 5.8 1.0 
NVP-AUY922 0.07±0.05 0.51±0.2 4.2 1.4 
control siRNA 0.14±0.1 0.59±0.1 5.0 1.1 
control siRNA +AUY 0.07±0.05 0.56±0.1 4.5 1.3 
Hsp70 siRNA 0.15±0.1 0.67±0.2 6.0 1.0 
Hsp70 siRNA +AUY 0.07±0.02 0.75±0.1 5.8 1.0 
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evidenced by the unchanged SF2 and D10 in comparison to control samples (Table 
16). The survival curve of A549 cells pre-silenced with Hsp70 siRNA and treated with 
NVP-AUY922 overlapped with that of cells treated with the drug only (Fig. 48A). In 
comparison to Hsp70 silencing alone, the combination treatment of Hsp70 siRNA 
and NVP-AUY922 sensitized SNB19 cells to radiation. However, the observed 
radiosensitization was weaker than after NVP-AUY992 treatment alone (Fig. 48B).  
 
4.3.5 Changes in the expression of several marker proteins after combined 
Hsp70 knock-down, NVP-AUY922 addition and irradiation 
 
Next, the protein expression analysis was performed in tumor cell lines A549 and 
SNB19 after combined Hsp70 siRNA-NVP-AUY922 treatment and irradiation. Figures 
49-52 show representative expression levels of marker proteins involved in cell 
proliferation (Akt, Raf-1), cell cycle (Cdk1, Cdk4, pRb) and apoptosis (caspase 3, 
survivin, PARP). 
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Figure 49. Expression of Akt, Raf-1, survivin, Cdk1, Cdk4, pRb, PARP and caspase 
3 in A549 cells 30 minutes post radiation (48 hours post transfection). Samples were 
transfected with Hsp70 siRNA, treated with NVP-AUY922 and irradiated with 8 Gy. 
Each band was normalized to ß-actin and the ratios are given in numbers. 
 
As shown in Figure 49, Hsp90 clients Akt (0.9 -> 0.6 a.u.) and Raf-1 (1.0 -> 0.8 a.u.) 
were down-regulated in non-irradiated, NVP-AUY922-treated A549 cells. 
Furthermore, we detected a reduction in the levels of Cdk1 (1.1 -> 0.6 a.u.) and Cdk4 
(1.2 -> 0.9 a.u.) in these A549 samples, indicating possible cell cycle disturbances. 
Treatment with NVP-AUY922 did not affect the expression of survivin in A549 cells 
(Fig. 49). 
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Figure 50. Expression of Akt, Raf-1, survivin, Cdk1, Cdk4, pRb, PARP and caspase 
3 in A549 cells 24 hours post radiation (72 hours post transfection). Samples were 
transfected with Hsp70 siRNA, treated with NVP-AUY922 and irradiated with 8 Gy. 
Each band was normalized to ß-actin and the ratios are given in numbers. 
 
In glioblastoma cells, Akt was depleted (1.2 -> 1.0 a.u.) and Raf-1 nearly completely 
vanished (from 0.8 to 0.1 a.u.) after NVP-AUY922 treatment (Fig. 51). Cyclin-
dependent kinases Cdk1 (1.0 -> 0.3 a.u.) and Cdk4 (0.6 -> 0.3 a.u.) were down-
regulated, as was the case with lung carcinoma cells. Treatment with NVP-AUY922 
alone did not influence the expression of survivin, caspase 3 or PARP in 
glioblastoma cells (Fig. 51). 
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Figure 51. Expression of Akt, Raf-1, survivin, Cdk1, Cdk4, pRb, PARP and caspase 
3 in SNB19 cells 30 minutes post radiation (48 hours post transfection). Samples 
were transfected with Hsp70 siRNA, treated with NVP-AUY922 and irradiated with 8 
Gy. Each band was normalized to ß-actin and the ratios are given in numbers. 
 
The silencing of Hsp70 alone did not induce any significant changes in the 
expression of examined proteins in comparison to control samples (Figs. 49-51). The 
combination of Hsp70 pre-silencing with NVP-AUY922 caused mostly the same 
protein level alterations as NVP-AUY922 alone in both examined tumor cell lines 
(Figs. 49-51). One exception was survivin, which was down-regulated from 1.0 to 0.4 
a.u. in A549 cells after combined Hsp70 siRNA-NVP-AUY922 treatment (Fig. 49, 48 
hours post transfection).  
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In pre-silenced and NVP-AUY922-treated SNB19 cells we detected the cleaved form 
of PARP (Fig. 51, 72 hours after transfection). 
 
Figure 52. Expression of Akt, Raf-1, survivin, Cdk1, Cdk4, pRb, PARP and caspase 
3 in SNB19 cells 24 hours post radiation (72 hours post transfection). Samples were 
transfected with Hsp70 siRNA, treated with NVP-AUY922 and irradiated with 8 Gy. 
Each band was normalized to ß-actin and the ratios are given in numbers. 
 
SNB19 cells treated with NVP-AUY922 and IR, either with or without siRNA 
transfection, expressed cleaved PARP (Fig. 52, 24 hours post IR). The expression of 
other tested proteins in pre-silenced, NVP-AUY922-treated and irradiated A549 and 
SNB19 cells was similar to that observed in samples after NVP-AUY922-IR treatment 
(Figs. 49-52). 
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4.3.6 DNA damage repair and cell cycle progression after combined Hsp70 
silencing, NVP-AUY922 addition and irradiation 
 
Finally, we determined the effects of Hsp70 pre-silencing in combination with Hsp90 
inhibition and irradiation on DNA damage and cell cycle distribution by flow 
cytometry. Pre-silenced for Hsp70, NVP-AUY922-treated and irradiated A549 and 
SNB19 cells were fixed 30 minutes and 24 hours after IR and stained for γH2AX as a 
marker of DNA double strand breaks. Representative histograms are shown in Figure 
53. 
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Figure 53. Histograms showing distribution of γH2AX, as a marker of DNA double 
strand breaks, in A549 (A) and SNB19 (B) cells. Transfected with Hsp70 siRNA, 
NVP-AUY922-treated samples were irradiated with single dose (8 Gy, black 
histograms) and analyzed 30 minutes and 24 hours post IR. Gray histograms 
represent non-irradiated samples. Numbers denote the mean γH2AX expression for 
the respective cell sample. The vertical, dashed line marks the γH2AX value of 
DMSO-treated, non-irradiated control. 
 
As observed in Figure 53, the background levels of γH2AX expression was 20 a.u. 
and 38 a.u. for A549 and SNB19 control samples respectively (30 minutes, gray 
histograms). Hsp70 silencing alone did not influence the amount of DNA damage in 
A549 or SNB19 (Fig. 53, A549 ~11 a.u., SNB19 ~40 a.u.). Treatment with 50 nM 
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NVP-AUY922 increased the levels of γH2AX about 2-fold in both tested cell lines 
(A549 from 20 to 48 a.u., SNB19 from 38 to 57 a.u.). The combination of Hsp70-
presilencing and NVP-AUY922 treatment in SNB19 samples did not further affect the 
γH2AX expression (~63 a.u.; Fig. 53B). In pre-silenced, NVP-AUY922-treated A549 
cells we measured DNA damage at ~35 a.u., which was higher than in controls, but 
lower than after NVP-AUY922 treatment alone (Fig. 53A).  
Irradiation alone induced the γH2AX expression in A549 from 20 to 71 a.u. and in 
SNB19 from 38 to 133 a.u. cells (Fig. 53, 30 minutes, black histograms). Pre-
silenced, NVP-AUY922-treated and irradiated SNB19 cells exhibited the highest 
amount of DNA damage of ~166 a.u. (Fig. 53B, 30 minutes, black histograms). In 
A549, the combination treatment Hsp70 siRNA-NVP-AUY922 and irradiation induced 
similar levels of γH2AX expression (~81 a.u.) as after NVP-AUY922-IR treatment 
(Fig. 53A, 30 minutes, black histograms). 
The treatment-induced DNA damage in A549 cell samples was restored to the level 
of controls within 24 hours (Fig. 53A, black histograms). In SNB19 we also observed 
DNA damage repair at 24 hours after irradiation, however it was slower in NVP-
AUY922-treated samples (with/without siRNA) (Fig. 53B, black histograms). 
 
In addition to γH2AX measurements, the cell cycle analysis of the silenced,
 NVP-AUY922-treated and irradiated A549 and SNB19 was performed (Fig. 54). The 
statistical analysis from 3 independent experiments was summarized in Tables 17 
and 18. 
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Figure 54. Cell cycle distribution of A549 (A) and SNB19 (B) tumor cell lines. Pre-
silenced for Hsp70, NVP-AUY922-treated and irradiated (8 Gy) samples were fixed 
30 minutes and 24 hours post irradiation. The percentage of cells in each phase 
(G1%-S%-G2%) and G2/G1 ratio are shown. 
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Table 17. Cell cycle distribution in A549 cells detected 30 minutes (A) and 24 hours 
(B) after irradiation. Samples were transfected, NVP-AUY922-treated and irradiated. 
Data are presented as means (±SD) from at least three independent experiments. 
 
Dose Treatment G0/G1, % S, % G2/M, % G2/G1 
 
A) 30 minutes post radiation (48 hours post transfection) 
0 Gy DMSO 67±4 24±3 8±1 0.1 
 NVP-AUY922 55±7 15±7 28±14 0.6 
 control siRNA 68±4 23±3 8±1 0.1 
 control siRNA +AUY 52±9 16±5 31±14 0.8 
 Hsp70 siRNA 68±4 20±6 11±3 0.2 
 Hsp70 siRNA +AUY 62±6 11±5 26±10 0.5 
8 Gy DMSO 66±3 20±6 12±4 0.2 
 NVP-AUY922 63±8 13±5 24±12 0.5 
 control siRNA 67±4 19±7 13±3 0.2 
 control siRNA +AUY 57±7 11±6 31±12 0.6 
 Hsp70 siRNA 67±3 18±6 14±5 0.2 
 Hsp70 siRNA +AUY 64±5 12±2 22±10 0.4 
 
B) 24 hours post radiation (72 hours post transfection) 
0 Gy DMSO 80±7 11±6 8±1 0.1 
 NVP-AUY922 64±10 12±4 23±12 0.5 
 control siRNA 78±7 12±7 9±1 0.1 
 control siRNA +AUY 62±10 13±3 24±13 0.5 
 Hsp70 siRNA 78±7 12±6 9±1 0.1 
 Hsp70 siRNA +AUY 57±8 14±4 27±11 0.5 
8 Gy DMSO 53±5 4±1 42±6 0.8 
 NVP-AUY922 50±7 5±2 44±6 1.0 
 control siRNA 59±8 7±1 33±9 0.6 
 control siRNA +AUY 53±3 4±1 41±4 0.8 
 Hsp70 siRNA 56±7 5±2 38±9 0.8 
 Hsp70 siRNA +AUY 52±4 2±1 45±4 0.9 
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Table 18. Cell cycle distribution in SNB19 cells detected 30 minutes (A) and 24 hours 
(B) after irradiation. Samples were transfected, NVP-AUY922-treated and irradiated. 
Data are presented as means (±SD) from at least three independent experiments. 
 
Dose Treatment G0/G1, % S, % G2/M, % G2/G1 
 
A) 30 minutes post radiation (48 hours post transfection) 
0 Gy DMSO 64±2 16±2 18±1 0.3 
 NVP-AUY922 53±4 9±2 38±3 0.7 
 control siRNA 65±2 17±1 17±1 0.3 
 control siRNA +AUY 49±5 7±2 42±6 0.8 
 Hsp70 siRNA 75±1 8±1 16±2 0.2 
 Hsp70 siRNA +AUY 51±6 8±1 40±6 0.8 
8 Gy DMSO 66±1 12±1 20±1 0.3 
 NVP-AUY922 52±5 8±1 39±4 0.7 
 control siRNA 63±3 18±4 17±1 0.3 
 control siRNA +AUY 47±4 11±2 40±3 0.8 
 Hsp70 siRNA 74±1 8±1 17±0 0.2 
 Hsp70 siRNA +AUY 51±4 6±1 42±3 0.8 
 
B) 24 hours post radiation (72 hours post transfection) 
0 Gy DMSO 79±3 6±1 13±2 0.2 
 NVP-AUY922 34±11 19±9 45±5 1.3 
 control siRNA 75±2 7±1 17±1 0.2 
 control siRNA +AUY 31±9 21±11 46±7 1.5 
 Hsp70 siRNA 76±3 8±1 15±2 0.2 
 Hsp70 siRNA +AUY 42±6 15±5 42±3 1.0 
8 Gy DMSO 62±4 7±0 30±3 0.5 
 NVP-AUY922 30±14 19±10 49±8 1.6 
 control siRNA 57±4 10±2 31±2 0.5 
 control siRNA +AUY 29±13 24±12 45±5 1.5 
 Hsp70 siRNA 70±2 5±1 24±1 0.3 
 Hsp70 siRNA +AUY 31±8 17±6 51±3 1.6 
 
As seen in Figure 54, no changes in the cell cycle distribution were revealed after 
Hsp70 silencing alone in the examined cancer cell lines. Exposure of A549 and 
SNB19 samples to NVP-AUY922, alone or in combination with Hsp70 siRNA, 
induced the S phase depletion and the increase of G2/M peak (Fig. 54). 
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In NVP-AUY922-treated and irradiated A549 cells the fraction of sub-G1 phase 
increased (Fig. 54A, 24 hours post IR). Apart from that, irradiation (8 Gy) of pre-
silenced and/or NVP-AUY922-treated cells did not further affect the cell cycle 
distribution.  
 
To gain deeper insight into the proliferation of pre-silenced, NVP-AUY922-treated 
and irradiated A549 and SNB19 cells, BrdU incorporation assay was performed and 
representative dot plots are shown in Figure 55. 
Figure 55. BrdU incorporation assay of A549 (A) and SNB19 (B) cells. Transfected, 
NVP-AUY922-treated and irradiated samples were incubated with BrdU for one hour. 
Staining with anti-BrdU antibody presents the incorporation of BrdU and thus the 
replication abilities of the cells. 7-AAD was used for cell cycle analysis. The 
percentage of the events in each quadrant is shown.  
 
As evident from Figure 55, NVP-AUY922 treatment alone depleted the amount of 
events in the S phase of both tested cell lines (A549: 6% -> 1%, SNB19: 15% -> 1%; 
left upper quadrant). Hsp70 silencing alone did not affect the replication abilities of 
A549 or SNB19 when compared with controls. The combination of Hsp70 knock-
down and NVP-AUY922 reduced the S phase of tested cells to the same extent as 
NVP-AUY922 treatment alone (Fig. 55). Irradiation (8 Gy) did not affect the 
replication phase of lung carcinoma cells (Fig. 55A). In contrast, in irradiated 
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glioblastoma samples the S phase was reduced from 15% to 4% (Fig. 55B). 
Exposure to NVP-AUY922 and/or Hsp70 siRNA in combination with IR completely 
depleted the S phase in A549 and SNB19 cells (Fig. 55). 
 
To summarize, Hsp70 and Hsc70 were successfully silenced in examined tumor cell 
lines A549 and SNB19. The down-regulation of the proteins was confirmed at the 
mRNA and protein level up to 72 hours after transfection. A reduced cell proliferation 
was observed after single and combined Hsc70/Hsp70 silencing. Hsp70 pre-silencing 
suppressed NVP-AUY922-induced Hsp70 over-expression in A549 and SNB19 cell 
lines. The combination of Hsp70 pre-silencing and NVP-AUY922 treatment did not 
increase the radiosensitivity of tumor cell lines when compared with drug treatment 
only. The combined Hsp70-siRNA-NVP-AUY922 treatment induced similar effects at 
the protein expression level, DNA damage or cell cycle distribution as did the NVP-
AUY922 treatment alone. 
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5. Discussion 
 
Nearly 50% of patients with solid tumors receive radiotherapy at some stage of their 
treatment (Bernier et al. 2004). Radiation therapy is usually combined with various 
chemotherapeutics that can sensitize tumor cells to irradiation (Seiwert et al. 2007, 
Bischoff et al. 2009). Heat shock protein 90 seems to be a promising target for 
cancer treatment, as it plays central role in the folding and activation of more than 
200 clients, among them proteins associated with radiation response (Picard et al. 
2002, Zhang et al. 2004, Dote et al. 2005). Inhibition of Hsp90 can provide an 
approach for the simultaneous targeting of multiple proteins contributing to 
carcinogenesis (Camphausen et al. 2007). One possibility for impairing Hsp90 
functions is to block the binding of ATP to the N-terminal domain of the chaperone 
(Zhang et al. 2004, Patel et al. 2012). Small molecule Hsp90 inhibitors NVP-AUY922 
and NVP-BEP800 belong to drugs targeting the N-terminal domain (Brough et al. 
2008, 2009) and were tested in the course of this work in combination with irradiation 
on human tumor and normal cell lines of different origin. 
 
5.1 Effects of NVP-AUY922 and NVP-BEP800 on the radiation 
response of lung carcinoma A549 and glioblastoma SNB19 cell 
lines 
 
Recent works in our group showed that treatment with novel Hsp90 inhibitors NVP-
AUY922 and NVP-BEP800 induced radiosensitization of cancer cell lines under 
normoxic (Stingl et al. 2010) and hypoxic (Djuzenova et al. 2012) conditions. Stingl et 
al. 2010 incubated tumor cells with either Hsp90 inhibitor for 24 hours before 
irradiation and removed the drug from the medium before IR (drug-first treatment). 
The cellular response to the combination of drug-first treatment was p53-independent 
and involved the degradation of several Hsp90 clients, impaired DNA repair, cell 
cycle arrest and increased apoptosis (Stingl et al. 2010). 
Most studies with Hsp90 inhibitors applied drug-first treatment to combination studies 
with irradiation (i.e. Bisht et al. 2003, Machida et al. 2003, Bull et al. 2004, Dote et al. 
2006, Noguchi et al. 2006, Shintani et al. 2006). However, contradictory report can
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be found showing that Hsp90 inhibitors administered after IR were superior in 
prostate cancer cell killing than the drug-first treatment (Enmon et al. 2003). These 
discrepancies prompted us to analyze whether the sequence of Hsp90 inhibition and 
irradiation could influence the radiosensitizing potential of NVP-AUY922 and NVP-
BEP800. 
Surprisingly, the simultaneous drug-IR treatment induced different effects in A549 
and SNB19 tumor cells when compared with the drug-first treatment used in the 
report from Stingl et al. 2010. When the simultaneous drug-IR treatment was applied 
to lung carcinoma cells, we observed strong cytotoxicity of the drugs, accompanied 
by the G1/S arrest and the induction of apoptosis. On the contrary, the drug-first 
treatment resulted in radiosensitization of A549 cells (Stingl et al. 2010). 
Glioblastoma SNB19 cells were sensitized to irradiation after the simultaneous drug-
IR treatment, as well as after the drug-first regimen (Stingl et al. 2010). However, 
judging by the SF2 and D10 values (48 hours post drug-IR), NVP-AUY922 and NVP-
BEP800 induced stronger radiosensitization after the simultaneous drug-IR treatment 
used here (Niewidok et al. 2012).  
To elucidate the different responses of A549 and SNB19 cell lines to the 
simultaneous drug-IR treatment, we analyzed the extent of DNA damage and its 
restitution, the expression of marker proteins and the cell cycle distribution. In A549 
lung carcinoma cells more DNA damage was induced by the simultaneous drug-IR 
treatment than by IR alone (30 minutes after treatment) and it was repaired within 24 
hours. In SNB19 glioblastoma cells 24 and 48 hours after Hsp90 inhibition and IR we 
observed an increased amount of DNA DSBs compared with control irradiated 
samples. At the protein level we observed both pro-survival (i.e. over-expression of 
Hsp90 and Hsp70) as well as pro-apoptotic effects (i.e. depletion of Akt or survivin) 
after Hsp90 inhibition with and without IR. Furthermore, we found marked changes in 
the expression of the cell cycle-related proteins (Cdk1, Cdk4 and pRb) 24 and 48 
hours after treatment with NVP-AUY922 and NVP-BEP800. Hsp90 inhibitors down-
regulated Cdk1 level in glioblastoma cells, whereas in lung carcinoma its level 
remained stable. The vanishing of Cdk1, protein regulating the progression into 
mitosis, would explain the massive G2/M arrest which was seen in SNB19 cells. In 
both tested cell lines the expression of Cdk4 and pRb decreased, but to a greater 
extent in A549 cells. The down-regulation of Cdk4 and pRb together with the fact that 
Discussion 
- 119 - 
 
lung carcinoma cells express wild type p53 corresponds with the observed G1/S 
arrest 24 and 48 hours after drug-IR treatment.  
As shown by the example of ErbB2 and Bcr-Abl, genetic alterations in cancer cells 
can be associated with the response to targeted therapeutics (Sos et al. 2009). Thus, 
based on the known mutations in A549 and SNB19 (3.2.1) we analyzed the 
expression of several oncoproteins, including p53, PTEN and k-RAS, to further 
examine the signaling pathways involved in the cellular response to the simultaneous 
drug-IR treatment (Fig. 56).  
 
Figure 56. Signalling pathways playing a role in the cellular response of A549 (A) 
and SNB19 (B) cells to Hsp90 inhibitor NVP-AUY922 and irradiation. In A549 cells 
(A) PTEN together with Hsp90 inhibition suppressed the PI3K-Akt pathway, which 
resulted in the reduction of Bcl-xL. The treatment activated caspase-dependent 
apoptosis through p53-dependent mechanisms. The drug-induced decrease of Cdk4 
led to the G1/S arrest in lung carcinoma cells. In SNB19 cells (B) the pro-survival 
PI3K-Akt pathway was activated. Combined NVP-AUY922-IR treatment induced DNA 
DSBs which could not be restored during the time of the experiment. The extent of 
DNA damage led to the over-expression of p21Waf1 that could block the cell cycle 
progression before entering mitosis. 
The schema was proposed using the data presented in Figures 12-28 and Tables 10-
12. Note the size of the letters/symbols and the thickness of the lines; gray means 
strong reduction or depletion of proteins. For the detailed description see text 
(reproduced from Niewidok et al. 2012 with kind permission from Neoplasia Press). 
 
In more than 50% of human cancers, mutations occur in TP53 gene. Hsp90 interacts 
with mutant p53 and protects it from the degradation by blocking the ligase activity of 
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MDM2 (Li et al. 2011c). It has been demonstrated that p53-mutant squamous 
carcinoma cells were less sensitive to 17-AAG treatment (Shintani et al. 2006). In 
contrast, we observed that SNB19 cells (p53mut) were more sensitive to the 
simultaneous drug-IR treatment than A549 (p53wt). It seems that p53 status can not 
be used for explaining or predicting the response of tumor cells to Hsp90 inhibition. 
Another difference between A549 and SNB19 cell lines is PTEN status. PTEN is a 
phosphatase whose activity restricts growth and survival signals mediated by the 
PI3K-Akt pathway and the loss of functional PTEN can lead to constitutive activation 
of this pathway (Ramaswany et al. 1999). Akt is a key regulator of cell survival and 
proliferation; it protects the cells from apoptosis by hindering the release of 
cytochrome c from mitochondria. Activated Akt stimulates the pro-survival protein 
Bcl-xL through Bcl-2-associated death promoter (Bad) and thereby inhibits apoptosis 
(Kennedy et al. 1999). Furthermore, Akt can inhibit caspase 3 and caspase 9 
activation, possibly by direct phosphorylation of caspase 9 (Zhou et al. 2000, Mayo et 
al. 2001). Akt can also interact with MDM2 to keep p53 in its inactive form (Haupt et 
al. 1997, Kubbutat et al. 1997). We observed elevated levels of PI3K and Akt in 
SNB19 samples, which indicate that the PI3K-Akt pathway was activated and could 
contribute to the cancer cell survival. In agreement, we observed no alterations in the 
expression of apoptotic markers caspase 3 and PARP. In A549 cells, wild type PTEN 
negatively regulates the PI3K-Akt pathway which, together with the down-regulation 
of Akt, survivin and Bcl-xL by simultaneous drug-IR treatment, resulted in the 
initiation of apoptosis, as confirmed by caspase 3 activation and PARP cleavage. 
k-RAS status was identified as next difference between A549 and SNB19 tumor cell 
lines. Cells expressing mutant k-RAS express higher levels of p19ARF mRNA, a 
protein that connects the k-RAS status with p53 expression (Brooks et al. 2001). 
p19ARF interacts with MDM2 or with p53 directly to destabilize its functions (Palmero 
et al.1998). k-RAS mutant cells are therefore more prone to DNA damage-induced 
apoptosis and reduced G2/M arrest. Indeed, lung carcinoma cells (k-RAS mut) 
exhibited an increased apoptosis rate and G1/S arrest after prolonged incubation 
with Hsp90 inhibitors and IR. Cells with k-RAS in wild-type form tend to G2/M arrest 
in response to DNA damage, which is consistent with the response of SNB19 cells. 
The strong G2/M arrest in SNB19 cells was most likely controlled by p21Waf1. The 
expression of p21Waf1 is regulated by p53, which can be activated by IR-induced
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reactive oxygen species (ROS, Vitiello et al. 2009). We did not detect ROS directly, 
but we measured the expression of γH2AX expression as a marker of DNA DSBs, 
which are known to correlate with ROS (Kang et al. 2009). Simultaneous drug-IR 
treatment induced more DNA damage, which persisted longer in SNB19 than in A549 
cells.  
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Figure 57. Summary of radiosensitization and cytotoxicity-related effects of the 
combined drug-IR (8 Gy) treatment on the protein expression, DNA damage, and cell 
cycle arrest induced in A549 (red) and SNB19 (blue bars) cell lines detected 48 
hours after NVP-AUY922-IR treatment. Relative changes are given in percentage 
with respect to the corresponding DMSO controls. Data for A549 and SNB19 were 
taken from Figures 12-28 and Tables 10-12. Radiosensitization was calculated from 
IF10 values (Table 10; reproduced from Niewidok et al. 2010 with kind permission 
from Neoplasia Press). 
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Figure 58. Summary of radiosensitization and cytotoxicity-related effects of the 
combined drug-IR (8 Gy) treatment on the protein expression, DNA damage, and cell 
cycle arrest induced in A549 (red) and SNB19 (blue bars) cell lines detected 48 
hours after NVP-BEP800-IR treatment. Cleaved PARP was not detected in cells 
treated with NVP-BEP800. For further details see legend to Figure 57.  
 
In summary, our data suggest that the cellular response to NVP-AUY922-IR or NVP-
BEP800-IR treatment depended on the tumor cell line used and its genetic status 
(Fig. 56). The combination of Hsp90 inhibition and irradiation may cause 
radiosensitization or cytotoxicity and cell death in tumor cell lines. The sequence of 
the treatment involving Hsp90 inhibitors and IR has to be individually adjusted to 
achieve the best therapeutic outcome.  
We observed some differences in the response of tumor cells to NVP-AUY922 in 
comparison with NVP-BEP800 (Figs. 57, 58), which most likely depended on the 
pharmacodynamic and pharmacokinetic features of both drugs (Brough et al. 2008, 
2009). NVP-BEP800 was less cytotoxic than NVP-AUY922 towards examined tumor 
cell lines. Incubation of glioblastoma cells with NVP-BEP800 led to stronger 
radiosensitization that correlated with more DNA damage and increased G2/M arrest 
than in cells incubated with NVP-AUY922. In contrast to NVP-AUY922, we did not
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detect any changes in the expression of k-RAS, PI3K or Bcl-xL 48 hours post NVP-
BEP800-IR. Treatment with NVP-BEP800 did not induce the cleavage of PARP. 
Despite the differences in the action of both drugs, they still proved to be effective 
Hsp90 inhibitors and promising therapeutics. 
 
5.2 Effects of NVP-AUY922 and NVP-BEP800 on the radiation 
response of normal fibroblast strains HFib1 and HFib2 
 
The introduction of the potential drug into the clinic depends not only on its effects on 
cancer cells, but also on its influence on surrounding non-malignant tissue(s). Until 
now, nothing was known about the activity of NVP-AUY922 or NVP-BEP800 in 
combination with IR on the non-malignant cells. Thus, in this thesis we investigated 
the effects of these Hsp90 inhibitors in combination with IR in two normal human skin 
fibroblast strains HFib1 and HFib2. Fibroblasts were treated in the same way as 
tumor A549 and SNB19 cell lines (chapter 4.1). Interestingly, forty-eight-hour 
incubation with either Hsp90 inhibitor did not affect the plating efficiency of HFib1, or 
decreased it slightly in HFib2 (48 hours after NVP-AUY922, from 0.04 to 0.03). In 
sharp contrast to fibroblasts, plating efficiency was reduced 3- to 6-fold in lung 
carcinoma and glioblastoma respectively (48 hours after NVP-AUY922).  
Thirty-minute and twenty-four-hour exposure to NVP-AUY922 or NVP-BEP800 did 
not influence the radiation response of both examined fibroblast strains. Only 
incubation with NVP-AUY922 for 48 hours post IR could moderately sensitize both 
fibroblast strains to radiation, as confirmed by the decreased SF2 and D10 values (i.e. 
HFib:1 SF2 ~0.61 -> ~0.52, D10 6.0 -> 5.1). For comparison, in glioblastoma cells, 
which responded very strongly to NVP-AUY922-IR treatment, SF2 decreased about 
2-fold from ~0.72 to ~0.3 and D10 from 8 to 3.9 (48 hours post drug-IR). The 
incubation of glioblastoma cells with NVP-BEP800 for 48 hours after IR resulted in 
the further decrease of SF2 (to 0.23) and D10 (to 3) values and stronger 
radiosensitization (Table 10). On the contrary, exposure to NVP-BEP800 for 48 hours 
did not increase the radiosensitivity of HFib1 and HFib2 cells. 
It is apparent that NVP-AUY922 and NVP-BEP800 preferentially sensitize tumor cell 
lines to radiation. To elucidate the mechanisms underlying the selectivity of Hsp90 
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inhibitors, we analyzed the expression of several marker proteins, DNA repair 
kinetics and cell cycle distribution. 
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Figure 59. Summary of radiosensitization and cytotoxicity-related effects of the 
combined drug-IR (8 Gy) treatment on the protein expression, DNA damage, and cell 
cycle arrest induced in A549 (red), SNB19 (blue), HFib1 (black) and HFib2 (green 
bars) cell lines, detected 48 hours after NVP-AUY922-IR treatment. Data for 
fibroblast strains HFib1 and HFib2 were taken from Figures 29-40 and Tables 13-15. 
For further details see legend to Figure 57. 
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Figure 60. Summary of radiosensitization and cytotoxicity-related effects of the 
combined drug-IR (8 Gy) treatment on the protein expression, DNA damage, and cell 
cycle arrest induced in A549 (red), SNB19 (blue), HFib1 (black) and HFib2 (green 
bars) cell lines, detected 48 hours after NVP-BEP800-IR treatment. Data for 
fibroblast strains HFib1 and HFib2 were taken from Figures 29-40 and Tables 13-15. 
For further details see legend to Figure 57. 
 
Our findings showed that the treatment of HFib1 or HFib2 cells with either NVP-
AUY922 or NVP-BEP800 up-regulated the expression of Hsp90 and Hsp70, but to a 
lesser extent than in cancer cell lines (24 and 48 hours post drug-IR treatment). In 
fibroblasts, as well as in tumor cells, Hsp90 clients (including Akt, pAkt, Raf-1 and 
survivin) were partially depleted. In addition, we observed cleavage of PARP in 
fibroblasts after NVP-AUY922 treatment, similarly as in lung carcinoma cells, but 
different from glioblastoma samples. In contrast to A549 and SNB19 tumor cell lines, 
where NVP-AUY922-IR treatment caused the depletion of Cdk1, in fibroblasts we 
observed an up-regulation of this kinase. Cyclin-dependent kinase 1 not only 
regulates G2/M transition, but may also be required for the induction of particular cell 
death pathways (Castedo et al. 2002). Forty-eight-hour incubation of HFib1 or HFib2 
cells after NVP-BEP800-IR treatment did not influence the expression of Cdk1. 
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The accumulation of DNA damage and the increased amount of events with low 
γH2AX expression in fibroblasts was observed 24 and 48 hours after NVP-AUY922-
IR treatment. On the contrary to NVP-AUY922, exposure to NVP-BEP800-IR for 48 
hours did not induce any additional DNA damage as compared with corresponding 
control samples. This differed from results previously described for cancer cells, 
where both Hsp90 inhibitors induced massive DNA damage in glioblastoma cells 
after the simultaneous drug-IR treatment that could not be restored throughout the 
duration of the experiments.  
The cell cycle analysis revealed further differences in the response of tumor and non-
malignant cells to combination of Hsp90 inhibition and IR. HFib1 and HFib2 cells 
treated with NVP-BEP800 (with/without IR) tended to moderate G1/S arrest, similarly 
as lung carcinoma cells. On the other hand, simultaneous NVP-AUY922-IR treatment 
shifted more HFib1 and HFib2 cells into the G2/M phase and depleted the S phase 
(24 hours post drug-IR). However, the G2/M arrest in fibroblasts was weaker than 
that observed in glioblastoma cell samples. In contrast to glioblastoma cells, 
treatment of both fibroblast strains with NVP-AUY922 for 48 hours (with or without IR) 
resulted in the increase of the sub-G1 phase. This together with cleavage of PARP 
indicates that 48-hour incubation with NVP-AUY922 could lead to the initiation of 
apoptosis in fibroblast strains.  
In summary, the cellular response of non-malignant fibroblasts to the combination of 
Hsp90 inhibition and irradiation differed from that observed in cancer cell lines (Figs. 
59, 60). The reasons underlying the selectivity of Hsp90 inhibitors, and especially 
NVP-AUY922 and NVP-BEP800, towards malignant cells remain elusive. Heat shock 
protein 90 is responsible for sustaining protein homeostasis in every human cell by 
the protein folding, intracellular transport and protein degradation of multiple 
regulators of cell growth and survival (Whitesell et al. 2005). It is apparent that non-
malignant cells are not as susceptible to Hsp90 inhibition as cancer cells. Work from 
Kamal et al. 2003 showed that Hsp90 isolated from normal cells has a 100-fold lower 
binding affinity to 17-AAG than Hsp90 from cancer cells. However, this was 
contradicted by a report that showed equal time-dependent binding of geldanamycin 
to Hsp90 from different cell types (Gooljarsingh et al.  2006). Hsp90 inhibitors 
including 17-AAG or 17-DMAG are known to concentrate in tumors, but not in normal 
cells (Banerji et al. 2005). It is suggested that heat shock protein 90 in non-malignant 
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cells does not form super-complexes with co-chaperones and has lower ATPase 
activity than in cancer cells (Kamal et al. 2004). More recent analysis proposed the 
presence of two distinctive forms of Hsp90 (Moulick et al. 2011). One form should 
function in non-malignant cells, whereas the other form would specifically chaperone 
aberrant mutant proteins required for tumor cell survival.  
Another probable explanation involves so called non-oncogene addiction hypothesis 
(Solimini et al. 2007). The development of malignancy includes an accumulation of 
mutations, which results in the expression of proteins that acquire new functions 
necessary for the survival of cancer cells or that cannot be correctly folded and 
aggregate. Apart from changed signalling pathways, tumor cells have to cope with 
extreme growth conditions like hypoxia or nutrient deprivation (Höckel et al. 2001, 
Luo et al. 2009). These intrinsic and extrinsic stress factors lead to the increasing 
dependency of cancer cells on the up-regulation of stress response pathways, and 
above all on the buffering potential of Hsp90 (Travers et al. 2012). When Hsp90 is 
inhibited, the protein homeostasis gets deregulated and cancer cells tend to be more 
vulnerable to therapy and drug-induced cell death (Hartl et al. 2011). Non-malignant 
cells do not experience such stress and therefore are less susceptible to Hsp90 
inhibition than tumor cells (Luo et al. 2009).  
 
5.3 Influence of Hsp70 pre-silencing combined with NVP-AUY922-
treatment on the radiation response of cancer cell lines A549 and 
SNB19 
 
A major problem of Hsp90 inhibitors is the drug-induced initiation of heat shock 
response, leading to the over-expression of heat shock proteins, including Hsp90 and 
Hsp70. In chapter 4.1 we have shown that exposure to NVP-AUY922 and NVP-
BEP800 increased the expression of Hsp90 and Hsp70 in A549 and SNB19 tumor 
cell lines (Figs. 14, 15). Heat shock protein 70 is characterized by strong anti-
apoptotic activities (see details in chapter 1.2.2), which promote cancer cell survival 
and can diminish the effects of Hsp90 inhibitors. Thus, one of the objectives of this 
thesis was to explore whether the suppression of Hsp70 up-regulation could 
influence the radiosensitizing effect of Hsp90 inhibitor NVP-AUY922. Since at the 
moment there are no specific, pharmacological inhibitors available, we used specific
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siRNA to down-regulate stress-inducible Hsp70 and constitutively expressed Hsc70. 
Hsp70 or Hsc70 siRNA significantly decreased the expression of target proteins at 
mRNA and protein level in A549 and SNB19 cell samples up to 72 hours after 
transfection. Apart from the target suppression, Hsc70 knock-down induced the 
expression of Hsp70. Similar results were presented by Powers et al. 2007a, where 
the authors proposed that either Hsp70 or Hsc70 can form a complex with Hsp90. 
When Hsp70 was silenced, Hsc70 could take over its place and functions in the 
Hsp90 chaperone complex (Powers et al. 2007a). 
Contrary data can be found in the literature on the influence of Hsp70 silencing on 
cell proliferation. Stable Hsp70 knock-down by shRNA reduced the cell growth and 
induced apoptosis in xenograft mouse models (Cai et al. 2011). Another report 
showed that the depletion of Hsp70 by adenovirus expressing antisense Hsp70 leads 
to the increased cell death in various cancer cell lines (i.e. glioblastoma; colon, breast 
and liver carcinoma, Nylandsted et al. 2006). On the contrary, Hsp70 silencing had 
no influence on the growth and survival of tumor cells of different origin in vitro (i.e. 
colon, ovarian, prostate and breast carcinoma; Gabai et al. 2005, Powers et al. 
2007a). In our hands, the cell growth was slightly reduced when cancer cells were 
treated with Hsp70 siRNA, Hsc70 siRNA or both siRNAs simultaneously. These 
discrepancies between the results may come from different design of the 
experiments and basal expression of heat shock protein 70 in tested cell lines. 
Next, we combined Hsp70 pre-silencing with NVP-AUY922 treatment and irradiation. 
The combination of Hsp70 silencing and Hsp90 inhibition has already been tested by 
other groups, although without irradiation (Guo et al. 2005, Powers et al. 2007a, 
Davenport et al. 2010). Hsp70 knock-down prior to treatment with 17-AAG increased 
the apoptotic effects of the Hsp90 inhibition in colon, ovarian carcinoma (Powers et 
al. 2007a) and multiple myeloma cells (Davenport et al. 2010). Similarly, the 
combination of Hsp70 silencing with 17-DMAG led to enhanced apoptosis in 
leukaemia cells (Guo et al. 2005). As expected from our previous works (Stingl et al. 
2010, Niewidok et al, 2012), treatment with NVP-AUY922 alone induced strong over-
expression of Hsp90, Hsp70 and Hsc70 in control A549 and SNB19 cells. The 
silencing of Hsp70 before NVP-AUY922-treatment suppressed the drug-induced 
Hsp70 up-regulation. At the same time, the combination of Hsp70 knock-down with 
NVP-AUY922 treatment induced heat shock response as indicated by the over-
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expression of Hsp90 and Hsc70. Similar effects at the protein expression level were 
observed when pre-silenced, NVP-AUY922-treated cells were irradiated.  
The influence of Hsp70 inhibition on radiosensitization remains to be elucidated. We 
have found only one study showing that Hsp70 silencing could sensitize endometrial 
cancer cells to irradiation (Du et al. 2009). In the present study we observed slight 
radiosensitization in lung carcinoma A549 cells and no changes in the radiation 
response of glioblastoma SNB19 cells after Hsp70 knock-down alone. To our 
knowledge this is the first study that combined Hsp70 silencing with Hsp90 inhibition 
and irradiation. In lung carcinoma cells, Hsp70 knock-down together with NVP-
AUY922 did not induce more radiosensitization than NVP-AUY922 alone. The 
strongest increase of the radiation response of SNB19 cells was observed after 
Hsp90 inhibition alone. On the other hand, the combination of Hsp70 siRNA and 
Hsp90 inhibitor moderately sensitized glioblastoma cells to radiation. Hsp70 silencing 
alone or with IR did not influence the expression of examined marker proteins, DNA 
damage response or the cell cycle progression of A549 and SNB19 tumor cell lines. 
When pre-silenced cells were treated with NVP-AUY922, the observed alterations 
(i.e. depletion of Hsp90 clients) were similar to those after drug treatment alone.  
To summarize, using specific siRNAs we have successfully down-regulated Hsp70 
and Hsc70 in A549 and SNB19 tumor cell lines. The knock-down of target proteins 
lasted for at least 72 hours and slightly reduced the proliferation potential of 
examined cells. Pre-silencing of Hsp70 suppressed the NVP-AUY922-induced up-
regulation of Hsp70 in examined A549 and SNB19 cells. However, the siRNA 
technique induced only transient target inhibition that was not sufficient for long-
lasting experiments like colony survival assay. 
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6. Summary 
 
Despite the recent improvements in oncology, cancer is still the leading cause of 
death in economically developed countries (Jemal et al. 2011). Heat shock protein 90 
can be a promising target in cancer treatment as it is responsible for sustaining 
protein homeostasis in every human cell by folding and activating of more than 200 
client proteins (Picard et al. 2002, Trepel et al. 2010). Hsp90 inhibition leads to 
degradation of Hsp90 client proteins by ubiquitin-proteasome pathway and thereby to 
impairment of multiple signaling pathways contributing to carcinogenesis (Zhang et 
al. 2004, Neckers et al. 2007). Apart from strong anti-tumor activities in vitro (Smith et 
al. 2005, Lundgren et al. 2009, Zhang et al. 2010) and in vivo (Supko et al. 1995, 
Lang et al. 2007, Solit et al. 2007), Hsp90 inhibitors can sensitize tumor cells to 
radiation (Bisht et al. 2003, Dote et al. 2005, Koll et al. 2008, Stingl et al.2010, 
Schilling et al. 2011). In the majority of the studies, the Hsp90 inhibitor was 
administered before IR (i.e. Bisht et al. 2003, Machida et al. 2003, Dote et al. 2006). 
However, other report claimed that the opposite schedule (Hsp90 inhibition after IR) 
was better for prostate cancer cell killing (Enmon et al. 2003). 
Recently, our group showed the radiosensitizing potential of two novel Hsp90 
inhibitors: NVP-AUY922 and NVP-BEP800 (Stingl et al. 2010). The drugs were 
administered to cancer cell lines of different origin 24 hours before irradiation (drug-
first treatment). In the present work, we explored the effects of a schedule other than 
drug-first treatment on A549 and SNB19 tumor cell lines. Cell samples were treated 
with either NVP-AUY922 or NVP-BEP800 one hour before IR and kept in the drug-
containing medium for up to 48 hours (simultaneous drug-IR treatment). After the 
drug-first treatment all tumor cell lines were sensitized to irradiation, regardless of 
their origin (Stingl et al. 2010). The same cell lines exposed to the simultaneous 
drug-IR treatment exhibited different cellular responses. SNB19 cells were sensitized 
to radiation and based on SF2 and D10 values, the radiosensitization was stronger 
than after drug-first treatment. The increase of radiation response correlated with 
massive DNA lesions that could not be restored during the time of experiment. The 
extent of DNA damage led to the over-expression of cell cycle inhibitor p21Waf1 that 
could stop the cell cycle progression at G2/M checkpoint. Detected elevated PI3K 
and Akt levels, together with PTEN null mutation, indicated that the PI3K-Akt
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pathway was activated and promoted SNB19 cell survival. Lung carcinoma A549 
cells exhibited cytotoxicity to simultaneous NVP-AUY922-IR or NVP-BEP800-IR 
treatment. In contrast to SNB19 cells, lung carcinoma A549 cells express functional 
PTEN that negatively regulates the pro-survival PI3K-Akt pathway. This, together 
with the drug-induced down-regulation of several pro-survival proteins Akt, survivin 
and Bcl-xL, led to the initiation of apoptosis in lung carcinoma cell line. The presence 
of mutation in k-RAS and the decrease of Cdk4 expression by Hsp90 inhibitors could 
explain the G1/S arrest observed in lung carcinoma cells. 
Overall, our findings showed that depending on the tumor cell line, the combination of 
Hsp90 inhibition and irradiation may result in radiosensitization or apoptosis of 
cancer cell lines. It is advised to adjust the sequence of treatment, involving Hsp90 
inhibition and irradiation, on the basis of the genetic background of tumor cells.  
 
Before entering the clinic, novel therapeutics should be tested on non-malignant 
tissue to exclude their possible toxic activities. The effects of NVP-AUY922 and NVP-
BEP800 on non-malignant cells have not been studied yet. Thus, we applied the 
simultaneous drug-IR treatment on human skin fibroblast strains (HFib1 and HFib2). 
The plating efficiency (PE) of non-malignant HFib1 and HFib2 cells was not affected 
by incubation with either Hsp90 inhibitor. This contrasted with the findings in tumor 
cell lines, where PE was strongly reduced 48 hours after NVP-AUY922 treatment. 
Normal fibroblasts were weakly sensitized to IR when the incubation with NVP-
AUY922 lasted 48 hours. Shorter incubation periods (30 minutes and 24 hours post 
NVP-AUY922-IR) did not affect the radiation response of HFib1 and HFib2 cells. 
Exposure to NVP-BEP800 did not sensitize human skin fibroblasts to IR; on the 
contrary it even seemed to induce some resistance to radiation (48 hours post drug-
IR). For comparison, 48-hour incubation post NVP-BEP800-IR or NVP-AUY922-IR 
treatment resulted in the strong radiosensitization of glioblastoma SNB19 cells. 
Furthermore, we examined the possible mechanism(s) underlying the selective action 
of NVP-AUY922 and NVP-BEP800. In contrast to cancer cells, we observed only a 
moderate up-regulation of Hsp90 and Hsp70 in both fibroblast strains after incubation 
with either Hsp90 inhibitor. At the same time, the depletion of Hsp90 clients 
(including Akt, pAkt and Raf-1) after drug treatment was similar to that observed in 
A549 and SNB19 cell samples. 
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Forty-eight hours after NVP-AUY922-IR treatment we observed an accumulation of 
DNA damage and moderate G2/M arrest in HFib1 and HFib2 cell samples. In 
addition, increased sub-G1 phase and cleavage of PARP indicated that the 
combined NVP-AUY922-IR treatment could lead to the apoptosis of non-malignant 
fibroblasts. In contrast to NVP-AUY922, incubation with NVP-BEP800 (with or without 
IR) did not affect DNA damage mechanisms or cell cycle phase distribution when 
compared with control fibroblasts.  
In conclusion, this work showed that Hsp90 inhibitors NVP-AUY922 and NVP-
BEP800 preferentially sensitize tumor cells to radiation, whereas the effect on normal 
fibroblasts was much weaker. The exact mechanisms underlying the Hsp90 
inhibitors’ selectivity towards malignant cells remain to be elucidated.  
 
It was shown previously that the administration of Hsp90 inhibitors, including NVP-
AUY922 and NVP-BEP800, induces heat shock response (Stingl et al. 2010, 
Niewidok et al. 2012, Patel et al. 2012). Heat shock response triggers the up-
regulation of Hsp70, which, due to its strong anti-apoptotic properties, might be 
responsible for reducing the effects of Hsp90 inhibition. In order to prevent this, we 
down-regulated Hsp70 and its constitutively expressed homologue Hsc70 in A549 
and SNB19 cancer cell lines using the siRNA-based approach. The silencing of 
target proteins lasted up to 72 hours and resulted in a reduction of cell proliferation. 
Next, we examined whether Hsp70 pre-silencing could improve the radiosensitizing 
potential of NVP-AUY922. Indeed, the transfection with Hsp70 siRNA suppressed the 
NVP-AUY922-induced over-expression of the target protein. However, on the long-
term scale, it did not influence the radiosensitivity of A549 and SNB19 cells.  
To summarize, the use of siRNA proved that Hsp70 inhibition could be used to 
support Hsp90 inhibition on the short-term scale. Therefore, for future works, more 
potent and stable methods of Hsp70 inhibition are needed, i.e. Hsp70 shRNA stable 
transfection or specific pharmacological inhibitors. 
 
This thesis presented the effects induced by two novel Hsp90 inhibitors NVP-
AUY922 and NVP-BEP800, in combination with irradiation in tumor cell lines as well 
as in normal skin fibroblasts. Hsp70 pre-silencing was tested as a method for 
improving radiosensitizing potential of NVP-AUY922. Recently, these in vitro results
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were corroborated in the in vivo study in our group, in which the combination of NVP-
AUY922 and IR increased the survival rate of tumor bearing mice (Kuger et al. 2012). 
In addition, it has been shown that NVP-AUY922 and NVP-BEP800 could decrease 
the migration and invasion of cancer cells at normoxic and hypoxic conditions 
(Hartmann et al. 2013). All these results support the use of NVP-AUY922 and NVP-
BEP800 in combination with irradiation in future clinical trials. However, further 
experiments on the extended group of cell lines should be carried out to identify the 
key regulators of the cell type-specific response to Hsp90 inhibition and IR. The role 
of Hsp70 in the radiation response of tumor cells and in combination with Hsp90 
inhibitors should be further studied.  
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7.  Zusammenfassung 
 
Trotz aller wissenschaftlicher Fortschritte, die in den letzten Jahren in der Onkologie 
erfolgten, ist Krebs eine der Haupttodesursachen in den wirtschaftlich entwickelten 
Ländern. Das Hitzeschockprotein 90 (Hsp90) stellt ein vielversprechendes neues 
Target für die Krebstherapie dar, weil es einen großen Anteil des 
Proteingleichgewichts in jeder humanen Zelle durch Faltung und Aktivierung seiner 
Klientenproteine kontrolliert (Picard et al. 2002, Trepel et al. 2010). Die Hsp90 
Inhibition verursacht den Abbau von Hsp90 Klientenproteinen durch den Ubiquitin-
Proteasom-Signalweg, und dadurch werden gleichzeitig viele 
Signaltransduktionswege behindert, die zur Krebsentstehung beitragen können 
(Zhang et al. 2004, Neckers et al. 2007). Es wurde gezeigt, dass Hsp90 Inhibitoren 
starke anti-proliferative Eigenschaften in vitro (Smith et al. 2005, Lundgren et al. 
2009, Zhang et al. 2010) und in vivo aufweisen (Supko et al. 1995, Lang et al. 2007, 
Solit et al. 2007). Außerdem führte die Hsp90 Inhibition zur Radiosensibilisierung 
unterschiedlicher Tumorzelllinien (Bisht et al. 2003, Dote et al. 2005, Koll et al. 2008, 
Stingl et al.2010, Schilling et al. 2011). In der Mehrheit der Arbeiten wurde der Hsp90 
Inhibitor vor der Bestrahlung hinzugegeben (z. B. Bisht et al. 2003, Machida et al. 
2003, Stingl et al. 2010). In anderen Arbeiten ist jedoch beschrieben, dass das 
umgekehrte Behandlungsschema (Hsp90 Inhibition nach der Bestrahlung) stärkere 
Radiosensibilisierung verursacht (Enmon et al. 2003, Koll et al. 2008).  
Vor Kurzem wurde in unserer Arbeitsgruppe gezeigt, dass die neuartigen Hsp90 
Inhibitoren NVP-AUY922 und NVP-BEP800 zur Erhöhung der 
Strahlenempfindlichkeit der Tumorzelllinien führen (Stingl et al. 2010). Die 
Krebszellen wurden 24 Stunden vor der Bestrahlung behandelt und bestrahlt (‚drug-
first’ Behandlungsschema). In dieser Doktorarbeit wurden die Effekte eines anderen 
Behandlungsschemas auf die A549 und SNB19 Tumorzelllinien untersucht. Die 
Zellen wurden entweder mit NVP-AUY922 oder NVP-BEP800 eine Stunde vor der 
Bestrahlung behandelt und bis zu 48 Stunden nach der Bestrahlung weiterhin mit 
Hsp90 Inhibitor kultiviert (simultane drug-IR Behandlungsschema). Das ‚drug-first’ 
Behandlungsschema führte zur Radiosensibilisierung von Tumorzellen, unabhängig 
von ihrem Ursprung (Stingl et al. 2010). Die gleichen Tumorzelllinien zeigten bei 
simultanem Behandlungsschema unterschiedliche zelluläre Antworten. 
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Die Hsp90 Inhibition in Kombination mit der Bestrahlung erhöhte die 
Strahlenempfindlichkeit von SNB19-Zellen und, basierend auf den SF2 und D10-
Werten, war die Radiosensibilisierung nach simultaner Behandlung stärker als nach 
dem ‚drug-first’ Behandlungsschema. Die Verstärkung der Strahlenantwort in 
SNB19-Zellen korrelierte mit den DNA Schäden, die während der Zeit des 
Experimentes nicht repariert werden konnten. Der Umfang von den DNA 
Doppelstrangbrüchen führte in dieser Glioblastomazelllinie zu einer Überexpression 
des Zellzyklusinhibitors p21Waf1, was den G2/M Arrest verursachen konnte. Es 
wurden erhöhte Expressionslevels von PI3K und Akt detektiert, die zusammen mit 
einer null Mutation in PTEN auf einen aktivierten PI3K-Akt Signalweg hindeuteten, 
der das Überleben der SNB19-Zellen förderte. Die simultane drug-IR Behandlung rief 
Zytotoxizität bei A549-Zellen hervor. Im Gegensatz zu SNB19-Zellen exprimieren 
A549 Lungenkarzinomzellen PTEN Wildtyp, das den PI3K-Akt Signalweg negativ 
regulieren kann. Dies, zusammen mit der Reduzierung der Expression der ‚pro-
survival’ Proteine Akt, Survivin und Bcl-xL, die durch die Behandlung induziert wurde, 
leitete die Apoptose ein. Eine Verminderung der Cdk4 Kinase nach simultaner drug-
IR Behandlung und eine vorliegende Mutation in k-RAS führten zu einem G1/S Arrest 
in den Lungenkarzinomzellen.  
Zusammenfassend zeigen die hier gewonnenen Ergebnisse, dass abhängig von der 
Tumorzelllinie, die Kombination der Hsp90 Inhibition mit Bestrahlung zur 
Radiosensibilisierung oder zur Apoptose führen kann. Die Reihenfolge der 
Behandlung mit Hsp90 Inhibitoren und Bestrahlung sollte individuell der Tumorart 
und den vorliegenden Mutationen angepasst werden.  
 
Bevor Medikamente in der Klinik angewendet werden können, müssen sie auf nicht-
malignem Gewebe getestet werden, um eine mögliche toxische Wirkung 
auszuschließen. Der Einfluss von NVP-AUY922 und NVP-BEP800 wurde noch nicht 
auf nicht-malignen Zellen getestet. Deshalb wurden in der vorliegenden Arbeit die 
zwei humane Hautfibroblastenlinien HFib1 und HFib2 nach dem simultanen 
Behandlungsschema mit Hsp90 Inhibitoren und Bestrahlung behandelt. Die 
Plattiereffizienz (PE) der nicht-malignen HFib1 und HFib2 Zellen wurde von der 
Behandlung mit Hsp90 Inhibitoren nicht beeinflusst. Dies stand im Gegensatz zu den 
Ergebnissen in Tumorzelllinien, bei denen eine starke Reduktion der Plattiereffizienz
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beobachtet wurde (48 Stunden nach Behandlung mit NVP-AUY922). Eine schwache 
Radiosensibilisierung der normalen Fibroblasten wurde nur nach 48 Stunden 
Inkubation mit NVP-AUY922 erreicht. Kürzere Inkubationszeiten (30 Minuten und 24 
Stunden nach NVP-AUY922-IR) hatten keinen Einfluss auf die Strahlenantwort der 
Zelllinien HFib1 und HFib2. Die Behandlung mit NVP-BEP800 sensibilisierte die 
Fibroblasten nicht für die Bestrahlung, im Gegenteil, die Substanz induzierte eine 
geringe Radioresistenz (48 Stunden nach NVP-BEP800-IR). Im Vergleich dazu, 
zeigten die SNB19 Glioblastoma Zellen die stärkste Radiosensibilisierung 48 
Stunden nach NVP-BEP800-IR Behandlung. 
Weiterhin wurde nach möglichen Mechanismen, die die selektive Wirkung des NVP-
AUY922 und NVP-BEP800 erklären können, untersucht. Im Gegensatz zu 
Krebszelllinien, wurde nur eine moderate Hochregulierung der Hitzeschockproteine 
in beiden Fibroblastenlinien beobachtet. Gleichzeitig war die Depletion von Hsp90 
Klientenproteinen (Akt, pAkt und Raf-1) nach Behandlung ähnlich wie die, die in 
A549- und SNB19-Zellen induziert war. Achtundvierzig Stunden nach NVP-AUY922-
IR Behandlung wurde eine Akkumulation von DNA Schäden und ein moderater G2/M 
Arrest in Fibroblasten gesehen. Zusätzlich, deutete eine erhöhter Zahl von Zellen, die 
sich in der Sub-G1-Phase befunden, und die Spaltung von PARP darauf hin, dass 
die simultane NVP-AUY922-IR Behandlung den Zelltod in Fibroblasten einleiten 
konnte. Im Gegensatz zu NVP-AUY922, induzierte die Inkubation mit NVP-BEP800 
für 48 Stunden (mit und ohne Bestrahlung) keine zusätzlichen DNA Schäden oder 
Zellzyklusstörungen verglichen mit den Kontrollen.  
Diese Arbeit zeigte, dass NVP-AUY922 und NVP-BEP800 Tumorzelllinien für die 
Bestrahlung sensibilisieren, wohingegen der Einfluss von Hsp90 Inhibitoren auf 
normale Fibroblasten geringer war. Der exakte Mechanismus der Selektivität der 
Hsp90 Inhibitoren auf Krebszellen ist aber noch unbekannt und erfordert weitere 
Experimente.  
 
Die Behandlung mit N-terminalen Hsp90 Inhibitoren, zum Beispiel mit NVP-AUY922 
oder mit NVP-BEP800, induziert die Hitzeschockantwort und unter anderem die 
Hochregulierung von Hsp70 (Stingl et al. 2010, Niewidok et al. 2012, Patel et al. 
2012). Hsp70 ist bekannt für seine starken anti-apoptotischen Eigenschaften, die das 
therapeutische Potenzial der Hsp90 Inhibitoren reduzieren können. Um das zu
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verhindern, wurde eine siRNA-basierte Strategie zur Unterdrückung von Hsp70-
Überexpression nach Hsp90 Inhibition getestet. Es wurde eine Verminderung der 
Expression von induzierbarem Hsp70 und konstitutiv exprimiertem Hsc70 in 
Krebszelllinien A549 und SNB19 erreicht. Die Unterdrückung von Target-Proteinen 
dauerte bis zu 72 Stunden und führte zu einer verlangsamten Zellproliferation. Die 
Behandlung mit siRNA reduzierte die von NVP-AUY922 induzierte Hsp70-
Überexpression, aber beeinflusste nicht die Strahlenempfindlichkeit der 
Tumorzelllinien A549 und SNB19. Die Transfektion mit siRNA hat bewiesen, dass die 
Hsp70 Inhibition als eine Unterstützung der Hsp90 Inhibition dienen kann. Dies ist 
jedoch eine kurzzeitige Methode der Hemmung und alternative Methoden, wie zum 
Beispiel stabile Hsp70 shRNA Transfektion oder pharmakologische Inhibition, zur 
Hemmung der Hsp70 Aktivitäten nötig sind. 
 
Die in dieser Arbeit gewonnen Erkenntnisse erläutern die Effekte, die von zwei 
neuartigen Hsp90 Inhibitoren NVP-AUY922 und NVP-BEP800 in Kombination mit 
Bestrahlung induziert werden, sowohl in Tumorzelllinien als auch in normalen 
Hautfibroblasten. Hsp70-Silencing wurde als Methode zur Erhöhung des 
radiosensibilisierenden Potenzials des Inhibitor NVP-AUY922 getestet. Diese in vitro 
Ergebnisse wurden durch eine Studie im Tiermodell bestätigt (Kuger et al. 2012). In 
dieser Studie erhöhte die Kombination der Hsp90 Inhibition mit Bestrahlung die 
Überlebensrate der Mäuse. Zusätzlich hat Hartmann et al. 2013 bewiesen, dass die 
Behandlung mit NVP-AUY922 und NVP-BEP800 die Motilität und Invasion der 
Tumorzellen unter Normoxie und Hypoxie reduziert. Alle diese Resultate zusammen 
sprechen für eine Anwendung von NVP-AUY922 und NVP-BEP800 in klinischen 
Studien, die alleine oder in Kombination mit Bestrahlung erfolgen könnte. Weitere 
Arbeiten an größeren Gruppen von Zelllinien sind zur Identifizierung von Proteinen 
nötig, die die zellspezifische Antwort zur Hsp90 Inhibition regulieren. Hier gewonnene 
Ergebnisse machen weitere Experimente erforderlich, um die exakte Rolle
der Hsp70 Proteine für die Strahlenantwort zu verstehen. 
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